# AMERICAN TRANSPLANT CONGRESS
Day-at-a-Glance, Saturday, May 30, 2009

<table>
<thead>
<tr>
<th>8:00 AM – 5:30 PM</th>
<th>Pre-Meeting Morning/Full Day Symposia</th>
</tr>
</thead>
</table>
| Page 59           | #1-Essential Immunology for the Clinician  
                    Ballroom B |
| Page 59           | #2-Clinical Updates and Donor Derived Infectious Disease  
                    Room 302/304 |
| Page 60           | #3-Transplantation Immunology for Basic Scientists  
                    Ballroom C |
| Page 60           | #4-Hot Topics in Infectious Disease and Donor-Derived Infections: Emerging Challenges and Potential Solutions  
                    Room 311 |
| 12:30 PM – 1:30 PM| Industry-Supported Satellite Symposium |
| Page 61           | The Systems Biology of Clinical Organ Transplantation  
                    Room 312 |
| 1:15 PM – 5:30 PM | Pre-Meeting Afternoon/Half Day Symposia |
| Page 61           | #5-Pediatric Transplantation  
                    Room 309 |
| Page 61           | #6-Management of Liver Cancer in Liver Transplantation  
                    Room 306 |
| Page 62           | #7-Hot Topics for the Transplant Professional Clinician Group  
                    Room 310 |
| Page 62           | #8-The Business of Transplantation: Key Success Factors for Establishing or Expanding a Transplant Program  
                    Room 210 |

<table>
<thead>
<tr>
<th>4:00 AM – 5:30 AM</th>
<th>ATC New Investigator Career Highlight Forum</th>
</tr>
</thead>
</table>
| Page 62           | Parallel #1: Basic Science  
                    Room 312 |
| Page 63           | Parallel #2: Clinical Science  
                    Ballroom A |
| 5:30 PM – 7:00 PM | Opening Reception with Exhibits and Poster Session I  
                    Exhibit Hall C |
| Page 151          | Economics, Public Policy, Allocation, and Ethics |
| Page 152          | Inflammation and Drug Toxicity |
| Page 154          | Innate Immunity: Chemokines, Cytokines |
| Page 156          | Islet: All Topics |
| Page 158          | Kidney Immunosuppression: Novel Agents |
| Page 160          | Kidney: Acute Rejection I |
| Page 162          | Kidney: BK Polyoma Virus |
| Page 164          | Kidney: Complications I |
| Page 166          | Kidney: Living Donors - Donor Exchange and Surgical Issues |
| Page 169          | Liver Malignancies: Hepatocellular and Cholangiocarcinoma |
| Page 171          | Liver: MELD, Allocation, and Donor Issues |
| Page 173          | PTLD/Malignancy |
| Page 175          | Small Bowel |
| Page 175          | Stem Cells and Cellular Transplantation |
| Page 177          | Xenotransplantation |
Pre-Meeting Morning/Full Day Symposia
8:00 AM – 5:30 PM

1. Essential Immunology for the Clinician
   Ballroom B

8:00 AM  Fundamental Overview of the Immune Response
          Fadi Lakkis, MD

Transplant Immunology I: Antigen Dependent Mechanisms
   Chair: Simon Robson, MD, PhD

8:30 AM  T Cell Activation, Differentiation and Function
          Joaquin Madrenas, MD, PhD

9:00 AM  Post-transplant Antibodies: Development and Consequences
          Kathryn Tinckam, MD

9:30 AM  Immunosuppression: Mechanisms of Action
          Philip Halloran, MD, PhD

10:00 AM Break

Transplant Immunology II: Antigen Independent Mechanisms
   Chair: Roslyn Mannon, MD

10:30 AM Innate Immunity in Solid Organ Transplantation
         William Baldwin, III, MD, PhD

11:00 AM Chemokines and Cell Trafficking
         Robert Fairchild, PhD

11:30 AM Effector Mechanisms Leading to Graft Destruction
         Anthony Jevnikar, MD

12:00 NN Allograft Fibrosis: The Response to Inflammation
         Roslyn Mannon, MD

12:30 PM Lunch Break (on your own)

2. Clinical Updates and Donor Derived Infectious Disease
   Room 302/304

Complications of Transplantation
   Chairs: Anil Chandraker, MD, and Martha Pavlakis, MD

Cardiovascular Issues

8:00 AM  Role of Cardiovascular Screening Before and After Transplantation
          Bertram Kasiske, MD

8:30 AM  The Impact of Left Ventricular Function on Survival Before and After Kidney Transplantation
          Angelo DeMattos, MD, MPH

9:00 AM  Post-transplant Hypertension: Does Treatment Matter?
          Stephen Textor, MD

9:30 AM  Break

Other Complications

10:00 AM Early Graft Loss: Consequences of Organ Quality on Immune Response and Transplant Outcome
         Stefan Tullius, MD, PhD

10:30 AM Fracture Prevention and Treatment of Post-transplant Bone Disease in Kidney vs. Non Kidney Organ Transplant Patients
         Margaret Bia, MD

11:00 AM Post-transplant Anemia: An Update
         Anil Chandraker, MD

11:30 AM Post-transplant Anemia: Effects on Patient and Graft Outcomes
         Roy Bloom, MD
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 NN</td>
<td>Lunch Break</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>TIM1-TIM4 Pathway in Rejection and Tolerance</td>
</tr>
<tr>
<td></td>
<td>Terry Strom, MD</td>
</tr>
<tr>
<td>12:00 NN</td>
<td>TIM 3-Galectin 9 in Rejection and Tolerance</td>
</tr>
<tr>
<td></td>
<td>Nader Najafian, MD</td>
</tr>
<tr>
<td>12:30 PM</td>
<td>Lunch Break (on your own)</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>Defining Risk of Living Donation</td>
</tr>
<tr>
<td></td>
<td>Robert Steiner, MD</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Expanding the Limits of Living Kidney Donation</td>
</tr>
<tr>
<td></td>
<td>Stephen Textor, MD</td>
</tr>
<tr>
<td>2:30 PM</td>
<td>Follow-up of Living Donors: The UNOS Perspective</td>
</tr>
<tr>
<td></td>
<td>Timothy Pruett, MD</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Break</td>
</tr>
<tr>
<td>3:30 PM</td>
<td>Current State of Donor Derived Infections</td>
</tr>
<tr>
<td></td>
<td>Michael Ison, MD, MS</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Estimating the Risk of Donor Derived Infections</td>
</tr>
<tr>
<td></td>
<td>Eugene Shweitzer, MD</td>
</tr>
<tr>
<td>4:30 PM</td>
<td>NAT for Donor Screening</td>
</tr>
<tr>
<td></td>
<td>Jutta Preiksaitis, MD</td>
</tr>
<tr>
<td>3. Transplantation Immunology for Basic Scientists</td>
<td></td>
</tr>
<tr>
<td>Ballroom C</td>
<td></td>
</tr>
<tr>
<td>Biology of T17 Cells and Role in Alloimmunity</td>
<td></td>
</tr>
<tr>
<td>Chairs: William Burlingham, PhD, and Xueli Yuan, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td>The Biology of Th/Tc17</td>
</tr>
<tr>
<td></td>
<td>William Burlingham, PhD</td>
</tr>
<tr>
<td>8:30 AM</td>
<td>Th17 Cells and Resistance to Tolerance</td>
</tr>
<tr>
<td></td>
<td>D. Keith Bishop, PhD</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>T17 and Tregs: An Intricate Balance</td>
</tr>
<tr>
<td></td>
<td>Terry Strom, MD</td>
</tr>
<tr>
<td>9:30 AM</td>
<td>T17 and Role in Rejection and CAV</td>
</tr>
<tr>
<td></td>
<td>John Iacomini, PhD</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Break</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>The TIM pathway as a Novel Pathway in Regulating Th1/Th2/Th17 Cell</td>
</tr>
<tr>
<td>Chairs: Terry Strom, MD, and Javeed Ansari, MBBS, MRCP</td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Targeting TIM1-TIM4 Pathway in Transplantation</td>
</tr>
<tr>
<td></td>
<td>Mohamed Sayegh, MD</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>TIM1-TIM4 Pathway in Rejection and Tolerance</td>
</tr>
<tr>
<td></td>
<td>Terry Strom, MD</td>
</tr>
<tr>
<td>12:00 NN</td>
<td>TIM 3-Galectin 9 in Rejection and Tolerance</td>
</tr>
<tr>
<td></td>
<td>Nader Najafian, MD</td>
</tr>
<tr>
<td>12:30 PM</td>
<td>Lunch Break (on your own)</td>
</tr>
<tr>
<td>1:15 PM</td>
<td>Human Tregs: Functionally Distinct Subsets</td>
</tr>
<tr>
<td></td>
<td>Clare Baecher-Allan, PhD</td>
</tr>
<tr>
<td>1:45 PM</td>
<td>Regulatory B10 Cells in Immune Responses</td>
</tr>
<tr>
<td></td>
<td>Thomas Tedder, PhD</td>
</tr>
<tr>
<td>2:15 PM</td>
<td>Tregs: The Secret of their Generation and Function</td>
</tr>
<tr>
<td></td>
<td>Xian Li, MD, PhD</td>
</tr>
<tr>
<td>2:45 PM</td>
<td>Break</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>NK T Cells as Regulatory Cells</td>
</tr>
<tr>
<td></td>
<td>Brian Wilson, MD</td>
</tr>
<tr>
<td>3. Mesenchymal Stem Cells</td>
<td></td>
</tr>
<tr>
<td>Chairs: Nicholas Zavazava, MD, PhD, and Reza Abdi, MD</td>
<td></td>
</tr>
<tr>
<td>3:30 PM</td>
<td>Immunomodulation by MSCs: Mechanisms</td>
</tr>
<tr>
<td></td>
<td>Francesco Dazzi, MD</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>MSCs in GVHD</td>
</tr>
<tr>
<td></td>
<td>Franco Locatelli, PhD</td>
</tr>
<tr>
<td>4:30 PM</td>
<td>Mesenchymal Stem Cells to Induce Transplant Tolerance</td>
</tr>
<tr>
<td></td>
<td>Marina Noris, PhD</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>MSCs in Autoimmune Disease</td>
</tr>
<tr>
<td></td>
<td>Paolo Fiorina, MD</td>
</tr>
<tr>
<td>4. Hot Topics in Infectious Disease and Donor-Derived Infections: Emerging Challenges and Potential Solutions</td>
<td></td>
</tr>
<tr>
<td>Room 311</td>
<td></td>
</tr>
<tr>
<td>This is an audience response system session, supported by Roche Laboratories, Inc.</td>
<td></td>
</tr>
<tr>
<td>Essentials of Infectious Disease</td>
<td></td>
</tr>
<tr>
<td>Chairs: Jay Fishman, MD, and Michael Ison, MD, MS</td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td>New Immunosuppressive Regimens and the Risk of Infections</td>
</tr>
<tr>
<td></td>
<td>Nicolas Mueller, MD</td>
</tr>
<tr>
<td>8:30 AM</td>
<td>TB – How to Screen and Who to Treat</td>
</tr>
<tr>
<td></td>
<td>Jennifer Daly, MD</td>
</tr>
</tbody>
</table>
9:00 AM  HIV-HCV: A Confounding Coinfection  
   Arthur Kim, MD  
9:30 AM  Antibiotic Prophylaxis – When is it Useful?  
   Emily Blumberg, MD  
10:00 AM  Break  
10:30 AM  Diagnosis of Emerging Fungal Infections  
   Kimberly Hanson, MD  
11:00 AM  Antifungal Management and Newer Antifungal Strategies  
   Michele Morris, MD  
11:30 AM  New Developments in CMV Prevention and Management  
   Raymund Razonable, MD  

Industry-Supported Satellite Symposium  
12:30 PM – 2:00 PM  
The Systems Biology of Clinical Organ Transplantation  
Room 312  
Sponsored and Supported by ROTRF  

Pre-Meeting Afternoon/Half Day Symposia  
1:15 PM – 5:30 PM  

6. Management of Liver Cancer in Liver Transplantation  
Room 306  
This is an audience response system session, supported by Roche Laboratories, Inc.  

Session I  
Chairs: Martin Hertl, MD, and Igal Kam, MD  
1:30 PM  Incidence and Pathogenesis of Hepatocellular Carcinoma  
   Robert Brown, MD  
1:50 PM  New Modalities for Downsizing HCC While Awaiting Transplant  
   Laura Kulik, MD  
2:10 PM  Chemotherapy for Hepatocellular Carcinoma  
   Andrew Zhu, MD, PhD  
2:30 PM  Allocation for HCC: Is it Working?  
   Richard Freeman, MD  
2:50 PM  Should Living Donors be Used for Transplantation of HCC?  
   Robert Fisher, MD  
3:10 PM  Panel Discussion  
3:30 PM  Break  

Session II  
Chairs: Debra Sudan, MD and Goran Klintmalm, MD, PhD  
4:00 PM  Surgical Resection in Setting of Cirrhotic Livers  
   Satoru Todo, MD  
4:20 PM  Transplantation for Hepatocellular Carcinoma: Is Bigger Okay?  
   Johnny Hong, MD  
4:40 PM  Transplantation for Cholangiocarcinoma  
   Charles Rosen, MD  
5:00 PM  Case Presentations  
   John Lake, MD
7. **Hot Topics for the Transplant Professional Clinician Group**  
Co-sponsored by the International Transplant Nurses Society (ITNS) and NATCO, The Organization for Transplant Professionals  
Room 310  

This is an audience response system session, supported by Roche Laboratories, Inc.  

**I. Transplant Oversight and Regulatory Issues**  
Chairs: Kathy Schwab, RN, BSN, and Lori Coleman, RN, CPTC  

1:30 PM CMS and the Case for Regulation  
Thomas Hamilton  

2:00 PM Center Perspective: When is Regulation too Much Regulation?  
Susan A Zylicz, RN, BSN  

2:30 PM Panel Discussion  

3:00 PM Break  

**II. Ethics vs Finances: What are the Issues for Donors and Recipients?**  
Chairs: Barry Friedman, BSN, MBA, and Deborah Hoch, MSN  

3:30 PM Making the Case for a Regulated System of Compensation for Donation  
Arthur Matas, MD  

4:00 PM The Ethical Hurdles for Paid Donation  
Jun Xu, MA  

4:30 PM What About Ethics and Financial Disincentives for Recipients?  
Wayne Paris, PhD  

5:00 PM Panel Discussion  

**New Investigator Career Highlight Forum**  

**Special ATC Session:** This session is open to all registered attendees of the ATC.  

**Parallel #1: Basic Science**  
Room 312  
Chairs: Peter Heeger, MD, and Jerzy Kupiec-Weglinski, MD, PhD  

4:00 PM Introduction by John Iacomini, PhD  

4:02 PM NK Cells Prevent the Development of Regulatory T Cells  
Jessamyn Bagley, PhD  
Previous Award: 2005 AST/Astellas Basic Scientist Career Development Faculty Grant  

4:22 PM Introduction by Mohamed Sayegh, MD  

4:24 PM Novel Insights into the Pathogenesis of Chronic Allograft Vasculopathy  
Mohammed Javeed Ansari, MBBS, MRCP  
Previous Award: 2006 AST/Wyeth Basic Science Faculty Development Grant  

4:44 PM Introduction by Daniel Kreisel, MD, PhD  

4:46 PM Orthotopic Mouse Lung Transplantation as Experimental Methodology to Study Transplant and Tumor Biology  
Alexander Kreapnick, MD  
Previous Award: 2005 ASTS-Novartis Fellowship in Transplantation  

5:06 PM Introduction by Simon Robson, MD, PhD
5:08 PM Novel Viral Vectors as a Tool to Study Liver Physiology and Pathophysiology
Seth Karp, MD
Previous Award: 2005 ASTS Astellas Faculty Development Award; 2006 ASTS-Vanguard Prize; 2008 ASTS Wyeth Collaborative Scientist Award

Parallel #2: Clinical Science
Ballroom A
Chairs: William Harmon, MD, and Barry Kahan, MD, PhD

4:00 PM Introduction by Mohamed Sayegh, MD

4:02 PM B Cells Making it on the VIP List in Autoimmune Diabetes and Islet Transplantation
Paolo Fiorina, MD, PhD
Previous Award: 2007 AST/JDRF Grant

4:22 PM Introduction by Gregory Everson, MD 4:24 PM Metabolic Complications after Liver Transplantation
Lisa Michelle Forman, MD
Previous Award: 2005 AST/Schering Plough Women & Minority Career Development Faculty Grant

4:44 PM Introduction by Allan Kirk, MD, PhD

4:46 PM Translational Research in Composite Tissue Allotransplantation
Linda Cendales, MD
Previous Award: 2008 ASTS-Astellas Faculty Development Award

5:06 PM Introduction by Robert Montgomery, D. Phil

5:08 PM Of Math and Medicine: Expanding Kidney Paired Donation
Dorry Segev, MD
Previous Award: 2004 ASTS-Novartis Fellowship in Transplantation; 2006 ASTS-Astellas Clinical Science Faculty Development Grant; 2006 ASTS Vanguard Prize

5:30 PM – 7:00 PM Opening Reception & Exhibits Open
Exhibit Hall D, Second Floor, John B. Hynes

Poster Session I
5:30 PM – 7:00 PM
Poster Viewing: 4:00 PM – 7:00 PM
Presenters in Attendance:
5:30 PM – 7:00 PM Exhibit Hall C, Second Floor,
John B. Hynes Convention Center

Page 151 Economics, Public Policy, Allocation, and Ethics

Page 152 Inflammation and Drug Toxicity

Page 154 Innate Immunity: Chemokines, Cytokines

Page 156 Islet: All Topics

Page 158 Kidney Immunosuppression: Novel Agents

Page 160 Kidney: Acute Rejection I

Page 162 Kidney: BK Polyoma Virus

Page 164 Kidney: Complications I

Page 166 Kidney: Living Donors - Donor Exchange and Surgical Issues

Page 169 Liver Malignancies: Hepatocellular and Cholangiocarcinoma

Page 171 Liver: MELD, Allocation, and Donor Issues

Page 173 PTLD/Malignancy

Page 175 Small Bowel

Page 175 Stem Cells and Cellular Transplantation

Page 177 Xenotransplantation
### AMERICAN TRANSPLANT CONGRESS
**Day-at-a-Glance, Sunday, May 31, 2009**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM – 8:15 AM</td>
<td>Sunrise Symposia</td>
<td>Page 67</td>
</tr>
<tr>
<td>7:00 AM – 8:15 AM</td>
<td>Sunrise Symposium I: Assessing Renal Function in Transplantation</td>
<td>Room 302/304</td>
</tr>
<tr>
<td>7:00 AM – 8:15 AM</td>
<td>Sunrise Symposium II: The Rise and Fall of Living Donor Liver Transplantation</td>
<td>Ballroom A</td>
</tr>
<tr>
<td>7:00 AM – 8:15 AM</td>
<td>Sunrise Symposium III: Immune Monitoring Moves to the Clinic: Markers of Rejection and Tolerance</td>
<td>Ballroom B</td>
</tr>
<tr>
<td>7:00 AM – 8:15 AM</td>
<td>Sunrise Symposium IV: SRTR Risk-Adjustment: What Does It Mean For My Transplant Program?</td>
<td>Room 210</td>
</tr>
<tr>
<td>7:00 AM – 8:15 AM</td>
<td>Sunrise Symposium V: (Beyond T Cell Tolerance) Is Targeting Naïve T Cells Enough to Induce Tolerance?</td>
<td>Ballroom C</td>
</tr>
<tr>
<td>7:00 AM – 8:15 AM</td>
<td>Sunrise Symposium VI: Incentives for Organ Donation</td>
<td>Room 312</td>
</tr>
<tr>
<td>8:15 AM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>8:15 AM – 10:00 AM</td>
<td>Early Morning Workshops</td>
<td>Page 68</td>
</tr>
<tr>
<td>8:15 AM – 10:00 AM</td>
<td>Plenary Session I</td>
<td>Auditorium</td>
</tr>
<tr>
<td>10:00 AM – 10:30 AM</td>
<td>State-of-the-Art Address</td>
<td>Page 69</td>
</tr>
<tr>
<td>10:30 AM Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 AM – 12:30 PM</td>
<td>Concurrent Symposia</td>
<td>Page 69</td>
</tr>
<tr>
<td>11:00 AM – 12:30 PM</td>
<td>Concurrent Symposium I: Multiorgan Transplantation – Worthy Investment?</td>
<td>Ballroom B</td>
</tr>
<tr>
<td>2:15 PM – 3:45 PM</td>
<td>Concurrent Sessions</td>
<td>Page 70</td>
</tr>
<tr>
<td>2:15 PM – 3:45 PM</td>
<td>Concurrent Session I: Basic: B-Cell/ Antibody</td>
<td>Room 310</td>
</tr>
<tr>
<td>2:15 PM – 3:45 PM</td>
<td>Concurrent Session 2: Clinical Heart Transplantation</td>
<td>Room 306</td>
</tr>
<tr>
<td>2:15 PM – 3:45 PM</td>
<td>Concurrent Session 3: Donor - Derived Infections and HIV</td>
<td>Ballroom B</td>
</tr>
<tr>
<td>2:15 PM – 3:45 PM</td>
<td>Concurrent Session 5: Kidney: Complications I</td>
<td>Room 302/304</td>
</tr>
<tr>
<td>2:15 PM – 3:45 PM</td>
<td>Concurrent Session 6: Liver IRI: Novel Mechanisms</td>
<td>Room 309</td>
</tr>
<tr>
<td>2:15 PM – 3:45 PM</td>
<td>Concurrent Session 7: Liver: Complications, Recurrent Disease, and Hepatitis I</td>
<td>Ballroom A</td>
</tr>
<tr>
<td>2:15 PM – 3:45 PM</td>
<td>Concurrent Session 8: Metabolic Complications</td>
<td>Room 206</td>
</tr>
</tbody>
</table>
Sunday, May 31, 2009

Concurrent Sunrise Symposia
7:00 AM – 8:15 AM

Sunrise Symposium I: Assessing Renal Function in Transplantation
Room 302/304
Chairs: Emilio Poggio, MD, and Christophe Mariat, MD, PhD

This is an audience response system session, supported by Roche Laboratories, Inc.

7:00 AM Measuring vs. Estimating GFR in Clinical Transplantation
Emilio Poggio, MD

7:15 AM Implementing the K/DOQI CKD Classification to Kidney Transplant Recipients: Advantages and Limitations
John Gill, MD, MD, MS

7:30 AM Can We Still Use EGFR as an Endpoint in Kidney Transplant Trials?
Christophe Mariat, MD, PhD

7:45 AM Improving GFR Estimation in Transplantation: Standardized Serum Creatinine, Cystatin C and Beyond
Greg Knoll, MD, MSC

8:00 AM Discussion

Sunrise Symposium II: The Rise and Fall of Living Donor Liver Transplantation
Ballroom A
Chairs: Kim Olthoff, MD, and R. Mark Ghobrial, MD, PhD

7:00 AM Why are LDLT Numbers Falling?
Elizabeth Pomfret, MD, PhD, FACS

7:25 AM Primum Non Nocere
Charlie Miller, MD

7:50 AM View of LDLT from the World’s Most Active Center
Sheung-Tat Fan, MD, PhD

Sunrise Symposium III: Immune Monitoring Moves to the Clinic: Markers of Rejection and Tolerance
Ballroom B
Chairs: Elaine Reed, PhD, and Robert Fairchild, PhD

7:00 AM Assays of Alloreactivity and Peripheral Cell Function Provide a Noninvasive Method for Identifying Risk of Rejection
Roslyn Mannon, MD

7:25 AM mRNA Expression Patterns Predictive of Allograft Status and Outcome
Manikkam Suthanthiran, MD

7:50 AM A Molecular Signature of Tolerance
Minnie Sarwal, MD

Sunrise Symposium IV: SRTR Risk-Adjustment: What Does It Mean For My Transplant Program?
Room 210
Chairs: Carl Berg, MD, and Robert Merion, MD

7:00 AM Understanding the SRTR Program-Specific Reports: Computing Observed and Expected Survival
Greg Levine, BA

7:25 AM Utilization of SRTR Reporting by the MPSC: What Happens if My Results Trigger a Review?
James Wynn, MD

7:50 AM Transplant Program Under Review: A Case Study and Tool Kit
Janie Morrison, BHS

Sunrise Symposium V: (Beyond T Cell Tolerance) Is Targeting Naive T Cells Enough to Induce Tolerance?
Ballroom C
Chairs: Joren Madsen MD, D.Phil, and Robert Colvin, MD

7:00 AM NK Cells, Graft Injury in the Presence of Tolerance
Xian Li MD, PhD

7:25 AM Eliminating Memory T Cells
Tatsuo Kawai, MD

7:50 AM Targeting B cells
Ali Naj, MD

Sunrise Symposium VI: Incentives for Organ Donation
Room 312
Chairs: Barbara Murphy, MD, and Arthur Matas, MD

7:00 AM Istanbul Document and Incentives for Organ Donation
Francis Delmonico, MD

7:20 AM Legal Ramifications of NOTA
Jack Daly, MD
Government Sponsored Health Insurance for Living Donors
John Roberts, MD

Discussion

Early Morning Workshops
7:00 AM – 8:15 AM

1. Quality of Life After Patient and Liver Graft Survival
   Sammy Saab, MD, MPH, AGAF
   C. Wright Pinson, MBA, MD
   Room 305

2. Aggressive Strategies to Increase Living Donor Kidney Transplantation
   Andrew Posselt, MD
   Bertram Kasiske, MD
   Room 308

3. Can You Assess Transplant Tolerance?
   James Mathew, PhD
   Sophie Brouard, PhD
   Room 301

4. mTor Inhibitors: Where is the Niche in Kidney Transplant?
   William M. Bennett, MD
   Jeremy Chapman, MD
   Room 103

5. Cardiac Allograft Vasculopathy: New Insights and Therapeutic Approaches
   David Briscoe, MD, MB, BCH
   Howard Eisen, MD
   Room 303

6. Do Chronic Kidney Disease Guidelines Apply to Renal Transplant Recipients?
   Bryan Becker, MD
   Aleksandra Kukla, MD
   Room 105

7. Infection in Transplantation: Resistant Organisms, Common Problems, Practical Approaches
   Andre Kalil, MD
   Emily Blumberg, MD
   Room 104

8. Non-adherence and Transition of Care for Pediatric Solid Organ Transplant Recipients
   Sharon Bartosh, MD
   Lorraine Bell, MD
   Room 109

9. Personalized Medicine in Transplantation
   Ron Shapiro, MD
   Patricia Birk, MD
   Room 110

10. Cholangiocarcinoma in Liver Transplantation
    Charles Rosen, MD
    Gregory Gores, MD
    Room 111

8:15 AM Break

Plenary Session I
8:30 AM – 10:00 AM

In Vivo Differentiation of Pdx1’CXCR4’ Definitive Endodermal Cells into Insulin Producing Cells Efficiently Correct Hyperglycemia in Diabetic Mice. (Abstract #1)
Sudhanshu P. Raikwar, Nicholas Zavazava. Iowa City, IA.

Early Results from the Clinical Trials in Organ Transplantation (CTOT-01) Trial Identify Noninvasive Markers as Correlates of 6-Month Renal Allograft Pathology. (Abstract #2)

Are HCC Candidates Advantaged in the Liver Allocation System? (Abstract #3)
W. Kenneth Washburn, Erick Edwards, Ann Harper, Richard Freeman. San Antonio, TX; Richmond, VA; Boston, MA.

9:15 AM ASTS Awards
9:30 AM  Primary Outcomes from a Randomized, Phase III Study of Belatacept vs Cyclosporine in Kidney Transplant Recipients (BENEFIT Study). (Abstract #4)

9:45 AM  Impact of Regional and Center Volume Variation in Pancreatic Allograft Utilization as Assessed by the Pancreas Risk Index. (Abstract #5)

State-of-the-Art Address
10:00 AM – 10:30 AM
Auditorium

10:00 AM  RNA in Biology and Disease
Phillip Sharp, PhD

10:30 AM  Break

Concurrent Symposia
11:00 AM – 12:30 PM

Concurrent Symposium I: Multiorgan Transplantation – Worthy Investment?
Ballroom B
Chairs: Alan Leichtman, MD, and John Fung, MD, PhD

This is an audience response system session, supported by Roche Laboratories, Inc.

11:00 AM  Overview
John Fung, MD, PhD

11:20 AM  Combined Heart and Kidney Transplantation
Edward Cole, MD

11:40 AM  Combined Liver and Lung & Combined Heart and Liver Transplantation
Guillermo Torre-Amione, MD, PhD

12:00 NN  Combined Liver and Kidney Transplantation
K. Rajender Reddy, MD

Concurrent Symposium II: Chronic Allograft Rejection and Antibody-Mediated Injury
Auditorium
Chairs: Carl Cardella, MD, and Mark Stegall, MD

11:00 AM  Histopathological and Molecular Phenotypes of Chronic Allograft Damage
Michael Mengel, MD

11:20 AM  Antibody and Vascular Endothelium: Novel Targets Mediating Injury
Elaine Reed, PhD

11:40 AM  Non-HLA Antibodies: Relevance to Kidney Injury
Kathryn Tinckam, MD

12:00 NN  Is there Treatment of Chronic Antibody Mediated Injury
Stanley Jordan, MD

12:20 PM  Panel Discussion

Concurrent Symposium III: Tissue Engineering
Ballroom A
Chair: R. Mark Ghobrial, MD, PhD

11:00 AM  The Emerging Field of Cell Transplantation and Tissue Engineering in Transplantation
P.R. Sanberg, MD

11:30 AM  Modular Tissue Engineering for the Construction of Vascularized Tissues with Multiple Cell Types
Michael Sefton, ScD

12:00 NN  Materials to Control Transplanted Cell Dispersement and Host Immune Cell Trafficking and Activation
D.J. Mooney, MD

Concurrent Symposium IV: Th17: The New Cells on the Block
Room 302/304
Chairs: Mohamed Sayegh, MD, and John Iacomini, PhD

11:00 AM  Reciprocal Relationship Between T-Reg and Th17 Cells
Vijay Kuchroo, DVM, PhD

11:30 AM  Role of T17 in Rejection and Tolerance
Mohamed Sayegh, MD

12:00 NN  Th17 and Autoimmune Disease
David Hafler, MD
Concurrent Symposium V: New UNOS Donor Allocation Policies for Pediatric Transplantation

Ballroom C
Chairs: William Harmon, MD, and Sue McDiarmid, MD

11:00 AM Impact of Share-35 Policy on Pediatric Kidney Allocation
Ruth McDonald, MD

11:20 AM New Allocation Schemes for Pediatric Lung/Heart Transplantation
Stuart Sweet, MD, PhD

11:40 AM New Allocation Schemes for Pediatric Liver and Intestinal Transplantation
Sue McDiarmid, MD

12:00 NN Where Do We Go from Here (and How To Get There)?
William Harmon, MD

12:20 PM Discussion

Concurrent Session 1: Basic: B-Cell/Antibody
2:15 PM – 3:45 PM
Room 310
Chairs: Anita Chong, PhD, and Brian Susskind, PhD

2:15 PM 15th IHIWS Antibody and Chronic Rejection Project – An International Collaborative Study Reinforces Evidence That Donor-Specific Antibodies Post-Transplantation Are Detrimental to Long-Term Success of All Solid Organ Allografts. (Abstract #6)
Miyuki Ozawa, Rene Castro, Matthew Everly, Paul I. Terasaki. Los Angeles, CA.

2:27 PM Long-Term Renal Allograft Survival and Accommodation in Presensitized Nonhuman Primates Via Early Complement Inhibition-Based Therapy. (Abstract #7)
Gang Chen, Song Chen, Junhua Li, Ying Xiang, Shan Zhong, Wanyu Wang, Yuliang Xiong, Hui Guo, Shi Chen. Wuhan, Hubei, China; Kunming, Yunnan, China.

2:39 PM Inhibitory Fc Receptors in Acute and Chronic Allograft Rejection. (Abstract #8)

2:51 PM Identifying an Affinity Threshold That Defines Self-Reactive Antibodies. (Abstract #9)
Freddy Romero, Lorenzo Benatui, John Iacomini. Boston, MA.

3:03 PM CD4 T Cell Help for the Generation of Alloreactive CD8 Memory T Cells Is Dependent upon Antigen Presentation by B Cells. (Abstract #10)
Yue-Harn Ng, Qiang Zeng, Autumn Marlowe, Rosemary Hoffman, Geetha Chalasani. Pittsburgh, PA.

3:15 PM Preformed Alloantibodies Prevent the Induction of Allograft Tolerance by Enhancing Alloreactive T Cell Priming. (Abstract #11)
Audrea M. Troutman, Anita Chong. Chicago, IL.

3:27 PM Rituxamab Inhibits Renal Allograft Rejection in a Mouse Model of Antibody-Mediated Rejection Model. (Abstract #12)
Daisuke Ishii, Joshua M. Rosenblum, Shiro Baba, Robert L. Fairchild. Cleveland, OH; Sagamihara, Kanagawa.

Concurrent Session 2: Clinical Heart Transplantation
2:15 PM – 3:45 PM
Room 306
Chairs: Maryl Johnson, MD, and Arun Singhal, MD

2:15 PM The Impact of Average First Year Heart Rate on Outcomes after Heart Transplantation: Does It Make a Difference? (Abstract #13)
Matt Kawano, Jon Kobashigawa, Jignesh Patel, Krista Kiyosaki, Esther Shao, Allison Ankor, Boris Arbor, Antoine Hage, Michelle Kittleson, Abbas Ardehali. Los Angeles, CA; Los Angeles, CA.
2:27 PM Impact of Ventricular Assist Device as Bridge to Heart Transplantation in the United States. (Abstract #14)

2:39 PM Risk Factors and Incidence of Cancer in Heart Transplant Recipients Reported by UNOS between 1988 and 2006. (Abstract #15)

Krista Kiyosaki, Jon Kobashigawa, Jignesh Patel, Michelle Kittleson, Matt Kawano, Antoine Hage, Abbas Ardehali. Los Angeles, CA.

3:03 PM Alemtuzumab Induction Therapy Allows Lower Intensity Maintenance Immunosuppression after Cardiac Transplantation, but Does Not Result in Improved Renal Outcomes at Six Months. (Abstract #17)
Michael Shullo, Rachelle Zomak, Christian Bermudez, Jay Bhama, Robert Kormos, Yoshi Toyoda, Dennis McNamara, Kenneth McCurry, Jeffrey Teuteberg. Pittsburgh, PA.

3:15 PM Factors Affecting Waitlist Times in Pediatric Heart Transplant Patients. (Abstract #18)
Anne I. Dipchand, Cedric Manlhiot, Paul F. Kantor, Seema Mital, Brian W. McCrindle. Toronto, ON, Canada.

3:27 PM Bacterial and Viral Infections Are Impacted by Different Genetic Polymorphisms – A Multicenter Pediatric Heart Transplant Study. (Abstract #19)

Concurrent Session 3: Donor-Derived Infections and HIV

2:15 PM – 3:45 PM

Ballroom B
Chairs: Staci Fischer, MD, and Michael Morris, MD


J. P. Orlowski, C. E. Alexander, M. G. Ison, J. D. Rosendale, F. L. Chabalewski. Richmond, VA.

2:39 PM HIV-1/HCV Nucleic Acid Testing (NAT) of Organ and Tissue Donors – How To Resolve Donor Specimens with NAT Inhibitors? (Abstract #22)
Claudia Chinchilla, Dem Brucal, James Schellenberg, Thomas Mone, Maria Stadler, Stephanie Collazo, Marek J. Nowicki. Los Angeles, CA.

2:51 PM Early and Unexpected Results in a Multicenter Study of Kidney Transplantation in HIV-Infected Recipients. (Abstract #23)
Peter Stock, Michelle Roland, Douglas Hanto, Scott Johnson, Martha Pavlakis, Jimmy Light, Bure Barin, Dushyantha Jayaweera, Barbara Murphy. San Francisco, CA; Boston, MA; New York, NY; Washington, DC; Rockville, MD; Miami, FL.
3:03 PM  Comparison of Long-Term Outcomes of Kidney Transplantation in HIV Positive Versus HIV Negative Recipients Treated with Similar Immunosuppression: Cyclosporine (CSA) and Sirolimus (SLR). (Abstract #24)
Mysore S. Anil Kumar, Karthik Ranganna, Gregory Malat, Fazle Noor, Jeffrey Jacobson, Muhammad I. Saeed, Arjun M. S. Kumar, Suganthi Soundararajan. Philadelphia, PA.

3:15 PM  The Effect of Hepatitis B Core Antibody Positive Kidneys on Graft and Patient Survival. (Abstract #25)
Rosemary Ouseph, Savitri Appana, Nicole Ferguson, Farida Mostajabi, Mary Eng, Kadiyala V. Ravindra, Joseph F. Buell, Guy N. Brock, Michael R. Marvin. Louisville, KY.

3:27 PM  The Incidence of Post Transplant Antibody Levels (TXPRA) Against Donor Major Histocompatibility Complex (MHC) Antigens and Their Effect on the Outcomes in HIV+ Kidney Recipients. (Abstract #26)
Gregory E. Malat, Mysore S. Anil Kumar, Karthik Ranganna, Suganthi Soundararajan. Philadelphia, PA.

Concurrent Session 4: Kidney Immunosuppression: CNI Minimization - Avoidance Protocols I
2:15 PM – 3:45 PM

Auditorium
Chairs: Matthew Weir, MD, and Alan Wilkinson, MD

2:15 PM  Primary Outcomes from a Randomized, Phase III Study of Belatacept vs Cyclosporine in ECD Kidney Transplants (BENEFIT-EXT Study). (Abstract #27)

2:27 PM  Belatacept Is Associated with Preservation of Renal Function and Structure at 1 Year Compared to Cyclosporine in Extended Criteria Donor (ECD) Kidney Transplant Patients (BENEFIT-EXT Study). (Abstract #28)

2:39 PM  Pre-Transplant Clonal Deletion Allows for HLA Mismatched Renal Transplantation without Maintenance Immunosuppression. (Abstract #29)

2:51 PM  Long-Term Outcomes of Alternative CNI-Based Regimens in Renal Transplantation. (Abstract #30)
Robert S. Woodward, Marc C. Flore, Gerardo Machnicki, Daniel C. Brennan. Durham, NH; St Louis, MO; East Hanover, NJ.

3:03 PM  Tacrolimus Preserves Renal Function Better Than Cyclosporin at 10 Years – Long Term Results of a Randomised Controlled Trial. (Abstract #31)
N. Kumar, R. Manimaran, C. Williams, R. Ravanan. Cardiff, United Kingdom.

3:15 PM  Comparison of Histological Lesions on Ten Year Protocol Biopsies in Kidney Transplant Recipients with or without Cyclosporine. (Abstract #32)
M. Weir, S. Mulgaonkar, T. Pearson, A. Patel, D. Patel, H. Shidban, J. Scandling. Baltimore, MD; Livingston, NJ; Atlanta, GA; Detroit, MI; Nutley, NJ; Los Angeles, CA; Palo Alto, CA.

Concurrent Session 5: Kidney: Complications I
2:15 PM – 3:45 PM
Room 302/304
Chairs: Kevin Abbott, MD, MPH, and Julie Yabu, MD

2:15 PM  Comparable Incidence and Severity of Wound-Healing-Associated Complications in the Presence of MMF or Everolimus Following Renal Transplantation. (Abstract #34)

2:27 PM  Outcomes Associated with Dose Manipulations of Enteric-Coated Mycophenolate Sodium (EC-MPS) vs. Mycophenolate Mofetil (MMF) in Renal Transplantation. (Abstract #35)
Matthew Cooper, Douglas Slakey, Kathleen Deering, Steven Arcona, Erin McCann, Flavia Rasetto, Sander Florman. Baltimore, MD; New Orleans, LA; Oak Brook, IL; East Hanover, NJ; Baltimore, MD.

2:39 PM  Mycophenolate Mofetil Dose Reductions and Discontinuations after Gastrointestinal Complications Are Associated with Graft Failure in Kidney Transplant Recipients. (Abstract #36)
Suphamai Bunnapradist, Uyen Duong, Marcelo Sampaio, Fei Yu. CA.

2:51 PM  Mycophenolate Mofetil Dose Reductions and Discontinuations after Gastrointestinal Complications Are Associated with Graft Failure in Asian American Renal Recipients. (Abstract #37)
Suphamai Bunnapradist, Uyen Duong, Marcelo Sampaio, Chalit Wanthakawikran, Gerardo Machnicki, Fei Yu. CA; NJ.

3:03 PM  The Maximum Tolerated Dose of Mycophenolic Acid (MPA) Is Higher with Enteric-Coated Mycophenolate Sodium (EC-MPS) Compared to Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients: Results of a Randomized, Multicenter Trial. (Abstract #38)
Magdi Shehata.

3:15 PM  African American Ethnicity and Risk of Proteinuria after Conversion to Sirolimus Therapy in Kidney Transplantation. (Abstract #39)
Joshua J. Augustine, Aparna Padiyar, Kenneth A. Bodziak, Mark I. Aeder, James A. Schulak, Donald E. Hricik. Cleveland, OH.

3:27 PM  Excellent Outcomes in Renal Transplant Recipients Switching to Rapamycin Due to Chronic Allograft Dysfunction with Low Proteinuria. (Abstract #40)
Maria J. Gutierrez, Esther Gonzalez, Amado Andres, Jose M. Morales. Madrid, Spain.

Concurrent Session 6: Liver IRI: Novel Mechanisms
2:15 PM – 3:45 PM
Room 309
Chairs: David Geller, MD, and David Gerber, MD

2:15 PM  Alleviation of Ischemia-Reperfusion Injury in Aged Mice Livers by Knocking-Down C3 and C5aR Genes. (Abstract #41)
Concurrent Session 7: Liver: Complications, Recurrent Disease, and Hepatitis I

2:15 PM – 3:45 PM

Ballroom A
Chairs: Robin Kim, MD, and Steve Rudich, MD, PhD

2:15 PM  Weaning of HBV Prophylaxis after Liver Transplantation: Preliminary Results in Patients with Undetectable cccDNA in Liver Tissue. (Abstract #48)
Giuseppe Tisone, Ilaria Lenci, C. F. Perno, Luca Toti, Tommaso Maria Manzia, Daniele Sforza, Leonardo Baiocchi, Irene Bellini, Daniele Di Paolo, Mario Angelico.

2:27 PM  Adoptive Immunotherapy with Liver Allograft-Derived NK/NKT Cells: A New Paradigm for Inducing Anti-HCV Response after Liver Transplantation. (Abstract #49)

2:39 PM  Hepatitis C+ Liver Grafts Might Be the Most Equitable Solution for Retransplantation in Hepatitis C Infected Recipients: An Analysis of 13+ Years of OPTN Data. (Abstract #50)

2:51 PM  Liver Transplantation Using HCV Positive Donor Allografts: A Case Controlled Analysis of the UNOS Database. (Abstract #51)
Shimul A. Shah, YouFu Li, Anand Singla, Adel Bozorgzadeh. Worcester, MA.

3:03 PM  Hepatitis C (HCV)-3 Study: Decreased Incidence of Severe HCV Recurrence (R) Post Liver Transplantation (OLT) in Patients (Pt) Treated with Mycophenolate Mofetil (MMF), Particularly, in the Absence of Steroids (Pred). (Abstract #52)
Goran B. Klintmalm, Carlos G. Fasola, Linda Jennings, Hepatitis C Three Group.

2:15 PM  Role of Interferon Regulatory Factor-1 (IRF-1) in Transplant Induced Liver Ischemia-Reperfusion Injury. (Abstract #42)

2:39 PM  Bone Marrow-Derived Macrophages Genetically Modified Ex-Vivo To Produce HO-1 Reduce Liver Ischemia/Reperfusion Injury. (Abstract #43)
Bibo Ke, Xiu-Da Shen, Feng Gao, Haofeng Ji, Bo Qiao, Yuan Zhai, Ronald W. Busuttil, Douglas G. Farmer. Los Angeles, CA.

2:51 PM  CD154, but Not IFN-γ, Is Critical for CD4 T Cell-Mediated Tissue Inflammation/Injury in Alloantigen-Sensitized Recipients. (Abstract #44)
Xiuda Shen, Feng Reng, Feng Gao, Ronald W. Busuttil, Yuan Zhai. Los Angeles, CA.

3:03 PM  Activation of PD-1 Negative T Cell Co-Stimulation Prevents Local Inflammation Response and Protects Livers from Ischemia and Reperfusion Injury. (Abstract #45)
Haofeng Ji, Xiua-Da Shen, Feng Gao, Coney Lee, Ronald W. Busuttil, Yuan Zhai. Los Angeles, CA.

3:15 PM  Regulated Hepatic Reperfusion Attenuates Post-Reperfusion Syndrome and Improves Survival after Prolonged Warm Ischemia in a Swine Model. (Abstract #46)

3:27 PM  Macrosestasosis Are Associate with Hepatocellular Necrosis in Ischemia and Reperfusion Injury after Human Liver Transplant. (Abstract #47)
Huda M. Noujaim, Vera L. Capellozzi, Edna F. S. Montero, Cristiane M. F. Ribeiro, Lilian Curvello, Regina Santos, Fabio Crescentini, Marcelo P. de Miranda, Tercio Genzini. Sao Paulo, Brazil.

3:27 PM Genotype 2/3, Cyclosporine Use, Lower Inflammatory Grade and Younger Donor Age Predict Sustained Virological Response to Antiviral Therapy for Recurrent Hepatitis C Following Liver Transplantation. (Abstract #54) Leslie B. Lilly, Nazia Selzner, Eberhard L. Renner, Markus Selzner, Oyedele Adeyi, Arash Kashfi, George Therapondos, Nigel Girgrah, Gary A. Levy. Toronto, ON, Canada; New Orleans, LA.

Concurrent Session 8: Metabolic Complications
2:15 PM – 3:45 PM

Room 206
Chairs: Herwig-Ulf Meier-Kriesche, MD, and Jeff Zaltzman, MD, FRCP(C)


2:27 PM Association between Body Mass Index (BMI) All Cause Mortality, Renal and Cardiac Endpoints in Renal Transplant Recipients in the Alert Extension Study. (Abstract #56) Sadollah Abedini, Alan Jardine, Bengt Fellstrom, Hallvard Holdaas. Oslo, Norway; Glasgow, United Kingdom; Uppsala, Sweden.


2:51 PM HbA1c, but Not Fasting Glucose or Insulin, Is Independently Associated with Early Pathophysiological Parameters Indicative of Worsening Glycemic Metabolism Post-Transplantation – A Multivariate Analysis. (Abstract #58) Adnan Sharif, Vinod Ravindran, Richard Moore, Gareth Dunseath, Steve Luzio, David Owens, Keshwar Baboolal. Birmingham, United Kingdom; Cardiff, United Kingdom; Penarth, United Kingdom.

3:03 PM New Onset Diabetes Mellitus in Kidney Transplant Recipients Receiving De Novo Steroid Free Maintenance Immunosuppression. (Abstract #59) Fu Lung Luan, Diane Steffick, Ojo O. Akinlolu. Ann Arbor, MI.

3:15 PM Influence of Rosuvastatin on Attenuation of the Metabolic Syndrome in Non-Diabetic Renal Transplant Recipients. (Abstract #60) Adnan Sharif, Vinod Ravindran, Richard Moore, Steve Luzio, Gareth Dunseath, David Owens, Keshwar Baboolal. Birmingham, United Kingdom; Cardiff, United Kingdom; Penarth, United Kingdom.

3:27 PM TCF7L2 Polymorphism Is an Independent Risk Factor for New Onset Diabetes Mellitus after Transplantation: A Cohort Study on 1229 Renal Transplant Patients. (Abstract #61) Lidia Ghisdal, Christophe Baron, Yvon Lebranchu, Yannick Le Meur, Jean-Philippe Rerolle, Arnaud Lionet, Francois Glowacki, Karl Martin Wissing, Daniel Abramowicz, Marc Abramowicz. Brussels, Belgium; Tours, France; Limoges, France; Lille, France; Brussels, Belgium.
Concurrent Session 9: Modulating Acute Rejection - Basic Mechanisms
2:15 PM – 3:45 PM

Room 311
Chairs: Ginny Bumgardner, MD, PhD, and Jonathan Maltzman, MD, PhD

2:15 PM  Anti-C5 mAb Plus Low Dose CTLA4 Ig Inhibit Alloreactive T Cells and Prolong Heart Graft Survival in Mice. (Abstract #62)
Staci A. Leisman, Russell Rother, Jeffrey Hunter, Krista Johnson, Peter S. Heeger. New York, NY; Cheshire, CT.

2:27 PM  Role of T Cells in Promoting Rejection of Renal Allografts during Mixed Antibody Mediated Rejection. (Abstract #63)

2:39 PM  Anti-Lymphocyte Function-Associated Antigen-1 (LFA-1) Monoclonal Antibody Prevents Graft-Infiltrating CD8 Memory Cells Early Post-Transplant. (Abstract #64)
Kiyoshi Setoguchi, Austin D. Schenk, Daisuke Ishii, Kazunari Tanabe, Robert L. Fairchild. Cleveland, OH; Tokyo, Japan.

2:51 PM  Naive and Memory CD4 T Cells Undergo Rapid Extensive Homeostatic Proliferation Following T-Cell Depletion. (Abstract #65)
Alp Sener, Anita L. Tang, Donna L. Farber. Baltimore, MD.

3:03 PM  Prevention of Allograft Rejection in Wild-Type Mice by Amplifying Suppressive Activity of Allospecific Foxp3+CD4+CD25+ Regulatory T (Treg) Cells. (Abstract #66)
Guliang Xia, Jie He, Joseph R. Leventhal. Chicago, IL.

3:15 PM  Emergency Granulopoiesis Prevents Lung Allograft Acceptance. (Abstract #67)
Wenjun Li, Seichiro Sugimoto, Jihong Zhu, Alexander S. Krupnick, Daniel Kreisel, Andrew E. Gelman. Saint Louis, MO.

3:27 PM  Targeting the NK Cell Cytotoxicity Receptor Nkp46 Delays Acute Graft Rejection in a Murine Model of Heart Transplantation. (Abstract #68)
Cam-Tien Le, Katrin Klippert, Diana Stauch, Michael Rothe, Katja Kotsch. Berlin, Germany.

Concurrent Session 10: Morphological Phenotypes of Chronic Renal Allograft Injury
2:15 PM – 3:45 PM

Room 210
Chairs: Michael Fischereder, MD, and Michael Mengel, MD

Lynn D. Cornell, Walter K. Kremers, Mark D. Stegall, James M. Gloor. Rochester, MN.

2:27 PM  Clustering Methods Used in the DeKAF Study. (Abstract #70)

2:39 PM  Cluster Analysis Determination of Pathological Entities in Deterioration of Kidney Allograft Function (DeKAF). (Abstract #71)

2:51 PM  A “Movie” Is Worth 100 Words: Histopathologic Parameters Associated with Chronic Allograft Injury in 632 Serial Kidney Allograft Biopsies. (Abstract #72)
Jesse L. Lloyd, Julio Pascual, Arjang Djamali, Luis Fernandez, Drew Roenneburg, Jon Odorico, Hans Sollinger, John Pirsch, Milagros Samaniego, Jose Torrealba. Madison, WI; Madrid, Spain; Madison, WI.
Concurrent Session 11: Novel Immune Monitoring Strategies

2:15 PM – 3:45 PM

Room 312
Chairs: Paul Keown, MD, DSc, MBA, and Teun Van Gelder, MD

2:15 PM Reconstitution of Peripheral Blood B-Cells after Rituximab Treatment of Acute Renal Transplant Rejection in Pediatric Patients. (Abstract #76)
Valeriya Zarkhin, Patricia Lovelace, Li Li, David Hirschberg, Minnie Sarwal.


2:39 PM Macrophage Gene Expression Is Skewed toward M1 Polarization in Acute Rejection Following Human Lung Transplantation. (Abstract #78)

2:51 PM New Parameters for Monitoring Long-Term Function after Renal Transplantation. (Abstract #79)
Dietmar K. Abdendroth, Michael Marzinzig, Juergen Kaden. Ulm, Germany; Berlin, Germany.

3:03 PM Messenger RNA for CTLA-4 in the Urine of Renal-Allograft Recipients. (Abstract #80)

3:15 PM B-Cell Antigen Presentation Is Significantly Decreased among Rejection-Free Pediatric Transplant Recipients. (Abstract #81)
Chethan Ashokkumar, Ankit Gupta, Mylarappar Ningappa, Qing Sun, Sara Snyder, George Mazariégos, Kyle Soltys, Geoff Bond, Rakesh Sindhi. Pittsburgh, PA.

3:27 PM Cellular Allo-Reactivity Against Paternal HLA (pHLA) Antigens (Ags) in Multiparous Normal Females (NF) as Detected by Intracellular Cytokine Flow Cytometry (CFC) Remains Elevated over Years Despite Diminution of Anti-HLA Antibody (AB) Levels, Suggesting allo-Ag Specific Memory Cell Activity. (Abstract #82)
Mieko Toyoda, Shili Ge, Andy Pao, Chih-Hung Lai, Ashely Vo, Qi Wang, Pavel Pichurin, Geraldine Ong, Nathan Deer, Kai Cao, Angela Aguiluz, Artur Karasyov, Nancy Reinsmoen, Stanley C. Jordan. Los Angeles, CA.

Concurrent Session 12: Pancreas Transplantation I

2:15 PM – 3:45 PM

Ballroom C
Chairs: Jonathan Fridell, MD, and Raja Kandaswamy, MD, FACS

2:15 PM Pancreas Transplantation Outcomes from Donation after Cardiac Death Donors. (Abstract #83)
David L. Scott, Stephen C. Rayhill, John M. Ham, Jordana Gaumond. Portland, OR.
**Pancreas Transplantation Using Expanded Criteria Donors.**
(Abstract #84)
Anand Sivaprakash Rathnasamy
Muthusamy, Nancy H. Suh, Jens G. Brockmann, Sanjay Sinha, ANIL

**Should Pancreas after Kidney Transplant Recipients Be Continued on Steroid-Free Maintenance Immunosuppression?** (Abstract #85)
M. Hill, T. Jie, A. Rezcallah, J. Aerts, T. Dunn, K. Gillingham, R. Kandaswamy,
D. Sutherland, Abhinav Humar. Minneapolis, MN.

**Use of Histidine-Tryptophan-Ketoglutarate for Pancreas Allograft Preservation Is Not Cost Effective Resource Utilization.** (Abstract #86)
Zoe A. Stewart, Andrew M. Cameron, Nabil N. Dagher, Andrew L. Singer,
Robert A. Montgomery, Dorry L. Segev. Baltimore, MD.

**A Randomized, Prospective Trial of Alemtuzumab Versus Rabbit Anti-Thymocyte Globulin Induction in Kidney-Pancreas Transplantation: A Single Center Experience.** (Abstract #87)
Rajinder Singh, Alan Farney, Jeffrey Rogers, William Doares, Erica
Hartmann, Amber Reeves-Daniel, Michael Gautreaux, Samy Iskandar,
Patricia Adams, Robert Stratta. Winston-Salem, NC.

**Lower Rate of Acute Rejection with Rapamycin vs. Mycophenolate Mofetil in Simultaneous Pancreas-Kidney Transplant Recipients: 8-Year Follow-Up.** (Abstract #88)
George W. Burke, Gaetano Ciancio,
Jeffrey J. Gaynor, Junichiro Sageshima,
Linda Chen, Anne Rosen, David Roth,
Warren Kupin, Joshua Miller. Miami, FL; Chicago, IL.

**Effects of Kidney and Kidney Pancreas Transplantation on Diabetic Enteropathy in Type 1 Diabetic Patients with End Stage Renal Disease: A 4 Years Longitudinal Study.** (Abstract #89)
Alessio Mocci, Elena Orsenigo,
Valentina Tomajer, Andrea Vergani,
Chiara Gremizzi, Rossana Caldara,
Carlo Staudacher, Paolo Fiorina,
Antonio Secchi. Milan, Italy.

**Kidney Transplantation from Pediatric Donors after Cardiac Death (DCD): 25 Year Experience in the Netherlands.** (Abstract #90)
Eva E. de Vries, Maarten G. Snoeijis,
Ernest van Heurn. Maastricht, Netherlands.

**Untapped Resources: The Spectrum of Quality among Pediatric Donor Kidneys in the US.** (Abstract #91)
Joseph F. Magliocca, Jesse D. Schold,
Shiro Fujita, Robin D. Kim, Alan W.
Hemming, Liise K. Kayler. Gainesville, FL.

**Transplanting Single Kidneys from Donors under 5 Years of Age into Standard Adult Recipients: Can We Achieve Optimal Outcomes?** (Abstract #92)
V. P. Balachandran, M. J. Aull, M.
Goris, J. M. Figueiro, D. B. Leeser,

**One OPO’s 12 Year Experience with Uncontrolled DCD Donation.** (Abstract #93)
Richard D. Hazs, Jr., Howard M.
Nathan, Peter L. Abt, David J. Reich,
John M. Edwards, Sharon M. West,
Michael J. Moritz. Philadelphia, PA.

**The U.S. Experience in DCD Transplants.** (Abstract #94)
Wida Cherikh, Shandie Covington,
Charlotte Carroll, Simon Horslen,
Stuart Sweet. Richmond, VA; Seattle, WA; St. Louis, MO.
3:15 PM  Cold Ischemia Time of More Than 20 Hours and Incision to Perfusion Time of More Than 7 Minutes Increase DGF Rate in DCD Kidneys. (Abstract #95)
Erik Schadde, Ami Koelliker, Stan Mitchell, Lori Markham, Jeffrey Reese, Richard Gilroy, Mark Wakefield, Dan Murillo, John Smith, Paul Nelson. Wichita, KS; Columbia, MO; Kansas City, MO; Westwood, KS; Kansas City, KS.

3:27 PM  Does Choice of Induction Immunosupression Matter in DCD Transplantation? (Abstract #96)
Jagbir Gill, Yong Cho, John Gill, David Landsberg, Marcelo Sampaio, Tariq Shah. Vancouver, BC, Canada; LA, CA.

3:45 pm  Break

Concurrent Session 14: Acute Kidney Rejection: Clinical
4:00 PM – 5:30 PM

4:00 PM  Late Increase in Subclinical Rejection Episodes in Patients Treated with Alemtuzumab Induction and Steroid-Free Immunosuppression. (Abstract #97)
Brian Cabral, Amna Daud, Lorenzo Gallon, Bing Ho, Joseph R. Leventhal, Xunrong Luo, Nedjema Reodica, John J. Friedewald. Chicago, IL.

4:12 PM  The CLEAR Study: A Prospective, Randomized, Controlled, Open-Label, Multicentre 6-Month Study Comparing the Efficacy and Safety of a 5-Day 3-g Daily Mycophenolate Mofetil (MMF) Loading Dose Versus Standard 2-g MMF Daily Dosing in Renal Allograft Transplant Recipients. (Abstract #98)
Sita Gourishankar, Isabelle Houde, Paul Keown, Michelle Wrobel, Bryce Kiberd. Edmonton, AB, Canada; Québec City; QC, Canada; Vancouver, BC, Canada; Mississauga, ON, Canada; Halifax, NS, Canada.

4:24 PM  EC-MPS Is Associated with Superior Efficacy Outcomes Compared to MMF in De Novo Kidney Transplant Patients: A Pooled Analysis. (Abstract #99)
M. Salvadori, K. Budde, H. Holzer, W. Arns, G. Civati, B. Lien. Italy; Germany; Austria; Germany; Italy; Norway.

4:36 PM  Renal Benefit of Belatacept vs Cyclosporine in Kidney Transplant Patients Is Not Impacted by Acute Rejection (BENEFIT Study). (Abstract #100)

Shilomo J. Cohney, Shaun Flint, Peter Hughes, Rosemary Masterson, Michael Haeusler, Chris Hogan. Parkville, Victoria, Australia.

5:00 PM  The Complex Relationships between Anti-HLA Antibodies (AB) and Acute Cellular Rejection (ACR). (Abstract #102)
Fernando G. Cosio, Donna L. Lager, Hatem Amer, Irfan Kundi, Elizabeth Lorenz, James M. Gloor, Mark D. Stegall. Rochester, MN.

5:12 PM  Rejection Characteristics of 200 Living Donor Kidney Transplants Using Alemtuzumab Induction and Tacrolimus Monotherapy: 4 Year Follow-Up. (Abstract #103)
Concurrent Session 15: Donor/Recipient Factors and SCDs
4:00 PM – 5:30 PM

Room 210
Chairs: Michael Moritz, MD, and Robert Stratta, MD

4:00 PM  Donor Hypertension Is the Most Important Pretransplant Factor Predicting Graft Loss in Kidney Transplantation from Donation after Brain Death Standard Criteria Donors. (Abstract #109)
Rajinder Singh, Alan Farney, Jeffrey Rogers, Michael Gautreaux, Amber Reeves-Daniel, Erica Hartmann, Samy Iskandar, Patricia Adams, Robert Stratta. Winston-Salem, NC.

4:12 PM  Donor and Recipient Gender Interactions Significantly Impact Kidney Transplant Outcome. (Abstract #104)

4:24 PM  Kidney and Recipient Weight Incompatibility: A Cause of Early Proteinuria and Reduced Long-Term Graft Survival. (Abstract #105)
Magali Giral, Yohann Foucher, Yann Labrune, Georges Karam, Michele Kessler, Bruno Huraudt le Digny, Matthias Büchler, Francois Bayle, Carole Meyer, Pascal Daguin, Jean Paul Souillou. Nantes, France; Nancy, France; Caen, France; Tours, France; Grenoble, France; Strasbourg, France.

4:36 PM  New Additions to the Donor Pool Do Not Benefit Young Kidney Recipients. (Abstract #106)
Edip Akpinar. Miami, FL.

4:48 PM  Charlson Comorbidity Index Predicts Patient Survival Independent of Age Following Deceased Donor Renal Transplantation. (Abstract #107)

5:12 PM  Excellent Results Transplanting Kidneys from Donors with Acute Renal Failure. (Abstract #108)

5:12 PM  Mitochondrial Membrane Potential as a Predictor of Post-Transplant Renal Graft Function. (Abstract #110)

Concurrent Session 16: Histocompatibility and Immunogenetics
4:00 PM – 5:30 PM

Room 310
Chairs: Howard Gebel, PhD, and Nancy Reinsmoen, PhD

4:00 PM  Report from a Kidney Paired Donation Centralized Lab Representing over 70 Transplant Programs and Performing 325 Crossmatches Resulting in 30 Transplants. (Abstract #111)
Annette R. Blair, Connie I. Smith, Laurie Reece, Amy Miller, Julie Melendez, Michael A. Rees. Toledo, OH.

4:12 PM  Circulating Anti-Class II Predicts the Inflammatory Burden in Renal Transplant Biopsies. (Abstract #112)
Luis G. Hidalgo, Patricia M. Campbell, Phil F. Halloran. Edmonton, AB, Canada.

4:24 PM  Why Can Sensitization by a HLA-DR2 Mismatch Lead to Antibodies That React Also with HLA-DR1? (Abstract #113)
Rene J. Duquesnoy, Marilyn Marrari. Pittsburgh, PA.
4:36 PM  
Pre-Transplant Autoantibodies Predispose to Chronic Human Lung Allograft Rejection (BOS) by Inducing Primary Graft Dysfunction (PGD) and Alloimmunity. (Abstract #114)  

4:48 PM  
Low Expressing IL-10 Genotypes (IL10-592 AA and IL10-819 TT) Are Strongly Associated with Histological Scores Characteristic of Chronic Allograft Failure. (Abstract #115)  

5:00 PM  
Conferral of Resistance Against Alloreactive Cytotoxicity to Primary Human Hematopoietic Progenitor Cells by siRNA Interference of HLA Class I Expression. (Abstract #116)  
James C. Cicciarelli, Nathan A. Lemp, Kazunori Haga, Kathryn Houston, Cecil Rhodes, Suhad Musa, Amy Lin, Katrin Hacke, Christopher R. Logg, Emmanuelle Faure-Kumar, Robert Mendez, Tariq Shah, Carol A. Kruse, Noriyuki Kasahara. Los Angeles, CA; La Jolla, CA.

5:12 PM  


Concurrent Session 18: Kidney: Complications II
4:00 PM – 5:30 PM
Room 302/304
Chairs: Sameh Abul-Ezz, MD, DrPH, and Marco Covarrubias Velasco, MD


5:00 PM Selective Use of Bilateral Native Nephrectomy in Renal Transplant Candidates & Recipients with Autosomal Dominant Polycystic Kidney Disease. (Abstract #130) David J. Rea, Patrick G. Dean, George K. Chow, Mark D. Stegall, Mikel Prieto. Rochester, MN.

5:12 PM Coronary Angiography as the Initial Diagnostic Test for Coronary Artery Disease in Diabetic Patients Being Evaluated for Renal Transplantation. (Abstract #131) Benjamin Tillinger, Miret Habashy- Ibrahim, Fawaz Allhumaid, Beth Bouthot, Sherif Labib, Richard Nesto. Burlington, MA.
Concurrent Session 19: Liver: Immunosuppression and Renal Function
4:00 PM – 5:30 PM

Ballroom C
Chairs: Elmahdi Elkhammas, MBBS, FACS, and Michael Zimmerman, MD

4:00 PM  Efficacy of Mycophenolate Mofetil/Sirolimus Maintenance Therapy after CNI Withdrawal in Liver Transplant Recipients: 1-Year Outcomes of the Spare-the-Nephron (STN) Trial. (Abstract #132)

4:12 PM  Everolimus Is Effective and Safe in Maintenance Liver Transplant Patients: Results of a Multicenter Randomized Conversion Study. (Abstract #133)
Paolo De Simone, Frederic Nevens, Harald Metselaar, Martina Sterneck, Jerome Dumortier, Lionel Rostaing, Emiliano Giostra, Evaristo Varo. Pisa, Italy.

4:24 PM  Converting Existing Patients to a Sirolimus Based Calcineurin Inhibitor Free Immunosuppression in Liver Transplant: It Can Be Done Safely. (Abstract #134)

4:36 PM  Outcomes and Characteristics of Liver Transplant Recipients Administered Sirolimus from Time of Discharge: An Analysis of the UNOS Database. (Abstract #135)
James F. Trotter, John Roberts, Mark Ghobrial, Gordon R. Ingle, Chris Freise, Jasmine Mathias, Igal Kam, Steve Arcona, William Irish. Aurora, CO; San Francisco, CA; Houston, TX; East Hanover, NJ; Durham, NC.

4:48 PM  The Influence of Induction Therapy on Patient Survival after Liver Transplantation as a Function of Baseline Renal Function. (Abstract #136)
Dilip K. Moonka, Alissa Kapke. Detroit, MI.

5:00 PM  Longterm Outcome of Liver Transplant Recipients with Poor Renal Function Treated with Induction Therapy by Basiliximab. (Abstract #137)
Fauouz Saliba, Valerie Delvart, Philippe Ichai, Marie Kouassi, Teresa Maria Antonini, Denis Castaign, Didier Samuel. Villejuif, France.

5:12 PM  Outcomes of Simultaneous Liver/Kidney (SLK) Transplants Are Equivalent to Kidney Transplant Alone (KTA): A Review of 1300 Recipients. (Abstract #138)
Steven Hanish, Milagros Samaniego, Joshua Mezrich, David Foley, Glen Levers on, David Lorentzen, Stuart Knechtle, Hans Sollinger, John Pirsch, Anthony D’Alessandro, Luis Fernandez. Madison, WI.

Concurrent Session 20: Living Donors and Partial Grafts I
4:00 PM – 5:30 PM

Ballroom A
Chairs: Elizabeth Pomfret, MD, PhD, and James Trotter, MD

4:00 PM  Laparoscopy-Assisted and Open Live Liver Donation: A Comparison of Outcomes and Cost. (Abstract #139)

4:12 PM  Portal Pressure Control Can Improve Survivals in Adult-to-Adult Living Donor Liver Transplant (A-LDLT), Even with Smaller Grafts Than before. (Abstract #140)
4:24 PM  Liver Regeneration in Donors and Recipients in the Adult-to-Adult Living Donor Liver Transplant Cohort Study (A2ALL). (Abstract #141)

4:36 PM  Population Based Comparison of Right Lobe Donor Hepatectomy with Elective Right Hepatectomy for Other Causes in New York from 2001-2006. (Abstract #142)

4:48 PM  Donor Specific B Cell Hyporesponsiveness after ABO Incompatible Living Donor Liver Transplantation. (Abstract #143)

5:00 PM  Excessive Portal Shunting Promotes Endothelin-1 (ET-1) Overexpression and Liver Failure in Small-for-Size Grafts. (Abstract #144)

5:12 PM  A Low Graft vs Body Weight Ratio down to 0.6 Does Not Predict Outcome Following Adult-to-Adult Right Lobe Living Donor Liver Transplantation. (Abstract #145)

4:24 PM  Liver Regeneration in Donors and Recipients in the Adult-to-Adult Living Donor Liver Transplant Cohort Study (A2ALL).

4:36 PM  Population Based Comparison of Right Lobe Donor Hepatectomy with Elective Right Hepatectomy for Other Causes in New York from 2001-2006.

4:48 PM  Donor Specific B Cell Hyporesponsiveness after ABO Incompatible Living Donor Liver Transplantation.

5:00 PM  Excessive Portal Shunting Promotes Endothelin-1 (ET-1) Overexpression and Liver Failure in Small-for-Size Grafts.

5:12 PM  A Low Graft vs Body Weight Ratio down to 0.6 Does Not Predict Outcome Following Adult-to-Adult Right Lobe Living Donor Liver Transplantation.
4:48 PM  
A Non-Human Primate Model for the Characterization of Systemic Inflammatory Changes Related to Brain Death. (Abstract #151)
Juan S. Danobeitia, Jamie M. Sperger, Juan L. Contreras, Matthew S. Hanson, Alice Schwarznau, Luis A. Fernandez.

5:00 PM  
Machine Perfusion vs. Cold Storage in Transplantation of Kidneys from Donors Older Than 65 Years: Results of a Randomized Multicenter Trial. (Abstract #152)

5:12 PM  
A Single Center Experience Using Extracorporeal Support in Donation after Cardiac Death Donors: Improved Outcomes for Renal and Extrarenal Transplantation. (Abstract #150)
Rajinder Singh, Michael Hines, Alan Farney, Jeffrey Rogers, Erica Hartmann, Amber Reeves-Daniel, Michael Gautreaux, David Kiger, Samy Iskandar, Patricia Adams, Robert Stratta. Winston-Salem, NC.

Concurrent Session 22: Novel Methods of Immune Regulation in Islet Transplantation
4:00 PM – 5:30 PM
Room 312

4:00 PM  
Prevention of Acute Islet Graft Rejection by In Vitro Generated CD4+CD25+Foxp3+ Regulatory T Cells. (Abstract #153)
Qing Yang, Kathryn Pothoven, Hong Zhang, Stephen D. Miller, Xunrong Luo.

4:12 PM  
Dendritic Cell Plus IL-2/TGF-β1 Differentiated FOXP3+CD25+CD4+ T Regulatory Cells Are Alloantigen Specific and Protect Islet Allografts with Exquisite H-2 Specificity. (Abstract #154)

4:24 PM  
Generation of Regulatory Lymphocytes by Mesenchymal Stem Cells. (Abstract #155)

4:36 PM  
Mesenchymal Stem Cells as an Immune Modulator in Pancreatic Islet Allograft. (Abstract #156)
Duck Han, Yang Hee Kim, Dong Gyun Lim, Yu Mee Wee, Monica Young Choi, Song Cheol Kim. Seoul, Korea.

4:48 PM  
Co-Transplantation of Syngeneic MSCs Delays Islet Allograft Rejection Generates a Local Immunoprivileged Site. (Abstract #157)
Andrea Augello, Andrea Vergani, Mollie Jurewicz, Shirine Dada, Francesca D’Addio, Alessio Mocci, Mohamed H. Sayegh, Reza Abdi, Paolo Fiorina. Boston, MA.

5:00 PM  
A Novel Clinically Relevant Strategy To Promote Fully Allogeneic Islet Cell Engraftment in NOD Mice. (Abstract #158)
Andrea Vergani, Francesca D’Addio, Mollie Jurewicz, Shirine Dada, Reza Abdi, John Williams, Christian Schuetz, Shaoping Deng, James Markmann, Mohamed H. Sayegh, Paolo Fiorina. Boston; Milan, Italy; Cambridge; Boston.

5:12 PM  
LFA-3-Ig (Alefacept) Prolongs Allograft Survival by Targeting Costimulation Blockade Resistant T Effector Memory Cells in Non-Human Primate Islet Transplantation. (Abstract #159)
Alexandra P. Turner, Timothy Weaver, Raul Badell, Jose Cano, Jose Avila, Pamela Turner, Frank Leopardi, Elizabeth Strobert, Christian P. Larsen, Allan D. Kirk. Atlanta, GA.
Concurrent Session 23: PTLD/Malignancy
4:00 PM – 5:30 PM
Room 206
Chairs: Michael Green, MD, MPH, and Camille Kotton, MD

4:00 PM  High Numbers of FOXP3+ T Cells and Poor Lymphocyte Proliferation Identifies Patients at High Risk of Developing Squamous Cell Cancer after Renal Transplantation. (Abstract #160)

4:12 PM  Association of HLA Polymorphisms with PTLD in Organ Transplant Recipients. (Abstract #161)

4:24 PM  DC Generated from EBV-Seronegative Pediatric Heart Transplant Patients Prime Tr1 (IL-10+) EBV-Specific CD8+ T Cells. (Abstract #162)

4:36 PM  EBV-Negative PTLD: 20 Year Experience in a Large Transplant Center. (Abstract #163)

4:48 PM  This Multicentre, Randomised Study Comparing Conversion from Calcineurin Inhibitors (CNIs) to Sirolimus Versus Standard Therapy in Renal Allograft Recipients Showed a Lower Rate of Development of Subsequent Malignant Disease in the Group Receiving Sirolimus. (Abstract #164)
Keshwar Baboolal, Micheal Zaiac, Aurelia Zamauskaite, Charles Newstead. Cardiff, Wales, United Kingdom; Maidenhead, Berkshire, United Kingdom; Leeds, West Yorkshire, United Kingdom.

5:00 PM  Incidence and Predictors of De Novo Renal Cell Carcinoma after Kidney Transplantation. (Abstract #165)
Lindsey J. Graham, Frank P. Hurst, Rahul M. Jindal, Edward M. Falta, Lawrence Y. Agodoa, Robert T. Neff, Kevin C. Abbott. Washington, DC; Washington, DC; Bethesda, MD.

5:12 PM  Inhibition of mTORC1 Attenuate Uroepithelial Carcinoma and Leads to AKT Activation. (Abstract #166)
Ming-Ju Wu, Chi-Hao Chang, Kuo-Hsiung Shu, Jian-Ri Li. Taichung, Taiwan.

Concurrent Session 24: Small Bowel
4:00 PM – 5:30 PM
Room 306
Chairs: Alan Langnas, DO, and Antonio Pinna, MD

4:00 PM  The Impact of MELD/PELD Modifications on Liver-Intestine Transplant Candidates. (Abstract #167)
Jonathan P. Fryer, Leo Han, Whitney Halgrimson, Eileen DeMayo, Ed Wang, Allan Buchman. Chicago, IL.

4:12 PM  Evolution and Minimization of Immunosuppression in Five Hundred Intestinal and Multivisceral Transplantations at a Single Center. (Abstract #168)
Kareem M. Abu-Elmagd, Guilherme Costa, Geoffrey J. Bond, Kyle Soltys, Rakesh Sindhi, Tong Wu, Noriko Murase, Ruy Cruz, Adriana Zeevi, George Mazariagos. Pittsburgh, PA.
4:24 PM  HLA Haplotype Distribution and Frequency of Panel Reactive Antibodies (PRA) Influencing Graft Outcome and Early Detection of Small Bowel Transplant Rejection. (Abstract #169)

4:36 PM  Outcomes after ABO-Identical and ABO-Comaptive Organ Matching in Intestinal Transplantation. (Abstract #170)

4:48 PM  Single Center Experience with Pediatric Multivisceral Transplantation: Factors Impacting Patient Survival. (Abstract #171)
Eddie R. Island, Seigo Nishida, David Levi, Genarro Selvaggi, Jang Moon, Akin Tekin, Lesley Smith, Andreas Tzakis. Miami, FL.

5:00 PM  Outcomes in Children Following Intestinal Transplant. (Abstract #172)
Oliver B. Lao, Patrick J. Healey, James D. Perkins, Jorge D. Reyes, Adam B. Goldin. Seattle, WA.

5:12 PM  Risk Stratification of Cytomegalovirus Disease in Intestinal Transplantation. (Abstract #173)

Concurrent Session 25: The Status of Desensitization: Outcomes, New Therapies and Immunological Insights
4:00 PM – 5:30 PM

Auditorium
Chairs: Mark Pescovitz, MD, and Milagros Samaniego, MD

4:00 PM  Long-Term (1,3,5,7 & 9 Year) Outcomes in Highly-HLA Sensitized Patients Receiving Desensitization. (Abstract #174)
Alice Peng, Rafael Villicana, Ashley Vo, Stanley Jordan. Los Angeles, CA.

4:12 PM  Monthly Ibandronate Prevents Bone Loss and Fractures after Liver Transplantation (LTX). (Abstract #175)
Daniel Kaemmerer, Gabriele Lehmann, Gunter Wolf, Schmidt Benjamin, Settmacher Utz, Hommann Merten. Bad Berka, Germany; Jena, Germany.

4:24 PM  Induction Immunosuppression in Crossmatch Positive Renal Transplant Recipients: Results of a Randomized Controlled Clinical Trial. (Abstract #176)

4:36 PM  Effect of Proteasome Inhibition on Alloantibody Secreting Cells In Vivo. (Abstract #177)
Tayyab Diwan, Justin Burns, Dana Perry, James Gloor, Manish Gandhi, Mark Stegall. Rochester, MN.

4:48 PM  Prevention of Acute Humoral Rejection with C5 Inhibition. (Abstract #178)
Mark D. Stegall, Tayyab S. Diwan, Justin M. Burns, Patrick G. Dean, Lynn D. Cornell, Manish J. Gandhi, Fernando G. Cosio, James M. Gloor. Rochester, MN.
Concurrent Session 26: Tolerance I: T Regulatory Cells
4:00 PM – 5:30 PM
Room 311
Chairs: Jessamyn Bagley, PhD, and Anne van Buskirk, PhD

4:00 PM Epigenetic Regulation of Foxp3 Expression in Tolerance and Inflammation. (Abstract #181)
Girdhari Lal, Nan Zhang, William van der Touw, Yaozhong Ding, Jonathan S. Bromberg. New York City, NY.

4:12 PM Proprotein Convertase Processing of Foxp3 at Two Discrete RXXR Motifs Generates Functionally Distinct Subpopulations of Regulatory T Cells. (Abstract #182)
Engin Ozkaynak, Edwin F. de Zoeten, Guanghui Ge, Wayne W. Hancock. Philadelphia, PA.

4:24 PM Identification of the Lysines in the Forkhead Domain of Foxp3 Required for Treg Suppressive Functions. (Abstract #183)
Yujie Liu, Engin Ozkaynak, Liqing Wang, Wayne W. Hancock. Philadelphia, PA.

4:36 PM FGL2 Transgenic Mice Accepted Fully-Mismatched Cardiac Allografts without the Need for Immunosuppression. (Abstract #184)
Agata Bartczak, Wei He, Itay Shalev, Michael Mendicino, Yi Zhu, Eric Kaplovitch, Oyedele Adeyi, James Phillips, David Grant, Gary Levy. Toronto, ON, Canada.

4:48 PM Jak3/Stat5a/b Signaling Is Critical for Both Natural (nTreg) and Inducible (iTreg) CD4+CD25+Foxp3+ Regulatory T Cell Function. (Abstract #185)
Mithun Khattar, Wennhao Chen, Stanislaw M. Stepkowski. Toledo, OH.

5:00 PM Strategies To Promote Tolerance through Augmented Treg Homeostasis. (Abstract #186)
Ying Wang, Geoffrey Camirand, Songyan Deng, Monica Froicu, David Rothstein. New Haven, CT; Pittsburgh, PA.

5:12 PM Regulatory T Cell Suppression of Allograft Rejection Does Not Require Secondary Lymphoid Organs. (Abstract #187)
Geoffrey Camirand, David M. Rothstein, Fadi G. Lakkis. Pittsburgh, PA; New Haven, CT.

Poster Session II
5:30 PM – 6:30 PM
Poster Viewing: 8:00 AM – 6:30 PM
Presenters in Attendance: 5:30 PM – 6:30 PM
Exhibit Hall C, Second Floor
John B. Hynes Convention Center
Poster Session II Program can be found on pages 135-152.

Industry – Sponsored Event
6:30 PM – 9:30 PM
Presented by Astellas and the Creative Coalition
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM – 8:15 AM</td>
<td><strong>Sunrise Symposiums</strong></td>
</tr>
<tr>
<td>Page 92</td>
<td>Sunrise Symposium I: Utility of Virtual Crossmatch in Solid Organ Transplantation – Debate Room 302/304</td>
</tr>
<tr>
<td>Page 92</td>
<td>Sunrise Symposium II: The New Era of Biologic Agents for Immunosuppression Ballroom B</td>
</tr>
<tr>
<td>Page 92</td>
<td>Sunrise Symposium III: Transplant Oversight and Regulatory Issues Ballroom A</td>
</tr>
<tr>
<td>Page 92</td>
<td>Sunrise Symposium IV: Progress in Intestinal Transplantation Ballroom C</td>
</tr>
<tr>
<td>Page 92</td>
<td>Sunrise Symposium V: Xenotransplantation Room 312</td>
</tr>
<tr>
<td>Page 93</td>
<td>Sunrise Symposium VI: Nanomedicine v. 2.0 - Insights from the Frontier of Nanotechnology Room 210</td>
</tr>
<tr>
<td>8:15 AM</td>
<td>Break</td>
</tr>
<tr>
<td>7:00 AM – 8:15 AM</td>
<td><strong>Early Morning Workshops</strong></td>
</tr>
<tr>
<td>Page 93</td>
<td>Plenary Session II Room 313</td>
</tr>
<tr>
<td>8:30 AM – 10:00 AM</td>
<td><strong>Auditorium</strong></td>
</tr>
<tr>
<td>10:00 AM – 10:30 AM</td>
<td><strong>State-of-the-Art Address</strong></td>
</tr>
<tr>
<td>Page 94</td>
<td>Stem Cells and the Molecular Control of Pluripotency for Regenerative Medicine Auditorium</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>Break</td>
</tr>
<tr>
<td>11:00 AM – 12:30 AM</td>
<td><strong>Concurrent Symposia</strong></td>
</tr>
<tr>
<td>Page 94</td>
<td>Concurrent Symposium I: The Future of Liver Transplantation Ballroom B</td>
</tr>
<tr>
<td>12:45 PM – 2:00 PM</td>
<td><strong>Industry-Supported Satellite Symposia</strong></td>
</tr>
<tr>
<td>Page 95</td>
<td>The Metabolic Syndrome in Transplantation: Risk of Cardiovascular Events and Implications for Immunosuppression Ballroom B</td>
</tr>
<tr>
<td>Page 95</td>
<td>New Paradigms in Transplant: Transplantation with no Immunosuppression and HLA Antibody Removal with Bortezomib Room 302/304</td>
</tr>
<tr>
<td>2:15 PM – 3:45 PM</td>
<td><strong>Concurrent Sessions</strong></td>
</tr>
<tr>
<td>Page 95</td>
<td>Concurrent Session 27: Clinical and Basic Science in Heart Transplantation Room 313</td>
</tr>
<tr>
<td>Page 96</td>
<td>Concurrent Session 28: Cytomegalovirus Ballroom B</td>
</tr>
<tr>
<td>Page 97</td>
<td>Concurrent Session 29: Genomics/Proteomics of Acute and Chronic Allograft Injury Room 312</td>
</tr>
<tr>
<td>Page 97</td>
<td>Concurrent Session 30: Improving Outcomes in Pediatric Liver Transplantation Room 208</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 31: Innate Immunity</td>
</tr>
<tr>
<td>------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td></td>
<td>Room 311</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 32: Ischemia Reperfusion: Molecular Aspects</td>
</tr>
<tr>
<td></td>
<td>Room 309</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 33: Kidney Immunosuppression: CNI Minimization - Avoidance Protocols II</td>
</tr>
<tr>
<td></td>
<td>Auditorium</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 34: Liver: Complications, Recurrent Disease, and Hepatitis II</td>
</tr>
<tr>
<td></td>
<td>Ballroom A</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 35: Liver: Donor Issues</td>
</tr>
<tr>
<td></td>
<td>Ballroom C</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 36: New Insights into Treg Biology</td>
</tr>
<tr>
<td></td>
<td>Room 310</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 37: Pancreas Transplantation II</td>
</tr>
<tr>
<td></td>
<td>Room 306</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 38: Performance Measures, Economics, Public Policy, and Allocation</td>
</tr>
<tr>
<td></td>
<td>Room 302/304</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 39: Predictors of Outcome</td>
</tr>
<tr>
<td></td>
<td>Room 206</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 40: Prognostic Phenotypes in Chronic Renal Allograft Injury</td>
</tr>
<tr>
<td></td>
<td>Room 210</td>
</tr>
<tr>
<td>3:45 PM</td>
<td>Break</td>
</tr>
<tr>
<td>4:00 PM – 5:30 PM</td>
<td>Concurrent Sessions</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 41: BK Polyoma Virus I: Immunological Aspects</td>
</tr>
<tr>
<td></td>
<td>Room 210</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 42: Delayed Graft Function</td>
</tr>
<tr>
<td></td>
<td>Ballroom B</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 43: Immune Monitoring: Tolerance and Immune Modulation</td>
</tr>
<tr>
<td></td>
<td>Room 309</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 44: Kidney Induction I</td>
</tr>
<tr>
<td></td>
<td>Auditorium</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 45: Kidney Living Donor Paired Exchange/Donor Chains</td>
</tr>
<tr>
<td></td>
<td>Room 302/304</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 46: Liver Malignancies: Hepatocellular and Cholangiocarcinoma</td>
</tr>
<tr>
<td></td>
<td>Ballroom C</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 47: Living Donors and Partial Grafts II</td>
</tr>
<tr>
<td></td>
<td>Ballroom A</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 48: Lung</td>
</tr>
<tr>
<td></td>
<td>Room 313</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 49: Organ Donation: Economics, Public Policy, and Ethics</td>
</tr>
<tr>
<td></td>
<td>Room 306</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 50: Pathways in Acute Rejection</td>
</tr>
<tr>
<td></td>
<td>Room 310</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 51: Psychosocial and Compliance Issues</td>
</tr>
<tr>
<td></td>
<td>Room 208</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 52: Stem Cell Modulation of Rejection and Alloimmunity</td>
</tr>
<tr>
<td></td>
<td>Room 312</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 53: Tolerance II: (Pre)Clinical/Th17</td>
</tr>
<tr>
<td></td>
<td>Room 311</td>
</tr>
<tr>
<td>Page</td>
<td>Concurrent Session 54: Viral Diseases and Diagnostics</td>
</tr>
<tr>
<td></td>
<td>Room 206</td>
</tr>
</tbody>
</table>
5:30 PM – 6:30 PM  Poster Session III
Presenters in Attendance – Beverages
Exhibit Hall C, Second Floor,
John B. Hynes Convention Center

Page 206  Basic Mechanisms of Acute Rejection II

Page 207  Composite Tissue

Page 207  Desensitization Protocols: Something
New and Something Old

Page 209  ECD, DCD, Preservation

Page 211  Genomics/Proteomics/
Pharmacogenetics

Page 213  Ischemia Reperfusion Injury II

Page 215  Kidney: Chronic Injury - Mechanisms
and Management

Page 218  Kidney: Complications III

Page 219  Kidney: Living Donors - Medical and
Psycho-Social Issues

Page 223  Liver: Complications, Recurrent
Disease, Hepatitis and
Retransplantation II

Page 225  Lung

Page 225  Pancreas Transplantation II

Page 227  Psychosocial and Compliance Issues

Page 227  Strategies in Immune Monitoring

Page 229  Tolerance I: Regulatory Cells

Page 231  Vascular and Interstitial Fibrosis and
Injury

6:00 PM – 7:00 PM  AST Business Meeting
Room 306
Monday, June 1, 2009

Concurrent Sunrise Symposia
7:00 AM – 8:15 AM

Sunrise Symposium I: Utility of Virtual Crossmatch in Solid Organ Transplantation – Debate
Room 302/304
Chairs: Lori West, MD, DPhil, and Andrea Zachary, PhD

This is an audience response system session, supported by Roche Laboratories, Inc.

7:00 AM Presentation #1: Virtual Crossmatch Should be used in Kidney Transplantation
Proponent: Howard Gebel, PhD
Opponent: Ronald Kerman, PhD

7:20 AM Rebuttals
7:25 AM Discussion
7:35 AM Virtual Crossmatch Should be used in Thoracic Transplantation
Proponent: Elaine Reed, PhD
Opponent: David Eckels, PhD

7:55 AM Rebuttals
8:00 AM Discussion

Sunrise Symposium II: The New Era of Biologic Agents for Immunosuppression
Ballroom B
Chairs: Barry Kahan, MD, PhD, and Donald Hricik, MD

7:00 AM A Paradigm Shift for the use of Biologic Agents
Flavio Vincenti, MD

7:15 AM Novel B cell Targets
Mark Pescovitz, MD

7:30 AM Novel T cell Targets and a Role for T cell: B cell Interactions
David Rothstein, MD

7:45 AM Effects of Biologic Agents on Treg Cells
Nader Najafian, MD

8:00 AM Discussion

Sunrise Symposium III: Transplant Oversight and Regulatory Issues
Ballroom A
Chairs: Michael Abecassis, MD, MBA, and James Wynn, MD

7:00 AM UNOS Oversight, Audit and the MPSC
James Wynn, MD

7:25 AM Transplant Center Compliance: Is it Really Required?
Michael Abecassis, MD, MBA

7:50 AM CMS- Transplant Interpretative Guidelines and Survey Results
Thomas Hamilton

Sunrise Symposium IV: Progress in Intestinal Transplantation
Ballroom C
Chairs: Thomas Fishbein, MD, and Douglas Farmer, MD

7:00 AM Intestinal Transplant: Graft Types and How They Impact the Patient and You
Cal Matsumoto, MD

7:25 AM Current Outcomes of Intestinal Transplants
Kareem Abu-Elmagd, MD

7:50 AM Immunology of Intestinal Transplantation
Kenneth Newell, MD, PhD

Sunrise Symposium V: Xenotransplantation
Room 312
Chairs: David Cooper, MD, PhD; Leo Buhler, MD, and Mohammed Mohiuddin, MD

7:00 AM Islet Xenotransplantation—On the Verge of Clinical Trials
Bernhard Hering, MD

7:15 AM Tolerance in Xenotransplantation
David Sachs, MD

7:30 AM Thoracic Xenotransplantation
Richard Pierson, III, MD

7:45 AM Infectious Risks in Xenotransplantation
Jay Fishman, MD

8:00 AM Discussion
**Sunrise Symposium VI: Nanomedicine v. 2.0 - Insights from the Frontier of Nanotechnology**

*Room 210*

**Chairs:** Anthony Jevnikar, MD, and Steven Paraskevas, MD, PhD

7:00 AM **Polysaccharide Structures as Immunologic Tolerogens**  
Todd Lowary, MD

7:25 AM **Nanoparticles for Controlled Targeted Delivery of Drugs, Genes, and Oligonucleotides**  
W. Mark Saltzman, PhD

7:50 AM **Constructing Pseudo-cell Nanofactories to Replace Cell and Organ Function**  
Philip Leduc, MD, PhD

---

**Early Morning Workshops**  
**7:00 AM – 8:15 AM**

11. **Dilemmas in Living Kidney Donor Selection**  
Carlton Young, MD  
Clifton Kew, II, MD  
*Room 305*

12. **Are Islets Ready for Prime Time?**  
Bernhard Hering, MD  
James Shapiro, MD, PhD  
*Room 308*

13. **A Burning Issue: The Pro and Con of a Closed ICU. What Does It Mean for the Transplant Team and Your Patients?**  
Dinesh Ranjan, MD  
Robert Goldstein, MD  
*Room 301*

14. **Induced Progenitor Cells from Skin Cells**  
Markus Frank, MD  
George Murphy, MD  
*Room 103*

15. **Issues in Behavioral Health Service in Your Transplant Program**  
James Rodrigue, PhD  
Alan Reed, MD  
*Room 303*

16. **NK Cells and DC Interactions in Tolerance and Graft Rejection**  
Xian Li, MD, PhD  
Angus Thomson, PhD, DSc  
*Room 104*

17. **Pregnancy After Transplantation**  
Vincent Armenti, MD, PhD  
Veronica Gomez-Lobo, MD  
*Room 105*

18. **Update On the New Kidney Allocation System**  
Peter Stock, MD, PhD  
Kenneth Andreoni, MD  
*Room 109*

19. **Composite Tissue Transplant: Facing the Future**  
Linda Cendales, MD  
Joseph Rosen, MD  
*Room 110*

20. **Emerging Therapies in Hepatitis C Liver Recipients**  
Gregory Everson, MD  
Lisa Forman, MD  
*Room 111*

8:15 AM **Break**

**Plenary Session II**  
**8:30 AM – 10:00 AM**

*Auditorium*

**Chairs:** Joren Madsen, MD, DPhil, and Barbara Murphy, MD

8:30 AM **Role of Circulating BKV-Specific Cytotoxic T Cells in Kidney Recipients with BKV Infection.**  
(Abstract #188)  
Patrizia Comoli, Michela Cioni, Antonella Gurrado, Angelica Parodi, Hans H. Hirsch, Sabrina Basso, Iris Fontana, Giancarlo Barbano, Franco Locatelli, Fabrizio Ginevri. Pavia, Italy; Basel, Switzerland; Genova, Italy.
8:45 AM  ITN029ST: Immunosuppression Withdrawal in Pediatric Recipients of Parental Living Donor Liver Transplants: Preliminary Results of a Pilot Study. (Abstract #189)

9:00 AM  Overcoming IL-17 Producing CD8 T Cell (T17) Mediated Resistance to Tolerance by Targeting the Novel TIM-1 T Cell Differentiation Pathway. (Abstract #190)
Xueli Yuan, M. Javeed Ansari, Francesca D’Addio, Jesus Paez-Cortez, Xiaozhi Zhao, Isabela Schmitt-Knosalla, Michela Donnarumma, Olaf Boenisch, Joyce Popoola, Michael R. Clarkson, Hideo Yagita, Hisaya Akiba, John Iacomini, Laurence A. Turka, Laurie Glimcher, Mohamed H. Sayegh. Boston, MA.

9:15 AM  AST Awards

9:30 AM  Increased Primary Non-Function in Transplanted Deceased-Donor Kidneys Flushed with Histidine-Tryptophan-Ketoglutarate Solution. (Abstract #191)
R. Brian Stevens, Jill Y. Skorupa, Theodore H. Rigley, Govardhana R. Yannam, Kathleen J. Nielsen, Lucile E. Wrenshall. Omaha, NE.

9:45 AM  OPO Viral Nucleic Acid Testing (NAT) and Provider Utilization of High-Risk Donor Organsa: Results of Two National Surveys. (Abstract #192)

State-of-the-Art Address
10:00 AM – 10:30 AM
10:00 AM  Stem Cells and the Molecular Control of Pluripotency for Regenerative Medicine
Rudolf Jaenisch, MD
Auditorium

10:30 AM  Break

Concurrent Symposia
11:00 AM – 12:30 AM

Concurrent Symposium I: The Future of Liver Transplantation
Ballroom B
Chairs: James Trotter, MD, and John Roberts, MD
11:00 AM  Organ Allocation: Is MELD the Last Word?
Russell Wiesner, MD
11:30 AM  Transplantation for Liver Malignancies: Where is the Metro Stopping?
Ronald Busuttil, MD, PhD
12:00 NN  Beyond Hepatitis C: What Diseases Will Need Transplantation?
Gregory Everson, MD

Concurrent Symposium II: Donor-Derived and “High Risk” Infections
Room 302/304
Chairs: Emily Blumberg, MD, and Peter Chin-Hong, MD
11:00 AM  What Are We Missing? What’s Coming?
Jay Fishman, MD
11:20 AM  Redefining Infectious Disease Transmission Risk in Donors
Matthew Kuehnert, MD
11:40 AM  Screening for Chagas, Strongyloides, and Other Parasites
Camille Kotton, MD
12:00 NN  The Donor with Altered Mental Status: Strategies to Enhance Safety
Michael Ison, MD, MS
12:20 PM  Discussion
Concurrent Symposium III: New Insights into Targeting B Cells  
**Ballroom C**  
**Chairs:** Anita Chong, PhD, and Marilia Cascalho, MD, PhD

11:00 AM  **BAFF: A Novel Therapeutic Target in Autoimmunity and Transplantation**  
Michael Cancro, PhD

11:30 AM  **Emerging Role of Regulatory B Cells**  
Thomas Tedder, PhD

12:00 NN  **B Cell Depletion in Clinical Trials in Transplantation: Is It All Good?**  
Robert Montgomery, MD, PhD

Concurrent Symposium IV: Immunomodulation by Mesenchymal Stem Cells  
**Ballroom A**  
**Chairs:** Reza Abdi, MD, and Marcus Frank, MD

11:00 AM  **Characterization and Mechanisms of Action of MSCs**  
Carla Baan, PhD

11:30 AM  **Immunomodulation by MSC and ES-Derived Hematopoietic Progenitor Cells**  
Nicholas Zavazava, MD, PhD

12:00 NN  **Challenges of Developing Cell-based Therapy with MSCs in Humans**  
Reza Abdi, MD

Concurrent Symposium V: Cutting Edge Topics in Transplantation: Regulation of the Immune Response  
**Auditorium**  
**Chairs:** Faddi Lakkis, MD, and Xian Li, MD, PhD

11:00 AM  **The Interaction of Inflammation and Immune Regulation**  
Terry Strom, MD

11:30 AM  **Potential of Regulatory T cells to Control Rejection**  
Kathryn Wood, MD

12:00 NN  **Regulation of Immune Privilege within the Tolerant Allograft**  
Randolph Noelle, PhD

Industry-Supported Satellite Symposia

**12:45 PM – 2:00 PM**

*The Metabolic Syndrome in Transplantation: Risk of Cardiovascular Events and Implications for Immunosuppression*

**Ballroom B**

**New Paradigms in Transplant: Transplantation with No Immunosuppression and HLA Antibody Removal with Bortezomib**

**Room 302/304**

Concurrent Session 27: Clinical and Basic Science in Heart Transplantation

**2:15 PM – 3:45 PM**

**Room 313**  
**Chairs:** Joseph Cleveland, Jr., MD, and David DeNofrio, MD

2:15 PM  **Achieving Therapeutic Levels and Exposure-Efficacy Analysis in De Novo Cardiac Transplant Recipients on Everolimus-Based Immunosuppression. (Abstract #193)**

Francesco Musumeci, Ugolino Livi, Jose Arizon, Marie Françoise Mattei, Massimo Maccherini, Luis Almenar, Juan F. Delgado, Robert Keinloog, Yonas A. Gezahegen, Yulan Li, Hans Lehmkhul. Rome, Italy.

2:27 PM  **Pathophysiologic Significance of Anti-Angiogenesis Factors and the Development of Cardiac Allograft Vasculopathy. (Abstract #194)**

Michael E. Seifert, Michael M. Givertz, Waleed Alhabeeb, Anju Nohria, Maria Stack, James Fang, Ravi Thadhani, Peter Ganz, S. Ananth Karumanchi, David M. Briscoe. Boston, MA.

2:39 PM  **HLA Alloantibodies Are Associated with Increased Inflammatory Transcript Expression in Cardiac Allograft Biopsies, and Related to Decreased Graft Function. (Abstract #195)**

Banu Sis, Daniel Kim, Michael Mengel, Patricia Campbell, Konrad Famulski, Jeffrey Burton, Wayne Tymchak, Philip Halloran. Edmonton, AB, Canada.
2:51 PM  Correlating Microarray Gene Expression Data with Histopathological Lesions in Human Heart Allograft Biopsies. (Abstract #196)

3:03 PM  Transplantation of Donor Specific Antibody Positive, Crossmatch Negative (AHG/FCXM) Cardiac Allograft Recipients. (Abstract #197)
Roberta Bogaev, Joggy George, O. H. Frazier, W. B. Etheridge, Farshad Raissi, Leon Jacob, Biswajit Kar, Reynolds Delgado, Pranav Loyalka, Igor Gregoric, Ronald H. Kerman. Houston, TX.

3:15 PM  Long-Term Survival in Female Heart Transplant Recipients Following Pregnancy. (Abstract #198)
Nicole M. Sifontis, Serban Constantinescu, Lisa A. Coscia, Linda Ohler, Michael J. Moritz, Vincent T. Armenti. Philadelphia, PA; Richmond, VA; Allentown, PA.

3:27 PM  The Value of Preoperative Sequential Organ Failure Assessment Score Compared with Other Prognostic Parameters in Prediction of Early Postoperative Mortality after Implantation of Ventricular Assist Devices. (Abstract #199)

The IMPACT Study: Valganciclovir Prophylaxis for until 200 Days Post-Transplant in High Risk Kidney Recipients Substantially Reduces the Incidence of CMV Disease. (Abstract #201)
Atul Humar, Yvon Lebranchu, Flavio Vincenti, Jeffery Punch, Daniel Abramowicz, Emily Blumberg, Ingeborg Hauser, Ajit Limaye, Jane Ives, Nigel Pluck, Patrick Peeters. Edmonton, AB, Canada; Tours, France; San Francisco, CA; Ann Arbor, MI; Brussels, Belgium; Philadelphia, PA; Germany; Seattle, WA; Welwyn Garden City, United Kingdom; Gent, Belgium.

2:39 PM  Prospective Comparison of Cytomegalovirus-Specific Immunity in Donor Seropositive/Recipient Seronegative Liver Transplant Patients Receiving Preemptive Therapy or Antiviral Prophylaxis. (Abstract #202)
Ajit P. Limaye, Nina Singh, Sam Chatterton-Kirchmeier, Mujalijn Thuntarug, Terry Stevens-Ayers, Michael Boeckh. Seattle, WA; Pittsburgh, PA.

Comparison of Highly Sensitive vs. Standard CMV Viral Load Assays for Monitoring Therapeutic Response. (Abstract #203)

3:03 PM  Ganciclovir Exposure under a 450 mg Daily Dosage of Valganciclovir for the Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients. (Abstract #204)
Oriol Manuel, Manuel Pascual, Nancy Perrottet, Frédéric Lamoth, Jean-Pierre Venetz, Laurent Decosterd, Thierry Buclin, Pascal R. Meylan. Lausanne, Switzerland.
3:15 PM Economic Analysis of Extended Cytomegalovirus Prophylaxis in High Risk Kidney Transplant Patients. (Abstract #205)
Fu Lung Luan, Linda Stucky, Jeong M. Park, Akinlolu Ojo. Ann Arbor, MI.

3:27 PM Blockade of PD1-Ligand Is Associated with Cytokine-Profile Up-Regulation in CMV-Specific T-Cells. (Abstract #206)
Adrian Egli, Jan Dirks, Urban Sester, Martina Sester, Hirsch Hans. Basel, Switzerland; Homburg, Germany.

Concurrent Session 29: Genomics/Proteomics of Acute and Chronic Allograft Injury
2:15 PM – 3:45 PM
Room 312
Chairs: William Oetting, PhD, and Adriana Zeevi, PhD

2:15 PM Tissue Damage, Graft Survival and the Role of a Functional FOXP3 Variant in Kidney Transplant Patients. (Abstract #207)

2:27 PM Overexpression of microRNAs Associated with Tubular Athrophy and Interstitial Fibrosis Post Kidney Transplantation. (Abstract #208)
Amiee Potter, Daniel Maluf, Jihee Suh, Benjamin Whitehill, Kennett Yanek, Robert Fisher, Marc Posner, Anne King, Valeria Mas. Richmond, VA.

2:39 PM Expression of PRAII-Associated Transcripts in Renal Biopsies Correlates with High Risk for Antibody-Mediated Graft Loss. (Abstract #209)
Luis G. Hidalgo, Patricia M. Campbell, Philip F. Halloran.

2:51 PM The Major Molecular Predictor of Graft Loss in Kidney Transplant Biopsies Is the Injury Response, Not Inflammation. (Abstract #210)
G. Einecke, J. Reeve, S. Bunnag, B. Sis, K. S. Famulski, M. Mengel, Philip Halloran. Canada.

3:03 PM The Transcriptome in Renal Allograft Biopsies Predicts the Risk for Graft Loss Independent of Clinical Variables and Histology. (Abstract #211)
G. Einecke, J. Reeve, S. Bunnag, B. Sis, Philip Halloran. Canada.

3:15 PM Identifying microRNAs Involved in the Regulation of Gene Expression in HCV-Induced HCC Progression. (Abstract #212)
Kellie Archer, Andre Williams, Robert Fisher, Patrik Vitzka, Andrea Ferreira-Gonzalez, Daniel Maluf, Valeria Mas. Richmond, VA.

3:27 PM Use of Transcriptional Biomarkers To Identify Liver Transplant Recipients Who Can Successfully Discontinue Immunosuppressive Therapy. (Abstract #213)
Carlos Benitez, Juan Jose Lozano, Marc Martinez-Llordella, Isabel Puig-Pey, Marta Lopez, Anna Rodriguez, Giuseppe Tisone, Jacques Pirenne, Jan Lerut, Alberto Sanchez-Fueyo. Barcelona, Spain; Rome, Italy; Leuven, Belgium; Louvain, Belgium.

Concurrent Session 30: Improving Outcomes in Pediatric Liver Transplantation
2:15 PM – 3:45 PM
Room 208
Chairs: Carlos Esquivel, MD, PhD, and Cal Matsumoto, MD

2:15 PM Improved Outcomes in Pediatric Liver Transplantation for Acute Liver Failure. (Abstract #214)

2:27 PM Factors Affecting Waitlist Mortality in Children with Biliary Atresia. (Abstract #215)
2:39 PM Pediatric Transplant Centers Performing Living Donor Liver Transplants Have Lower Waitlist Mortality in the PELD Era. (Abstract #216)
Ronald T. Cotton, Jacfranz J. Guiteau, Janine N. Pettiford, Christine A. O’Mahony, John A. Goss. Houston, TX.

2:51 PM High Pediatric Transplant Center Volume Improves Graft and Patient Survival in PELD Patients. (Abstract #217)
Ronald T. Cotton, Jacfranz J. Guiteau, Janine N. Pettiford, Christine A. O’Mahony, John A. Goss. Houston, TX.

3:03 PM Successful Immunosuppression Minimization in Pediatric LT. (Abstract #218)

3:15 PM Graft Fibrosis in Operationally Tolerant Patients after Liver Transplantation; Antigen-Dependent or Independent? (Abstract #219)

Dominique Jan, Robert Cowles, Kara Ventura, Martinez Mecedes, Joanne Carol, Steven Lobritto. New York, NY.

Concurrent Session 31: Innate Immunity
2:15 PM – 3:45 PM
Room 311
Chairs: Hans-Dieter Volk, MD, and Sheri Krams, PhD

2:15 PM Modification of N-glycosylation Impairs Dendritic Cell Maturation/ Migration and Prolongs Conveal Allograft Survival. (Abstract #221)
Stephan Schlickeiser, Svetlana Stanojlovic, Christine Appelt, Stefanie Haase, Simone Vogel, Thomas Ritter, Hans D. Volk, Uwe Pleyer, Birgit Sawitzki. Berlin, Germany; Belgrade, Serbia; Galway, Ireland.

2:27 PM Kidney Tubular Epithelial Cells Express Osteopontin To Promote Natural Killer Cell Chemotaxis and Kidney Injury. (Abstract #222)

2:39 PM Tolerance Associated Gene 1 Inhibits TLR4 Mediated p38 MAP Kinase Activation, Dendritic Cell Maturation and Subsequent T Cell Priming. (Abstract #223)
Simone Vogel, Stephan Schlickeiser, Christine Appelt, Ulrike Schliesser, Kathrin Keeren, Katrin Vogt, Manuel Guerreiro, Thomas Ritter, Dieter Volk, Birgit Sawitzki. Berlin, Germany; Galway, Ireland.

2:51 PM IRAK-M Is a Negative Regulator of Inflammation That Inhibits the Graft Prolonging Effects of Costimulatory Blockade. (Abstract #224)
Hua Shen, Daniel R. Goldstein. New Haven, CT.

3:03 PM Natural Killer Cell Interactions with Dendritic Cells and Tumor Cells Are Mediated by Different NK Cell Receptors. (Abstract #225)
Lu-En Wai, Olivia M. Martinez, Sheri M. Krams. CA.

3:15 PM NK-Cell Chimerism Is a Unique Feature of Liver Transplantation and May Modulate Recipient’s Response Against the Graft. (Abstract #226)

Rima C. Abdel Massih, Sueng H. Kang, Robert A. Brown, Albert J. Eid, Raymund R. Razonable. Rochester, MN.
Concurrent Session 32: Ischemia Reperfusion: Molecular Aspects
2:15 PM – 3:45 PM

Room 309
Chairs: Osun Kwon, MD, and Stephan Tullius, MD, PhD


2:27 PM Ex Vivo Application of Carbon Monoxide in UW Solution To Prevent Renal Cold Ischemia/Reperfusion (I/R) Injury in the Pig. (Abstract #229) Junichi Yoshida, Kikumi S. Ozaki, Mike Nalesnik, Mohamed Ezzelarab, Burcin Ekser, Gabriel J. Echeverri, Shinya Ueki, Marcela Castillo-Rama, Gaetano Falco, Atsunori Nakao, Noriko Murase. Pittsburgh, PA.


3:03 PM Donor Pretreatment with Simvastatin Reduces Graft Immunogenicity Following Prolonged Cold Ischemia in the Long-Term. (Abstract #232) Katja Kotsch, Manije Sabet, Maja Frankuski, Anja Reutzel-Selke, Andreas Pascher, Peter Neuhaus, Johann Pratschke. Berlin, Germany.


Concurrent Session 33: Kidney Immunosuppression: CNI Minimization - Avoidance Protocols II
2:15 PM – 3:45 PM

Auditorium
Chairs: Stuart Flechner, MD, and Todd Pesavento, MD


2:51 PM Influence of Immunosuppression, Donor Age, and Rejection on Chronic Banff Scores of 1 Year Protocol Biopsies in a Prospective Randomized Trial of Tacrolimus (TAC) + Mycophenolate Mofetil (MMF) vs. Sirolimus (SRL) + MMF Therapy Following Thymoglobulin (THY) Induction with Rapid Steroid Taper (RST). (Abstract #238)

3:03 PM Immediate vs. Delayed Everolimus Treatment in De Novo Renal Transplant Patients at Risk of Delayed Graft Function: Results of a 12-Month Randomized, Multicentre Trial. (Abstract #239)
Jacques Dantal, Francois Berthoux, Marie-Christine Moal, Lionel Rostaing, Christophe Legendre, Anne-Sandrine Blanc, Fabienne Di Giambattista, Elisabeth Cassuto.

3:15 PM Prospective Randomized Study To Evaluate Feasibility of Conversion of CNI to SRL in a Pred-Free Immunosuppressive Regimen. Impact on Treg Generation. (Abstract #240)
Lorenzo Gallon, Grafals Monica, John Friedewald, Brian Cabral, Josh Miller, Nader Najafaijan, Joe Leventhal, Xunrong Lu, Luting Xu. Chicago, IL; Boston, MA.

3:27 PM Impact on Renal Function of Early Conversion at 3 Months from Cyclosporine (CsA) to Sirolimus (SRL) in Association with Mycophenolate Mofetil (MMF) in Kidney Transplantation: 30-Months Follow up of a Multicenter Randomized Controlled Trial: The Concept Study. (Abstract #241)
Y. Lebranchu, O. Toupane, G. Touchard, E. Thervet, I. Etienne, H. Mazouz, B. Hurault de Ligny, B. Moulin, J. P. Rerolle, T. Frouget, D. Glotz, C. Randoux, F. Bayle, A. E. Heng, F. Allano, M. Buchler. Tours; Reims; Poitiers; Paris; Rouen; Amiens; Caen; Strasbourg; Limoges; Rennes; Grenoble; Clermont Ferrand; Neuilly; Tours, France.

Concurrent Session 34: Liver: Complications, Recurrent Disease, and Hepatitis II
2:15 PM – 3:45 PM
Ballroom A
Chairs: Mark Johnson, MD, and Alan Reed, MD

2:15 PM Outcomes of Pregnancy Related to Time Interval from Transplant to Conception in Liver Transplant Recipients. (Abstract #242)

2:27 PM Liver Transplantation in HIV Positive Patients: A Case Control Study. (Abstract #243)
Umberto Baccarani, Gian Luigi Adani, Marcello Tavio, Dario Lorenzin, Angela Londero, Francesco Bragantini, Chiara Comuzzi, Anna Rossetto, Andrea Risaliti, Claudio Avellini, Federico Pea, Vittorio Bresadola, Pierluigi Viale. Udine, Italy.

2:39 PM Post-Transplant Hemodialysis Drastically Reduces One-Year Survival in Patients Entering Liver Transplantation without Renal Dysfunction. (Abstract #244)
Michael Ma, Todd Brennan, Isabel Reyes, Manjula Tamura, Sandy Feng. San Francisco, CA; Palo Alto, CA.

2:51 PM Progression of Fibrosis Despite Achievement of SVR in Hepatitis C Patients after Liver Transplantation (LT). (Abstract #245)
Bahr Madani, Shaid Malik, Igor Dvorchik, Michael E. de Vera. Pittsburgh, PA.

3:03 PM Outcomes in Combined and Sequential Liver-Kidney Transplants – UNOS Data Analysis. (Abstract #246)
Vinaya Rao, Elizabeth Lyden, Sandeep Mukherjee. Omaha, NE.
3:15 PM  Risk Factors for Chronic Kidney Disease (CDK) after Liver Transplantation: Implications for Performing Combined Liver and Kidney Transplantation (CLKT). (Abstract #247)

3:27 PM  Thymoglobulin Improves Renal Function without Accelerating Hepatitis C Virus Recurrence in HCV Positive Liver Transplant Recipients. (Abstract #248)
Iman Bajjoka, Lama Hsaiky, Kimberly Brown, Magan Ma, Marwan Abouljoud. Detroit, MI.

Concurrent Session 35: Liver: Donor Issues
2:15 PM – 3:45 PM
Ballroom C
Chairs: James Eason, MD, and Devin Eckhoff

Zoe A. Stewart, Andrew M. Cameron, Nabil N. Dagher, Andrew L. Singer, Robert A. Montgomery, Dorry L. Segev. Baltimore, MD.

2:27 PM  Liver Transplantation and ECMO-Assisted Donation after Cardiac Death. (Abstract #250)
Shawn J. Pelletier, Jonathan C. Hundley, Michael J. Englesbe, Alvaro P. Rojas, Robert H. Bartlett, Jeffrey D. Punch. Ann Arbor, MI; Detroit, MI.

2:39 PM  Predictors of Graft Failure for U.S. DCD Liver Recipients. (Abstract #251)

2:51 PM  Liver Transplantation from Non-Heart-Beating Donors: An Analysis Using Matched Pairs. (Abstract #252)
James Pine, Amer Aldouri, Alistair Young, Mervyn Davies, Giles Toogood, Stephen Pollard, Peter Lodge, Raj Prasad. Leeds, West Yorkshire, United Kingdom.

3:03 PM  Donor Race Must Be Removed from the Donor Risk Index. (Abstract #253)

3:15 PM  Prophylaxis Against Denovo Hepatitis B for Liver Transplantation Utilizing Hep B Core(+) Donors: Does HBIG Provide a Survival Advantage? (Abstract #254)
Michael R. Marvin, Guy N. Brock, Farida Mostajabi, Nicole Ferguson, Savtri Appana, Kadiyala V. Ravindra, Mary Eng, Joseph F. Buell. Louisville, KY.

3:27 PM  Recipient Age Affects Hepatitis C Recurrence and Graft Survival of Older Livers Following Transplantation. (Abstract #255)

Concurrent Session 36: New Insights into Treg Biology
2:15 PM – 3:45 PM
Room 310
Chairs: Xian Li, MD, PhD, and Yuan Zhai, MD, PhD

2:15 PM  OX40 Plays a Key Role in Transplant Tolerance by Regulating Homeostasis and Functions of Foxp3+ Tregs. (Abstract #256)
Xiang Xiao, Alexander Kroemer, Wentao Liu, Zemin Fang, Wenda Gao, Naoto Ishii, Gulcin Demirci, Xian C. Li. Boston, MA.


3:03 PM  IL-6 and TLR2 Differentially Inhibit Foxp3 Expression in Regulatory T Cells by Epigenetic Regulation. (Abstract #260) Girdhari Lal, Na Yin, Bernd Schroppel, Jonathan S. Bromberg. New York City, NY.


3:27 PM  Indoleamine 2,3-Dioxygenase Down-Regulates Cytotoxicity of Effector CD8+ T Cells through Inhibition on Mitochondrial Function. (Abstract #262) Hanzhong Liu, Xingyi Zhang, Peyman Bizargity, Jiguang Zhao, Kaifeng Liu, Gary A. Visner. Boston, MA; Changchun, Jilin, China.

Concurrent Session 37: Pancreas Transplantation II
2:15 PM – 3:45 PM
Room 306
Chairs: Christopher Barry, MD, PhD, and Mikel Prieto, MD


3:15 PM  An Ex-Vivo Model for Hypothermic Pulsatile Perfusion of Porcine Pancreata. (Abstract #268)


Concurrent Session 38: Performance Measures, Economics, Public Policy, and Allocation
2:15 PM – 3:45 PM
Room 302/304
Chairs: John Magee, MD, and Charles Miller, MD

2:15 PM  Cost of Care Increases with Declining 12 Month Post-Transplant Renal Function. (Abstract #270)
Mark A. Schnitzler, Yong Yuan, A. V. Tuomari, Ross Maclean.

2:27 PM  Cessation of ESRD Medicare Insurance Is Associated with an Increased Risk ofraft Loss in Patients with Lower Median Household Income. (Abstract #271)
John Gill, Edward Cole, Caren Rose, Arthur Matas. Vancouver, BC, Canada; Toronto, ON, Canada; Minneapolis, MN.

2:39 PM  Increased Regulatory Oversight of Center Performance Led to Rare Declines in Kidney Transplantation Rates? (Abstract #272)

Matthew Cooper, Sener Alp, Raghava Munivenkatappa, Manish Singh, Rolf Barth, Stephen Bartlett, Benjamin Philosoph, Abdolreza Haririan. Baltimore, MD.

3:03 PM  264 HLA-0MM Kidneys Shipped to a Single Center: Superior 8 yr Graft Survival Correlates with High Incidence of Donor-Specific Regulation. (Abstract #274)
William J. Burlingham, Hans Sollenger, David Lorentzen, Alejandro Munoz del Rio, Ewa Jankowska-Gan, Anthony D’Alessandro. Madison, WI.

3:15 PM  Associations of HLA-Matching with Graft Outcomes and Costs of Deceased-Donor Kidney Transplantation. (Abstract #275)
Krista Lentine, Ralph Graff, Patrick Ercole, Paula Buchanan, Paolo Salvalaggio, Harvey Solomon, Mark Schnitzler.

3:27 PM  Allocation of HCV+ Organs in Kidney Transplantation: Balancing Shortened Wait Against Decreased Survival. (Abstract #276)
Daniel G. Maluf, Kellie J. Archer, Valeria R. Mas, Eric Gibney. Richmond, VA.

Concurrent Session 39: Predictors of Outcome
2:15 PM – 3:45 PM
Room 206
Chairs: Martha Pavlakis, MD, and Jane Tan, MD, PhD

2:15 PM  Creatinine Increase during Pregnancy Is Associated with Decreased Graft Survival after Delivery in Kidney Recipients. (Abstract #277)
Jolene Seibel-Seamon, Vincenzo Berghella, Serban Constantinescu, Lisa A. Coscia, Michael J. Moritz, Vincent T. Armenti. Philadelphia, PA; Allentown, PA.

2:27 PM  Urinary Cystatin C and KIM-1: A Tale of Two Novel Biomarkers of Acute Kidney Injury in Predicting the Need for Dialysis after Kidney Transplantation. (Abstract #278)
Isaac E. Hall, Sri Yarlagadda, Mona Doshi, Richard Marcus, Won K. Han, Zhu Wang, Chirag R. Parikh. New Haven, CT; Detroit, MI; Pittsburgh, PA; Philadelphia, PA.
2:39 PM Abnormal Diurnal Blood Pressure Change at 1-Year Correlates with Poor Allograft Function in Kidney Transplant Recipients with Normal Histology and No History of Rejection. (Abstract #279)
Hani M. Wadei, Hatem Amer, Sandra J. Taler, Mark D. Stegall, Stephen C. Textor. Jacksonville, FL; Rochester, MN.

2:51 PM Final Results of Pretransplant Pharmacogenetic Adaptation of Tacrolimus (TAC) Treatment after Renal Transplantation. (Abstract #280)
Eric Thervet, Marie Anne Loriot, Stephane Barbier, Matthias Buchler, Maxence Ficheux, Gabriel Choukroun, Christophe Legendre, Olivier Toupane, Guy Touchard, Jo Rivalan, Bruno Moulin, Corinne Alberti, Philippe Beaune. Paris, France; Rouen, France; Tours, France; Caen, France; Amiens, France; Reims, France; Poitiers, France; Rennes, France; Strasbourg, France.

3:03 PM Poorer Graft Survival in Ethnic Minorities: Results from a Multi-Centre U.K. Study of Kidney Transplant Outcomes. (Abstract #281)
James F. Medcalf, On Behalf of STEPP Research Group. Leicester, United Kingdom.

3:15 PM Validation of Clinical Outcome Prediction Tools in Kidney Transplantation. (Abstract #282)
Sita Gourishankar, Thomas Mueller. Edmonton, AB, Canada.

3:27 PM Low Serum Mannose Binding Lectin as a Risk Factor for New Onset Diabetes Mellitus after Renal Transplantation. (Abstract #283)
Daniel Seron, Meritxell Ibernon, Juan M. Fernandez-Real, Wifredo Ricart, Joana Sellares, Josep M. Cruzado, Oriol Bestard, Josep M. Grinyó, Francesc J. Moreso. Barcelona, Spain; Girona, Spain.

Concurrent Session 40: Prognostic Phenotypes in Chronic Renal Allograft Injury
2:15 PM – 3:45 PM
Room 210
Chairs: Marcello Cantarovich, MD, and Daniel Seron, MD, PhD

2:15 PM Natural History of Subclinical Antibody-Mediated Rejection (SC AMR) in Kidney Transplant Recipients (KTR) with Preexisting DSAs. (Abstract #284)

2:27 PM Prophylactic Anti-CD20 Combined with Plasmapheresis (PP) Reduces Chronic AMR in Kidney Transplant Recipients (KTR) with Preexisting DSAs. (Abstract #285)

2:39 PM Donor Employment of Desmopressin (DDAVP) Is Associated with Superior Long-Term Allograft Survival, but Has No Effect on Delayed Graft Function after Kidney Transplantation. (Abstract #286)
Urs Benck, Hui Song, Uwe Goettmann, Simone Hoeger, Benito A. Yard, Peter Schmuelle. Mannheim, Germany.

2:51 PM Association of Antibodies Against Endothelial Cell Antigens with Poor Outcome of Kidney Regrafts. (Abstract #287)
Bhavna Lavingia, Zhiqiang Qin, Ashley Comeaux, Peter Stastny. Dallas, TX.

3:03 PM Donor Age and P-glycoprotein Determine Chronic Histological Damage Progression in Renal Allografts. (Abstract #288)
Maarten Naesens, Evelyne Lerut, Hylke de Jonge, Boudewijn Van Damme, Yves Vanrenterghem, Dirk Kuypers. Belgium.
3:15 PM  Clustering of Kidney Transplants by Banff Lesions Shows Antibody-Mediated Damage as the Main Culprit of Late Kidney Transplant Loss. (Abstract #289)
Banu Sis, Jeff Reeve, Sakarn Bunnaag, Gunilla Einecke, Michael Mengel, Bruce Kaplan, Philip Halloran. Edmonton, AB, Canada; Chicago, IL.

3:27 PM  C4d (+) and Donor Specific Antibody (DSA) Have Differential Impact on Outcome after Late Renal Allograft Biopsy. (Abstract #290)
Robert Gaston, A. Fieberg, R. Leduc, J. Connett, F. Cosio, S. Gourishankar, J. Grande, P. Halloran, L. Hunsicker, B. Kasiske, A. Matas, D. Rush, J. M. Cecka. Birmingham, AL; Minneapolis, MN; Rochester, MN; Edmonton, AB; Iowa City, IA; Winnipeg, MB; Los Angeles, CA.

3:45 PM  Break

Concurrent Session 41: BK Polyoma Virus I: Immunological Aspects
4:00 PM – 5:30 PM
Room 210
Chairs: Cinthia Drachenberg, MD, and Hans Hirsch, MD, MS

4:00 PM  Impact of BK Virus Treatment on Adult Kidney Transplant Recipients – An Analysis of OPTN/UNOS Database. (Abstract #291)
Tariq Shah, Suphamai Bunnapradist, Marcelo S. Sampaio, Ian V. Hutchinson, Yong W. Cho. Los Angeles, CA.

4:12 PM  VP3-Specific Multifunctional CD4-Positive T Cells as a New Marker of Cellular Immunity in Patients with BKV-Associated Nephropathy. (Abstract #292)

4:24 PM  Immunodominant VP1 and 4 Other Subdominant Antigens as Important Targets of BKV-Specific Immunity in KT Patients with BKV Infection. (Abstract #293)
Thomas Schachtner, Karin Müller, Malik Stein, Nina Babel, Petra Reinke. Berlin, Germany.

4:36 PM  Pre-Transplant IgG Antibodies to BK PolyomaVirus in Pediatric Renal Transplants. (Abstract #294)
Vanessa Bijol, Adela Cimic, Raphael P. Viscidi, Leonard C. Hymes. Baltimore, MD; Atlanta, GA.

4:48 PM  CD4+ T-Cells from HLA-DR04 + Subjects Recognize a BK Virus (BKV) Epitope from a Zinc Finger in the DNA Polymerase Domain of Large T Antigen (LTA). (Abstract #295)
Bala Ramaswami, Iulia Popescu, Camila Macedo, Diana Metes, Ron Shapiro, Parmjeet Randhawa. Pittsburgh, PA.

5:00 PM  Monitoring of Activated T Cell Is Important for Patients with High BK Viral Load in Renal Transplantation. (Abstract #296)
Wen-Yao Yin, Ning-Sheng Lai, Ming-Chi Lu, Teng-Yi Lin, Ming-Che Lee. Chia-Yi, Taiwan; Hualien, Taiwan.

5:12 PM  The Significance of Renal C4D Deposits in Patients with BK Viruria, Viremia, and Nephropathy. (Abstract #297)

Concurrent Session 42: Delayed Graft Function
4:00 PM – 5:30 PM
Ballroom B
Chairs: Michelle Josephson, MD, and Fuad Shihab, MD

4:00 PM  Pretransplant Chronic Hypotension – An Independent Risk Factor for Primary-Nonfunction of Renal Allografts. (Abstract #298)
4:12 PM Delayed Graft Function (DGF) in Two Sirolimus (SRL)–Based Regimens Compared with Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) in De Novo Renal Allograft Recipients. (Abstract #299)
Stuart M. Flechner, Maciej Glyda, Sandi See Tai, For the ORION Trial Investigators. Cleveland, OH; Poznan, Poland; Collegeville, PA.

4:24 PM Incidence of Delayed Graft Function (DGF) in a Sirolimus (SRL)–Based Versus Cyclosporine (CsA)-Based Regimen in De Novo Renal Allograft Recipients. (Abstract #300)
Stuart M. Flechner, Alihan Gurkan, Sandi See Tai, Seth L. Schulman. Cleveland, OH; Antalya, Turkey; Collegeville, PA.

4:36 PM The Impact of De Novo mTOR (SRL) vs. Calcineurin Inhibitor (CNI) Drugs on the Recovery of Renal Allograft Function. (Abstract #301)
Ho Yee Tiong, Ithaar Derweesh, Jesse D. Schold, Titte Srinivas, Alvin Wee, Ismail Saad, Barbara Mastroianni, Kathy Savas, Charles Modlin, Stuart M. Flechner. Cleveland, OH; Gainesville, FL.

4:48 PM Donor DIC Is Associated with Recipient Thrombocytopenia and DGF in Deceased Kidney Transplantation. (Abstract #302)
Shahzad Shafique, Dennis Diederich, Franz Winklhofer, Connie Wang. Kansas City, KS; Shawnee, KS.

5:00 PM Delayed Graft Function Is Only Harmful If Associated with Rejection and This Effect Is Predominant in the First Year. (Abstract #303)

5:12 PM Recipient Predictors for Developing Delayed Graft Function (DGF). A Paired Kidney Analysis in a Single Center. (Abstract #304)
Giuliana Bacchi, Andrea Buscaroli, Elisa Carretta, Serena Corsini, Sergio Stefoni. Bologna, Italy.

Concurrent Session 43: Immune Monitoring: Tolerance and Immune Modulation
4:00 PM – 5:30 PM
Room 309
Chairs: Geetha Chalasanni, MBBS, and Douglas Hale, MD

4:00 PM Gene Arrays May Predict Stable Clinical Tolerance and Support Safe Immunosuppression Withdrawal. (Abstract #305)
Minnie M. Sarwal, Li Li, Szu-chuan Hsieh, Robert Lowsky, Stephan Busque, John Scandling, Sussan Jones, Samuel Strober.

4:12 PM Profound Donor Specific Immune Unresponsiveness in Donor Bone Marrow Cell Infused Renal Transplant Patients. (Abstract #306)
James M. Mathew, Gaetano Ciancio, George W. Burke, Violet Esquenazi, Rolando Garcia-Morales, Anne Rosen, Laphalle Fuller, Jeff Gaynor, Edward Wang, Camillo Ricordi, Miller Joshua. Chicago, IL; Miami, FL.

4:24 PM B Cell Immunity in the Context of T Cell Tolerance after Combined Kidney and Bone-Marrow-Transplantation in Humans. (Abstract #307)

4:36 PM Changes in T Cell Subsets after TLI/ATG Conditioning That Promotes Tolerance to Combined Kidney and Hematopoietic Cell Transplants in Human. (Abstract #308)
Sussan Dejbakhsh-Jones, Jhon Scandling, Stephan Busque, Roland Nador, David Hongo, Claudia Benike, Aditi Mukhopadhyay, Edgar Engleman, Samuel Strober. Stanford, CA.

4:12 PM  Impact of Induction with Biologics in Kidney Transplant Patients with a Positive Serology for Hepatitis C: Long-Term Assessment in a Collaborative Study. (Abstract #313) Beatriz Dominguez-Gil, Nuria Esforzado, Amado Andrés, Federico Oppenheimer, Gregorio Castellano, Jose M. Campistol, Jose M. Morales. Madrid, Spain; Barcelona, Spain.

5:00 PM  Modulation of Dendritic Cells by Soluble CD83 Induces Kidney Allograft Tolerance. (Abstract #310) Zhu Lan, Wei Ge, Miren Baroja, Jacqueline Arp, Jifu Jiang, Weihua Liu, Stephen Brand, Charles Nicolette, Bertha Garcia, Hao Wang. London, ON, Canada; Durham, NC.


5:12 PM  Similar Longer-Term Graft Survival in African American and Non-African American African Kidney Recipients Treated with Rabbit Anti-Thymocyte Globulin (RATG) Induction in Conjunction with Tacrolimus and Mycophenolate Mofetil. (Abstract #318)
Melissa Bleicher, Jennifer Trofe, Peter Reese, Simin Goral, Alden Doyle, Peter Abt, Roy D. Bloom.

Concurrent Session 45: Kidney Living Donor Paired Exchange/Donor Chains
4:00 PM – 5:30 PM
Room 302/304
Chairs: Joseph Buell, MD, and Marc Melcher, MD

4:00 PM  From Concept to Reality: Increasing Transplantation through Donor Chains. (Abstract #319)

4:12 PM  Factors Influencing Willingness of the General Population To Participate in Kidney Paired Donation. (Abstract #320)

4:24 PM  Allocation of Kidneys from True Samaritan Donors. Justification of the Domino-Paired Procedure. (Abstract #321)

4:36 PM  The MATCH: Modified-Sequence Asynchronous Transplant Chain. (Abstract #322)
Fauzia K. Butt, H. Albin Gritsch, Peter Schulam, Gabriel Danovitch, Alan Wilkinson, Joseph Del Pizzo, Sandip Kapur, David Serur, Steve Katznelson, Stephan Busque, Marc L. Melcher, Suzanne McGuire, Marian Charlton, Garet Hil, Jeffrey L. Veale. Los Angeles, CA; New York, NY; San Francisco, CA; Palo Alto, CA.

Ann D. Smith, Robert C. Harland, Giuliano Testa, Sommer Gentry. Chicago, IL; Annapolis, MD.

5:00 PM  Report from a 73 Transplant Center Multi-Regional Kidney Paired Donation Program. (Abstract #324)
Michael Rees, David Barnes, Jonathan Kopke, Annette Blair, Connie Smith, Laurie Reece.

5:12 PM  Experience with over 50 Altruistic and “Bridge” Donors Involved in Never-Ending Altruistic Donor Chains and Kidney Paired Donation. (Abstract #325)

Concurrent Session 46: Liver Malignancies: Hepatocellular and Cholangiocarcinoma
4:00 PM – 5:30 PM
Ballroom C
Chairs: David Reich, MD, and Charles Rosen, MD

4:00 PM  Multicenter Analysis of Liver Transplantation (LT) for Metastatic Neuroendocrine Tumor (NET): Is a MELD Exception Justified? (Abstract #326)
Concurrent Session 47: Living Donors and Partial Grafts II  
4:00 PM – 5:30 PM

Ballroom A
Chair: Robert Brown, Jr., MD, MPH, and Jean Emond, MD

4:00 PM  The Impact of Pretransplant Recipient’s Disease Severity on Outcome after Adult Living Donor Liver Transplantation (LDLT).  
(Abstract #333)

4:12 PM  Incorporating Safety Risks in the Assessment of Health State Preferences for Living Donor Versus Deceased Donor Liver Transplantation.  
(Abstract #334)

4:24 PM  Using the Duodenum To Reconstruct the Biliary System in Live Donor Liver Transplantation Is Superior to a Roux-en-Y.  
(Abstract #335)
J. Campsen, M. Zimmerman, S. Mandell, T. Bak, M. Wachs, I. Kam. Aurora, CO.

4:36 PM  Split Liver Transplantation in Adult and Pediatric Recipients: A 16 Year Experience in a Single Center.  
(Abstract #336)

4:48 PM  Split Liver Transplantation for Two Adult Recipients in a European MELD-Based Allocation System.  
(Abstract #337)
5:00 PM  Extremely Low Morbidity in LLS Donors to Pediatric Recipients: The Columbia University Experience.  
(Abstract #338)  
Benjamin Samstein, Thalis Christophedes, Dianne LaPointe-Rudow, Jean C. Emond. New York, NY.

5:12 PM  Rapid Decision Analysis Pathway Can Prevent Donor Death and Lead to Life-Saving Transplant Following Donor Right Hepatectomy (RH).  
(Abstract #339)  

Concurrent Session 48: Lung  
4:00 PM – 5:30 PM

Room 313  
Chairs: Scott Palmer, MD, MHD, and Martin Zamora, MD.

4:00 PM  Lung Transplantation Using Donation after Cardiac Death: Single-Center Update.  
(Abstract #340)  
James J. Yun, David P. Mason, Sudish C. Murthy, Marie M. Budev, Gosta B. Pettersson. Cleveland, OH.

4:12 PM  Minimally Invasive Approach in Double Lung Transplantation.  
(Abstract #341)  

4:24 PM  Receptor for Advanced Glycation End Products (RAGE) Levels Are Increased in Donor Lungs That Develop Primary Graft Dysfunction Post-Transplantation.  
(Abstract #342)  

4:36 PM  Early Risk Factors for Moderate or Severe Renal Insufficiency in Lung Transplant Recipients.  
(Abstract #343)  
Erin Elliott, Samir Patel, Nadine Haykel, A. Osama Gaber, Ramesh Kesavan, Harish Seethamraju. TX.

4:48 PM  Development of Immune Responses to Self Antigens (K<sub>1</sub>Tubulin & CollagenV) Following Human Lung Transplant Plays a Pivotal Role in the Pathogenesis of Chronic Rejection.  
(Abstract #344)  

5:00 PM  Epidemiology of CMV Disease in CMV-Naive Lung Transplant Recipients in the Era of Valganciclovir Prophylaxis.  
(Abstract #345)  

5:12 PM  Successful Outcome after Lung Transplantation in Hepatitis C Virus Seropositive Patients in the United States.  
(Abstract #346)  
Yong W. Cho, James Cicciarelli, Ian V. Hutchinson, Tse-Ling Fong. Los Angeles, CA.

Concurrent Session 49: Organ Donation: Economics, Public Policy, and Ethics  
4:00 PM – 5:30 PM

Room 306  
Chairs: Michael Abecassis, MD, and Robert Higgins, MD, MSHA.

4:00 PM  Changing Patterns of Organ Donation at a Single Center; Are Potential Brain Dead Donors Being Lost to Donation after Cardiac Death?  
(Abstract #347)  
Reza F. Saidi, James Bradley, David Greer, Richard Luskin, Kevin O’Connor, Francis Delmonico, Peter Kennauley, Nahel Elias, Martin Hertl, James Markmann.

4:12 PM  Presumed Consent Laws Are Associated with Higher Donation Rates around the World.  
(Abstract #348)  
**4:24 PM**  Heart Transplantation Defies Goals of Organ Donation Breakthrough Collaborative. Will Other Solid Organs Follow Suit? (Abstract #349)
Jose Nativi, Josef Stehlik, Robert N. Brown, David O. Taylor, James K. Kirklin.

**4:36 PM**  Patients Transplanted Overseas: A Summary of UK Data. (Abstract #350)
Antonia Cronin, Rachel Johnson, Robert Lechler.

**4:48 PM**  Special Informed Consent and Hospital Policies Are Associated with Increased Utilization of High Risk Donor Organs. (Abstract #351)

**5:00 PM**  Regional Differences in Mortality Significantly Impact Organ Availability. (Abstract #352)
Ellen Sheehy, Kevin O’Connor, Richard Luskin, Frederick Selek, Richard Howard, Danielle Cornell, Jan Finn, Thomas Mone, Francis Delmonico. Newton, MA; Gainesville, FL; Westwood, KS; Los Angeles, CA; Boston, MA; Newton, MA.

**5:12 PM**  Transplant Tourism: We Can Intervene. (Abstract #353)
Olivier Diec, John Gill, R. J. Shapiro, David Landsberg, Jagbir Gill. Vancouver, BC, Canada.

**Concurrent Session 50: Pathways in Acute Rejection**

**4:00 PM – 5:30 PM**

*Room 310*

*Chairs: Donna Farber, PhD, and Kenneth West, MD*

**4:00 PM**  Decreased Cardiac Allograft Rejection in Mice Over-Expressing Human GTP Cyclohydrolase I. (Abstract #354)

**4:12 PM**  Does Interleukin 17A Contribute to Acute Cellular Rejection of Human Renal Allografts? (Abstract #355)
Janani Rangaswami, Dany Anglicheau, Vijay K. Sharma, Manikkam Suthanthiran. NY.

**4:24 PM**  STAT6 or T-bet Is Required for Acute Allograft Rejection. (Abstract #356)
Yu Yang, Jiangnan Xu, Jordi C. Ochando, Jonathan S. Bromberg, Yaozhong Ding. New York, NY.

**4:36 PM**  Prolonged Loss of Donor Graft Indoleamine-2,3 Dioxygenase (IDO) Expression Accelerates Kidney Allograft Immune Injury. (Abstract #357)

**4:48 PM**  TH17 Cells Are Not Suppressed by IL-10 and Induce Acute Allograft Rejection. (Abstract #358)
Yu Yang, Jiangnan Xu, Jordi C. Ochando, Jonathan S. Bromberg, Yaozhong Ding. New York, NY.

**5:00 PM**  Administration of Recipient-Derived Dendritic Cells (DC) Knockdown of CD80 and/or CD86 Prolongs Survival of Cardiac Allografts. (Abstract #359)
Xiaodong Shen Shen, Jun Hong, Xiaodong Gu, Jianbin Xiang, Shiguang Qian, Zongyou Chen. Shanghai, China; Cleveland, OH.

**5:12 PM**  CD28:B7 Signaling Prevents Acute Rejection in a Class II Mismatched Cardiac Allograft Model That Is Dependent on Tregs for Long-Term Survival. (Abstract #360)
Leonardo V. Riella, Jun Yang, Olaf Boenisch, Mohamed H. Sayegh, Anil Chandraker. Boston, MA.
Concurrent Session 51: Psychosocial and Compliance Issues
4:00 PM – 5:30 PM
Room 208
Chairs: James Rodrigue, PhD, and Nataliya Zelikovsky, PhD

4:00 PM  Living Donation Willingness Explained: Find a Volunteer, Don’t Ask. (Abstract #361)
Amy D. Waterman, Elena Deych, Shelley S. Hyland, Andrea L. Paiva, Mark L. Robbins. Saint Louis, MO; Kingston, RI.

4:12 PM  Patient Reported Outcome Measures (PROMS) in Living Kidney Donation and Transplantation: Recipient Expectations Exceeded While Some Donors Report a Poorer Outcome. (Abstract #362)

4:24 PM  Psychosocial Impact of Transplantation on Spouse Caregivers. (Abstract #363)
James R. Rodrigue, Timothy Antonellis, Noelle Dimitri, Amanda Reed, Didier Mandelbrot, Martha Pavlakis, Michael Curry. Boston, MA.

4:36 PM  Development of the Essen Compliance Score – Measurement of Adherence in Kidney Transplant Patients. (Abstract #364)
Tobias R. Türk, Gabriele H. Franke, Melanie Jagla, Leif Haferkamp, Jens Reimer, Andreas Kribben, Oliver Witzke. Essen, Germany; Stendal, Germany; Hamburg, Germany.

4:48 PM  Dialysis Providers Ability To Educate Patients about Transplant: Good Education Partners? (Abstract #365)
Amy D. Waterman, Christina Goalby, Shelley S. Hyland. Saint Louis, MO.

5:00 PM  Transition Readiness and Adherence among Pediatric Liver Transplant Recipients. (Abstract #366)

5:12 PM  Cognitive Abilities, Quality of Life and Psychosocial Burden in Liver-Transplanted Children and Their Families. The Project “Live!®” (Abstract #367)
Karl-Heinz Schulz, Tanja Kaller, Nadine Langguth, Kristin Ziegler, Rainer Ganschow, Bjoern Nashan, Martin Burdelski, Andreas Richterich. Hamburg, Germany; Kiel, Germany.

Concurrent Session 52: Stem Cell Modulation of Rejection and Alloimmunity
4:00 PM – 5:30 PM
Room 312
Chairs: Desai Niraj, MD, and Daniel Salomon, MD

4:00 PM  Endothelial Cells Co-Cultured with Embryoid Bodies Enhance Insulin-Producing Beta Cell Differentiation through BMP-2 Signaling. (Abstract #368)
Dodanim Talavera-Adame, Gordon Wu, Tina T. Ng, Yao He, Jae Y. Hwang, Daniel L. Farkas, Donald C. Dafoe. Los Angeles, CA.

4:12 PM  Embryonic Stem Cell-Derived Lin-c-kit+ and Lin-Sca-1+ Hematopoietic Progenitor Cells Highly Express H60 Which Abrogates Their Engraftment Due to NK Cell-Mediated Killing. (Abstract #369)
William Tabayoyong, Jon Salas, Sabrina Bonde, Nicholas Zavazava. Iowa City, IA.

4:24 PM  Expression of Lentivirus Encoded Protective MHC Class II Alleles in the Thymus of NOD Mice Prevents the Development of Diabetes. (Abstract #370)
Michela Donnarumma, Jessamyn Bagley, Chaorui Tian, Jonathan G. Godwin, John Iacomini. Boston, MA.

4:36 PM  Restoring the Proliferation of Endogenous Treg Is Pivotal To Abrogate Autoimmune Destruction of Islet in NOD Mice. (Abstract #371)
Qixin Shi, Donna Farber, David Scott, Stephen Bartlett. Baltimore, MD.
4:48 PM  Allogeneic Mesenchymal Stem Cell Transplantation for Prevention and Therapy of Autoimmune Diabetes in NOD Mice. (Abstract #372)
Mollie Jurewicz, Paolo Fiorina, Andrea Augello, Andrea Vergani, Shirine Dada, Mohamed H. Sayegh, Reza Abdii.
Boston, MA.

4:24 PM  Tolerance to a Composite Tissue Allografts after the Induction of Mixed Chimerism in a Pre-Clinical Large Animal Model. (Abstract #377)
David W. Mathes, James Edwards, Tiffany Miwongtum, Scot Graves, Rainer Storb.
Seattle, WA.

4:36 PM  Anti-Inflammatory Macrophages Suppress Allospecific T Cell Responses and Induce Treg Via Reactive Oxygen Species (ROS) Production. (Abstract #378)
Cees van Kooten, Marina D. Kraaij, Sandra W. van der Kooij, Karin Koekkoek, Kyra A. Gelderman.
Leiden, Netherlands.

4:48 PM  SMILE, a New Molecule Involved in Operational Tolerance in Transplantation. (Abstract #379)
Beatrice Charreau, Jean-Paul Soulillou, Sophie Brouard.
Nantes, France.

4:50 PM  Concurrent Session 53: Tolerance II: (Pre)Clinical/Th17
Room 311
Chairs: Edward Geissler, PhD, and Stuart Knechtle, MD

4:00 PM  Alloreactive Memory T Cells in Cynomolgus Monkeys and Their Relationships to Rejection of and Tolerance to Kidney Allografts. (Abstract #375)
Ognjenka Nadazdin, Roger Wiseman, David O’Connor, Svjetlan Boskovic, Joren Madsen, Tatsuo Kawai, Anthony B. Cosimi, Gilles Benichou.
Boston, MA; Madison, WI.

5:12 PM  The Reciprocal Relationship between Th17 Immunity and Foxp3-Expressing Tregs in the Allograft Response. (Abstract #381)
Dusan Hanidziar, Zhigang Fan, Terry B. Strom, Maria Koulmanda.
Boston, MA.

5:00 PM  CLEC-1, a C-type Lectin-Like Receptor, Is Specifically Over-Expressed by Endothelial Cells in Tolerated Allografts and Seems To Alter T Cell Activation. (Abstract #380)
Pamela Thebault, Natacha Lhermite, Gaelle Tilly, Laetitia Le Texier, Thibaut Quillard, Michele Heslan, Beatrice Charreau, Maria Cristina Cuturi, Elise Chiffoleau.
Nantes, France.

5:12 PM  The Reciprocal Relationship between Th17 Immunity and Foxp3-Expressing Tregs in the Allograft Response. (Abstract #381)
Dusan Hanidziar, Zhigang Fan, Terry B. Strom, Maria Koulmanda.
Boston, MA.
Concurrent Session 54: Viral Diseases and Diagnostics
4:00 PM – 5:30 PM

Room 206
Chairs: Michael Ison, MD, MS, and Jutta Preiksaitis, MD

4:00 PM  Incidence and Prognosis of West Nile Virus Following Kidney Transplantation. (Abstract #382)
Brian M. Cohee, Joshua D. Hartzell, Frank P. Hurst, Rahul M. Jindal, Lawrence Y. Agodoa, Kevin C. Abbott, Robert T. Neff, Washington, DC; Bethesda, MD.

4:12 PM  The Costs and Savings of Polyoma Virus Screening in Kidney Transplantation. (Abstract #383)
Frederick Smith, Bryce Kiberd. Halifax, NS, Canada.

4:24 PM  Impact of Immunosuppressive Therapy on the Natural History of Chronic Hepatitis E Virus Infection in Solid-Organ-Transplant Patients. (Abstract #384)

4:36 PM  Donor Serologic Screening: Current Practices and Future Challenges – A Survey Reported by the OPTN/UNOS Ad Hoc Diseases Transmission Advisory Committee (DTAC). (Abstract #385)

4:48 PM  Persistent Norovirus Infection in Adult Renal Allograft Recipients: Molecular Evidence for Immunity-Driven Viral Evolution. (Abstract #386)
Thomas Fehr, Robert Schorn, Walter Bossart, Marina Hoehne, Eckart Schreier, Nicolas Müller, Rudolf P. Wüthrich. Zurich, Switzerland; Berlin, Germany.

5:00 PM  Natural Polymorphisms in CMV Genes and Their Effect on Viral Fitness. (Abstract #387)
Atul Humar, Anders Asberg, Anders Hartmann, Mark Pescovitz, Halvor Rollag, Alan Jardine, Guy Boivin. IN.

5:12 PM  Clinical Utility of Routine Virologic Surveillance for CMV after Antiviral Prophylaxis in High-Risk Patients. (Abstract #388)
Luiz F. Lisboa, Jutta K. Preiksaitis, Atul Humar, Deepali Kumar. Edmonton, AB, Canada.

Poster Session III
5:30 PM – 6:30 PM
Poster Viewing: 8:00 AM – 6:30 PM
Presenters in Attendance: 5:30 PM– 6:30 PM
Exhibit Hall C, Second Floor
John B. Hynes Convention Center
Poster Session III Program can be found on pages 153-169.

AST Business Meeting
6:00 PM – 7:00 PM
Room 306
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM – 8:15 AM</td>
<td>Sunrise Symposia</td>
</tr>
<tr>
<td>Page 118</td>
<td>Sunrise Symposium I: Strategies for Minimizing Health Care Disparities in Organ Transplantation- A Global View Ballroom C</td>
</tr>
<tr>
<td>Page 118</td>
<td>Sunrise Symposium II: C-Peptide Positive Diabetics: Appropriate Candidates for Pancreas Transplantation? Room 312</td>
</tr>
<tr>
<td>Page 118</td>
<td>Sunrise Symposium III: CMV and BK Virus: Controversies and Challenges Ballroom B</td>
</tr>
<tr>
<td>Page 118</td>
<td>Sunrise Symposium IV: Donation After Cardiac Death and Liver Transplantation: Where are We in 2009? Ballroom A</td>
</tr>
<tr>
<td>Page 118</td>
<td>Sunrise Symposium V: Innate Regulation of Adaptive Immunity Room 302/304</td>
</tr>
<tr>
<td>7:00 AM – 8:15 AM</td>
<td>Early Morning Workshops</td>
</tr>
<tr>
<td>Page 119</td>
<td>8:30 AM – 10:00 AM Plenary Session III</td>
</tr>
<tr>
<td>Page 119</td>
<td>10:00 AM – 10:45 AM Controversies in Transplantation – Making Clinical Trials Relevant Page 120 Auditorium</td>
</tr>
<tr>
<td>10:45 AM Break</td>
<td>11:00 AM – 12:00 NN Presidential Addresses Page 120 Auditorium</td>
</tr>
<tr>
<td>12:00 NN – 12:30 PM</td>
<td>AST/ASTS Distinguished Awards Page 120 Auditorium</td>
</tr>
<tr>
<td>12:45 PM – 2:00 PM</td>
<td>Industry-Supported Satellite Symposium Contemplating CMV Auditorium Page 120</td>
</tr>
<tr>
<td>2:15 PM – 3:45 PM</td>
<td>Concurrent Sessions</td>
</tr>
<tr>
<td>Page 120</td>
<td>Concurrent Session 55: Acute Kidney Rejection: Gene Expression Ballroom B</td>
</tr>
<tr>
<td>Page 121</td>
<td>Concurrent Session 56: Antibody, Endothelium and Vasculopathy Room 312</td>
</tr>
<tr>
<td>Page 121</td>
<td>Concurrent Session 57: Anti-HLA Antibodies Room 206</td>
</tr>
<tr>
<td>Page 122</td>
<td>Concurrent Session 58: Barriers and Surgical Issues of Kidney Living Donation Room 210</td>
</tr>
<tr>
<td>Page 123</td>
<td>Concurrent Session 59: Biopsy Scoring and ECDs Room 302/304</td>
</tr>
<tr>
<td>Page 123</td>
<td>Concurrent Session 60: Composite Tissue Transplants Room 208</td>
</tr>
<tr>
<td>Page 124</td>
<td>Concurrent Session 61: Genomics/Proteomics of Kidney Allograft Dysfunction Room 309</td>
</tr>
<tr>
<td>Page 125</td>
<td>Concurrent Session 62: Immunosuppression Preclinical Studies I Room 310</td>
</tr>
<tr>
<td>Page 125</td>
<td>Concurrent Session 63: Islet: Clinical Issues Room 306</td>
</tr>
<tr>
<td>Page 126</td>
<td>Concurrent Session 64: Kidney Immunosuppression: Novel Agents Auditorium</td>
</tr>
</tbody>
</table>
AMERICAN TRANSPLANT CONGRESS
Day-at-a-Glance, Tuesday, June 2, 2009

Page 127 Concurrent Session 65: Liver: Complications, Recurrent Disease, and Hepatitis III
Ballroom A

Page 128 Concurrent Session 66: Liver: Immunosuppression Issues
Ballroom C

Page 128 Concurrent Session 67: Miscellaneous Pathogens
Room 313

Page 129 Concurrent Session 68: T Cell Costimulation: New Pathways and Implications
Room 311

3:45 PM Break

4:00 PM – 5:30 PM Concurrent Sessions

Page 130 Concurrent Session 69: Acute Kidney Rejection: Antibody-Mediated
Auditorium

Page 130 Concurrent Session 70: BK Polyoma Virus II: Virological and Clinical Aspects
Ballroom B

Page 131 Concurrent Session 71: Chemokines and Cytokines
Room 310

Page 132 Concurrent Session 72: Ischemia Reperfusion: Immune Mediators
Room 312

Page 132 Concurrent Session 73: Kidney Immunosuppression: Steroid Minimization – Avoidance Protocols
Room 302/304

Page 133 Concurrent Session 74: Kidney Living Donor Outcomes I
Ballroom C

Page 134 Concurrent Session 75: Kidney: Complications III
Room 210

Page 134 Concurrent Session 76: Liver: MELD/Allocation
Ballroom A

Page 135 Concurrent Session 77: Molecular and Humoral Phenotypes of Chronic Renal Allograft Injury
Room 311

Page 136 Concurrent Session 78: Non-Organ Specific: Disparities to Outcome and Access to Healthcare
Room 206

Page 137 Concurrent Session 79: Optimizing Islet and Cell Transplantation
Room 306

Page 137 Concurrent Session 80: Pediatric Transplantation: Kidney
Room 208

Page 138 Concurrent Session 81: Tolerance III: Chimerism (Rodent Models)/Regulatory Cells
Room 309

5:30 PM – 6:30 PM Poster Session IV
Presenters in Attendance – Beverages
Exhibit Hall C, Second Floor,
John B. Hynes Convention Center

Page 233 Bacteria and Fungi

Page 234 Deceased Donor Issues and Allocation

Page 235 Heart

Page 239 Immune Monitoring in Clinical and Preclinical Transplantation

Page 240 Immunosuppression Preclinical Studies: Poster Session

Page 242 Islet Cell and Stem Cell and Cell Transplantation Posters

Page 245 Kidney Induction I

Page 246 Kidney: Complications IV
Tuesday, June 2, 2009

Concurrent Sunrise Symposia
7:00 AM – 8:15 AM

Sunrise Symposium I: Strategies for Minimizing Health Care Disparities in Organ Transplantation- A Global View
Ballroom C
Chairs: Jerry McCauley, MD, MPH, and Ross Isaacs, MD

7:00 AM State-of-the-Art in Disparities in Organ Transplantation
Robert Higgins, MD

7:25 AM Current Strategies to Mitigate Disparities in Organ Donation - Best Practices
Winfred Williams, MD

7:50 AM Future Strategies and Ongoing Research Aimed at Mitigating Disparities in Organ Donation
Jerry McCauley MD, MPH

Sunrise Symposium II: C-Peptide Positive Diabetics: Appropriate Candidates for Pancreas Transplantation?
Room 312
Chairs: Peter Stock, MD, PhD, and Alexander Wiseman, MD

This is an audience response system session, supported by Roche Laboratories, Inc.

7:00 AM Defining Diabetes: C Peptide and Beyond
Jennifer Larsen, MD

7:15 AM Selection of Appropriate Candidates and Outcomes of Pancreas Transplantation for C-Peptide Positive Diabetics
Robert Stratta, MD

7:30 AM Pancreas Transplantation for C-Peptide Positive Diabetics
PRO: David Sutherland, MD, PhD
CON: David Harlan, MD

8:00 AM Audience Response/Discussion

Sunrise Symposium III: CMV and BK Virus: Controversies and Challenges
Ballroom B
Chairs: Atul Humar, MD, MSC, and David Snydman, MD

7:00 AM The Case for CMV Prophylaxis: Universal vs Pre-emptive Treatment
David Snydman, MD

7:15 AM Assessing Risk: CMV Immunity in Transplantation
Martina Sester, PhD

7:30 AM Treatment of CMV: Newer Options and Lessons from Clinical Trials
Atul Humar, MD, MSC

7:45 AM Risk and Prevention of BK Nephropathy
Hans Hirsch, MD, MSC

8:00 AM Discussion

Sunrise Symposium IV: Donation After Cardiac Death and Liver Transplantation: Where are We in 2009?
Ballroom A
Chairs: Anthony M. D’Alessandro, MD, and R. Mark Ghoeniali, MD, PhD

7:00 AM Selecting the Appropriate DCD Donor
Hani Grewal, MD

7:25 AM Donation after Cardiac Death and Liver Transplantation: The United States’ Experience
Shawn Pelletier, MD

7:50 AM Donation After Cardiac Death and Liver Transplantation: The European Experience
Jacques Belghiti, MD

Sunrise Symposium V: Innate Regulation of Adaptive Immunity
Room 302/304
Chairs: Jessamyn Bagley, PhD, and Anita Chong, PhD

7:00 AM Colitis Driven by T-bet Deficiency in Dendritic Cells
Wendy Garrett, MD, PhD

7:25 AM NK Cell Tolerance to Self and Others
Wayne Yokoyama, MD

8:00 AM Complement Regulation Exerts Control over T cell Immunity and Tolerance
Peter Heeger, MD
Early Morning Workshops

7:00 AM – 8:15 AM

21. HLA Epitope Matching for Organ Transplantation: What’s the Role?
Rene Duquesnoy, PhD
Frans Claas, PhD
Room 105

22. Strategies for Infection-free Life After Transplant
Deepali Kumar, MD
Robin Avery, MD
Room 305

23. Transplanting in HIV
Emily Blumberg, MD
John Fung, MD, PhD
Room 308

24. Expanding the Liver Donor Pool
A. Joseph Tector, MD
John Renz, MD, PhD
Room 301

25. Micro RNA Regulation of the Immune Response
Alexander Rudensky, MD
Mark Lindsay, PhD
Room 104

26. Imaging Immune Responses (Labeling Cells, Cell Trafficking)
Michael Dustin, PhD
Thorsten Mempel, MD, PhD
Room 303

8:15 AM Break

Plenary Session III
8:30 AM – 10:00 AM

8:30 AM Analysis of HLA Alloantigen Immunogenicity Based on the Physiochemical Properties of Polymorphic Amino Acids Enables Prediction of the Magnitude of Humoral Immune Responses. (Abstract #389)

8:45 AM The Immunoproteasome Beta Subunit Ten Is Increased in Chronic Antibody Mediated Allograft Rejection; Proteasome Inhibition as a Novel Therapeutic Strategy. (Abstract #390)
Joanna Ashton-Chess, Vojislav Jovanovic, Mai Le Hoa, Karine Renaudin, Yohann Foucher, Magali Giral, Anne Moreau, Emilie Dugast, Michael Mengel, Maud Raczapé, Richard Danger, Claire Usal, Helga Smit, Marina Guillet, Wilfried Gwinner, Jean-Paul Soulillou, Sophie Brouard. Nantes, France; Alberta, Canada; Nantes, France; Hannover, Germany.

9:00 AM AEB071, a Novel Protein Kinase C-Inhibitor: First Clinical Results of an AEB071 Plus Tacrolimus Regimen in Renal Transplant Recipients. (Abstract #391)
Klemens Budde, Claudia Sommerer, Thomas Becker, Argiris Asderakis, Frank Pietruck, Josep M. Grinyo, Paolo Rigotti, Jacques Dantal, Jennifer Ng, Markus J. Barten, Markus Weber.

9:15 AM ASTS Awards

9:30 AM The New Heart Allocation System: Is It Working as Designed? (Abstract #392)
Leah B. Edwards, Maryl R. Johnson, J. David Vega, On Behalf of the OPTN/UNOS Thoracic Transplantation Committee. Richmond, VA; Madison, WI; Atlanta, GA.

9:45 AM Prevention of Endothelial Activation with C5 Inhibition in Positive-Crossmatch Kidney Transplants (+XMKTx). (Abstract #393)
Lynn D. Cornell, Justin M. Burns, Mark D. Stegall. Rochester, MN.
Controversies in Transplantation
10:00 AM – 10:45 AM

Making Clinical Trials Relevant
Auditorium
Chairs: Flavio Vincenti, MD, and Goran Klintmalm, MD, PhD

10:00 AM Trends in Trial Design—Is it Time to Re-Assess Non-Inferiority?
  Herwig-Ulf Meier-Kriesche, MD

10:12 AM Is it Time to Change Control Groups in Transplant Studies?
  Arthur Matas, MD

10:24 AM What are the Key FDA Issues in Registration Trials in Transplantation?
  Patrick Archdeacon, MD

10:36 AM Discussion

10:45 AM Break

ASTS/AST Presidential Addresses
11:00 AM – 12:00 NN
Auditorium

ASTS President’s Address
John Roberts, MD

AST President’s Address
Barbara Murphy, MD

ASTS/AST Distinguished Awards
12:00 NN – 12:30 PM
Auditorium

Industry-Supported Satellite Symposium
12:45 PM – 2:00 PM
Contemplating CMV
Auditorium

Concurrent Session 55: Acute Kidney Rejection: Gene Expression
2:15 PM – 3:45 PM

Ballroom B
Chairs: Darshana Dadhania, MD, and Philip Halloran, MD, PhD

2:15 PM Intragraft Expression Profiles by Quantitative PCR in Kidney Transplant Patients Reflect Variability in the Response to Anti-Rejection Treatment with Corticosteroids. (Abstract #394)

  Michael Mengel, D. Kayser, W. Gwinner, A. Schwarz, J. Reeve, H. Haller, P. Halloran. Canada; Germany.

2:39 PM High Expression of Markers of Alternative Macrophage Activation Is a Feature of Canonical T Cell Mediated Rejection. (Abstract #396)
  Konrad S. Famulski, Gunilla Einecke, Banu Sis, Philip F. Halloran. Edmonton, AB, Canada.

2:51 PM NK Cells Likely Produce IFNγ in Response to Allo-Antigens (Ags) and Contribute to Antibody Mediated Rejection (AMR) in Highly Sensitized Patients (HS). (Abstract #399)
  Mieko Toyoda, Shili Ge, Pavel Pichurin, Andy Pao, Ashley Vö, Nathan Deer, Angela Aguiluz, Artur Karasyov, Stanley C. Jordan. Los Angeles, CA.

3:03 PM Foxp3 Levels Predict Clinical Outcome in Patients with Borderline Change after Renal Transplantation. (Abstract #398)
3:15 PM  Reassessing “Subclinical Rejection” Using Molecular Features: Typical T Cell Mediated Rejection Is Rare in Protocol Biopsies. (Abstract #397)
Daniel Kayser, Michael Mengel, Wilfried Gwinner, Anke Schwarz, Jeff Reeve, Hermann Haller, Philip F. Halloran. Edmonton, AB, Canada; Hannover, Germany.

3:27 PM  Reassessing Banff: Using Molecular Analysis To Test the Histologic Classification. (Abstract #400)
Nathalie Kayser, Jeff Reeve, Michael Mengel, Banu Sis, Philip F. Halloran. Edmonton, AB, Canada.

Concurrent Session 56: Antibody, Endothelium and Vasculopathy
2:15 PM – 3:45 PM
Room 312
Chairs: David Briscoe, MD, and Paul Grimm, MD

2:15 PM  Nox-2 May Be a Modulator of Chronic Cyclosporine A (CsA) Nephrotoxicity. (Abstract #401)
Arjang Djamali, Aparna Vidyasagar, Elizabeth Sadowski, Lynn Jacobson, Deb Hullett, Shannon Reese. Madison, WI.

2:27 PM  Impaired Notch4 Activity Is an Hallmark of Endothelial Dysfunction Associated with Chronic Allograft Vasculopathy. (Abstract #402)
Thibaut Quillard, Stephanie Coupel, Flora Coulon, Juliette Fitau, Mathias Chatelais, Maria-Cristina Cuturi, Elise Chiffoleau, Beatrice Charreau. Nantes, France.

2:39 PM  Apoptotic Endothelial Cells Promote Myofibroblast Differentiation through Secretion of Connective Tissue Growth Factor (CTGF) in a Caspase-3-Dependent and a TGFbeta1-Independent Manner. (Abstract #403)
Alain Beliveau, Patrick Laplanche, Isabelle Sirois, Marc-Andre Raymond, Victor Kokta, Alexandre Prat, Alexei V. Pshezhetsky, Marie-Josee Hebert. Montreal, QC, Canada.

2:51 PM  Apoptosis Triggers Exosome-Dependent Release of TCTP Downstream of Caspase-3 Activation: A Novel Pathway for Anti-Apoptotic Intercellular Communication. (Abstract #404)
Isabelle Sirois, Marc-Andre Raymond, Jean-Francois Caillier, Nathalie Brassard, Alexei V. Pshezhetsky, Hebert Marie-Josee. Montreal, QC, Canada.

3:03 PM  Development of Antibodies to Collagen V during Post-Transplantation Are Associated with Adverse Graft Outcome in Cardiac Transplant Recipients. (Abstract #405)
Dilip S. Nath, Deepi Saini, Sabarinathan Ramachandran, Gregory A. Ewald, Nader Moazami, T. Mohanakumar. St. Louis, MO.

3:15 PM  Autoantibody Contributes to the Development of Allograft Vasculopathy, but Only in Concert with Conventional Alloimmune Responses. (Abstract #406)

3:27 PM  Targeting CCR5 Attenuates the Development of CAV in a Primate Model. (Abstract #407)
Tiffany A. Stoddard, Sean Kelishadi, Tianshu Zhang, Christopher Avon, Emily Welty, Amal Laaris, Xiangfei Cheng, Amy Berson, Man-Ling Sung, Minh Diem Vu, Dominic C. Borie, Jose M. Lora, Johannes Auer, Karim Dabbagh, Agnes Azimzadeh, Richard N. Pierson III. Baltimore, MD; Palo Alto, CA.

Concurrent Session 57: Anti-HLA Antibodies
2:15 PM – 3:45 PM
Room 206
Chairs: Mark Laftavi, MD, and V. Ram Peddi, MD

2:15 PM  Impact of Repeat HLA Antigen Mismatch (RMM) in Second Renal Transplant Recipients (RTR). (Abstract #408)
K. Tinckam, C. Rose, S. Harrihan, J. Gill. Toronto, ON, Canada; Vancouver, BC, Canada; Milwaukee, WI.
Concurrent Session 58: Barriers and Surgical Issues of Kidney Living Donation
2:15 PM – 3:45 PM
Room 210
Chairs: Dicken Ko, MD, and Jean Paul Squiffet, MD, PhD

2:15 PM The Changing Landscape of Living Kidney Donors in the US. (Abstract #415)
Jennifer L. Wainright, Matthew Cooper, D. L. Bolton, Connie L. Davis.

Didier Mandelbrot, Martha Pavlakis, Scott Johnson, Seth Karp, Doug Hanto, James Rodrigue. Boston, MA.

2:39 PM Disparities in the Utilization of Live Donor Renal Transplantation. (Abstract #417)
Jennifer S. Singer, John L. Gore, Mark S. Litwin, Phuong-Thu T. Pham, Gabriel M. Danovitch. Los Angeles, CA.

2:51 PM Clinical Significance of Slow Recovery of Graft Function in Living Donor Kidney Transplantion. (Abstract #418)
So Young Lee, Hye Eun Yoon, Bok Jin Hyoung, Youn Joo Jeon, Hyeon Seok Hwang, Joon Chang Song, Bum Soon Choi, Yong-Soo Kim, Suk Young Kim, Yeong Jin Choi, Chul Woo Yang. Seoul, Republic of Korea.

3:03 PM Current Trends and Short-Term Outcomes of Live Donor Nephrectomy: A Population Based Analysis. (Abstract #419)
Anand Singla, Nicholas G. Csikesz, YouFu Li, Rodney Taylor, Adel Bozorgzadeh, Shimul A. Shah. Worcester, MA.

3:15 PM Laparoscopic Procurement Results in Better Outcomes for Pediatric Recipients; an Analysis of 306 Cases. (Abstract #420)
Nizam Mamode, Rachel Johnson, Vassilis Hadjianastassiou. London, United Kingdom; Bristol, United Kingdom.
3:27 PM  Long-Term Follow-Up of a Randomized Trial Comparing Laparoscopic and Mini-Incision Open Donor Nephrectomy. (Abstract #421) 
Leonienke F. C. Dols, Niels F. M. Kok, Noortje Wentink, Khe T. C. Tran, Willij C. Zuidema, Ine M. Dooper, Willem Weimar, Jan N. M. Ijzermans. Rotterdam; Nijmegen, Netherlands.

Concurrent Session 59: Biopsy Scoring and ECDs
2:15 PM – 3:45 PM
Room 302/304
Chairs: Jeffrey Rogers, MD, and Brian Shames, MD

2:15 PM  Improving Long Term Outcomes in Recipients of Older Kidneys Utilizing a Pre-Implantation Biopsy Scoring System (MAPI). (Abstract #422) 
Benjamin Philosophe, Christine Tabor, Ashley Jackson, Erin McCann, Rolf Barth, Eugene Schweitzer, Matthew Cooper, Sameh Fayek, Stephen Bartlett, Raghava Munivenkatappa. Baltimore, MD.

2:27 PM  Use of Baseline Kidney Biopsies (BX) and Pulsatile Perfusion Parameters To Predict Graft Outcome in Deceased Donor (DD) Kidney Transplants. (Abstract #423) 
Todd E. Pesavento, Uday S. Nori, Anjali Satoskar, Dorrie Dils, Mitchell L. Henry, Jon R. Von Visger, Neeraj Singh. Columbus, OH.

2:39 PM  Time-Zero Biopsy Gene Expression Data Predict Short and Long Term Outcomes Post Kidney Transplantation. (Abstract #424) 
Daniel Maluf, Kellie Archer, Kenneth Yanek, Adrian Cotterell, Amit Sharma, Marc Posner, Robert Fisher, Anne King, Valeria Mas. Richmond, VA.

2:51 PM  Cellular or Humoral Presensitization Increases the Risk of Delayed Graft Function and Acute Rejection in Recipients of Expanded Criteria Donor Kidneys. (Abstract #425) 

3:03 PM  Expanded Criteria Deceased Donor Renal Transplants Are Not Significantly More Costly Than Standard Criteria Deceased Donor Renal Transplants. (Abstract #426) 

3:15 PM  Improved Long-Term Outcomes of ECD Transplants Using Pulsatile Perfusion Preservation. (Abstract #427) 
Richard Perez, Denise Simao, Christoph Troppmann, Michael Daily, John McVicar, Brian Gallay, Mehul Gandhi, Muralikrishna Golconda, Angelo de Mattos. Sacramento, CA.

3:27 PM  Expanding the Definition of Extended Criteria Donors: Successful Utilization of 70 Year Old Deceased Donor Kidneys. (Abstract #428) 
Alp Sener, Poornima Vanguri, Raghava Munivenkatappa, Wana Manitpisitkul, Rolf N. Barth, Abdolreza Haririan, Stephen T. Bartlett, Benjamin Philosophe, Matthew Cooper. Baltimore, MD.

Concurrent Session 60: Composite Tissue Transplants
2:15 PM – 3:45 PM
Room 208
Chairs: Linda Cendales, MD, and Scott Gruber, MD, PhD, MBA

2:15 PM  First Face Allograft in Human: A Three Years Follow Up. (Abstract #429) 
Lionel Badet, Emmanuel Morelon, Palmina Petruzzo, Sylvie Testelin, Jean Kanitakis, Assia Eljafari, Christophe Malcus, Nathalie Parquet, Xavier Martin, Bernard Devauchelle, Olivier Hequet, Mauricette Michallet, Jean-Michel Dubernard. Lyon, France; Amiens, France; Paris, France.
2:27 PM  Transplant Vasculopathy and Humoral Alloresponse in Composite Tissue Allotransplantation: Role of Multiple Acute Rejections. (Abstract #430)

Concurrent Session 61: Genomics/Proteomics of Kidney Allograft Dysfunction
2:15 PM – 3:45 PM
Room 309
Chairs: Valeria Mas, PhD, and Thomas Mueller, MD, PD

2:39 PM  Interleukin-2 Induced Immunomodulation for Long-Term Survival of Composite Tissue Allotransplantation. (Abstract #431)
Jignesh Unadkat, Rishi Jindal, Tim Ng, Mario Solari, Kia Washington, Yong Wang, Vijay Gorantla, W. P. Andrew Lee, Xin Xiao Zheng. Pittsburgh, PA.

2:51 PM  An Unusual PTLD-Like Syndrome in Hand Transplant Recipient 2 Years Post Transplant. (Abstract #432)
Warren Breidenbach, Roger Herzig, Christina Kaufman, Stephen Slone, Brenda Blair, Wyndom Wilson, Joseph Buell, Kadiyala Ravindra. Louisville, KY; MD.

3:03 PM  Using a FACES Score To Create a Face Transplant Candidate Registry. (Abstract #433)
Chad R. Gordon, Daniel Alam, Steven Bernard, Risal Djohan, Frank Papay, James E. Zins, Kathy Coffman, Maria Siemionow. Cleveland, OH.

3:15 PM  Steroid Free Immunosuppression in Hand Transplantation: First Large Series in World Literature. (Abstract #434)
Kadiyala Ravindra, Joseph Buell, Christina Kaufman, Michael Marvin, Brenda Blair, Warren Breidenbach. Louisville, KY.

Warren Breidenbach, Kadiyala Ravindra, Joseph Buell, Brenda Blair, Christina Kaufman. Louisville, KY.

3:39 PM  Differential Immunogenicity and Clinical Relevance of Kidney Compartment Specific Antigens after Renal Transplantation. (Abstract #436)
Li Li, Minnie Sarwal.

3:41 PM  Integrated Peptidomic and Genomic Analyses of Renal Allograft Dysfunctions Revealed Altered Protein Catabolism Resulting Predictive Urine Peptide Biomarkers. (Abstract #439)

3:43 PM  Single Nucleotide Polymorphism Associated with Acute Rejection in Renal Transplants. (Abstract #440)
3:15 PM Discovery and Validation of Diagnostic Peripheral Blood Gene Expression Signatures for Acute Rejection: Report of the TGCG Study. (Abstract #441) Sunil Kurian, Adam Williams, Christopher Marsh, Tony Mondala, Steven Head, Daniel Salomon. La Jolla, CA.


Concurrent Session 62: Immunosuppression Preclinical Studies I 2:15 PM – 3:45 PM Room 310 Chairs: Douglas Hale, MD, and Nader Najafian, MD


2:27 PM Targeting and Modulating Human Lymphocytes and Monocytes with a Novel Polyclonal Rabbit Anti-Human Leukocyte Antibody. (Abstract #444) He Xu, Yusong Fang, Liangming Zhu, Yong Jiang, Allan D. Kirk. Jinan, China; Atlanta.


2:51 PM Local, Graft Specific Immunosuppression Is a Safe Treatment Option To Prevent Acute and Chronic Rejection in an Airway Transplant Model. (Abstract #446) Tobias Deuse, David Weill, Hermann Reichenspurner, Robert C. Robbins, Bruce Reitz, Sonja Schrepfer. Stanford, CA; Hamburg, Germany.


Concurrent Session 63: Islet: Clinical Issues 2:15 PM – 3:45 PM Room 306 Chairs: Paolo Fiorina, MD, PhD, and Jose Oberholzer, MD

2:27 PM Islet Allograft Survival in Type 1 Diabetics Using a Calcineurin Inhibitor-Free Protocol Based on the Anti-LFA-1 Antibody Efalizumab. (Abstract #451)

2:39 PM Development of HLA Sensitization Post Islet Transplantation: Are There Implications for Allograft Function? (Abstract #452)
Luis Fernandez, Milagros Samaniego, Matthew Hanson, David Hirsch, David Lorentzen, Nancy Radke, and Jon Odorico. Madison, WI.

2:51 PM Immune Monitoring in Clinical Islet Transplantation by Assessment of Induced-Activation of CD4+ T-Lymphocytes. (Abstract #453)
Davide Mineo, Tatiana Froud, David A. Baidal, Eva Herrada, Manuel Carrero, Philip Ruiz, Luigi Meneghini, Camillo Ricordi, and Rodolfo Alejandro. Miami, FL.

3:03 PM Evidence of Islet Survival and Revascularization Following Intramuscular Autotransplantation in the Minipig. (Abstract #454)
Adrien Sterkers, Thomas Hubert, Robert Caiazzo, Valery Gmyr, Nathalie Delalleau, Julie Kerr-Conte, Francois Pattou, and Francois Pattou. France.

3:15 PM Biopsy Monitoring after Clinical Islet Transplantation. (Abstract #455)

Rodolfo Alejandro, Francois Pattou, James F. Markmann, Franca B. Barton, Enrico Cagliero, Stephen Wease, Ali Naji, Bernhard J. Hering. Miami, FL; Lille, Cedex, France; Boston, MA; Rockville, MD; Minneapolis, MN; Philadelphia, PA.

2:15 PM Tacrolimus Pharmacokinetics When Combined with the Protein Kinase C Inhibitor AEB071 in De Novo Kidney Transplant Patients. (Abstract #457)

2:27 PM AEB071, a Novel Protein Kinase C-Inhibitor: Evaluation of an AEB071 Plus Mycophenolate Regimen in Renal Transplant Recipients. (Abstract #458)

2:39 PM Pharmacometrics of Voclosporin: Predicting Clinical Outcome with Calcineurin Activity in a Phase 2b Renal Transplant Trial. (Abstract #459)

2:51 PM Pharmacometrics of Voclosporin: Quantification of a Therapeutic Window in a Phase 2b Renal Transplant Trial. (Abstract #460)
Spencer Ling, Rita Alloway, A. Osama Gaber, Shamkant Mulgaonkar, Herwig-Ulf Meier-Kriesche, Anthony Jevnikar. Edmonton, AB, Canada; Cincinnati, OH; Houston, TX; Livingston, NJ; Gainesville, FL; London, ON, Canada.
Concurrent Session 65: Liver:
Complications, Recurrent Disease,
and Hepatitis III

Saturday, June 2

2:15 PM – 3:45 PM

Ballroom A

Chairs: Thomas Collins, MD, and Dong-Sik Kim, MD, PhD

2:15 PM  Efficacy of Combined Steroid-Free
Immunosuppression with Low Dose
Preemptive Anti-HCV Therapy
for Hepatitis C Virus Infection in
Living Donor Liver Transplantation.
(Abstract #464)
Shigeru Marubashi, Hiroaki Nagano,
Shogo Kobayashi, Yutaka Takeda,
Masahiro Tanemura, Keizo Dono, Koji
Umeshita, Morito Monden, Yuichiro
Doki, Masaki Mori. Suita, Osaka, Japan.

2:27 PM  Induction with Rabbit Antithymocyte
Globulin Delays Recurrent Disease
Following Orthotopic Liver
Transplantation for Hepatitis C Virus. (Abstract #465)
Reza Saidi, M. Hertl, D. S. C. Ko, P.
Kennealey, T. Kawai, J. Markmann, A. K.
Bhan, R. Chung, A. B. Cosimi, N. Elias.

2:39 PM  The Effects of Smoking on Liver
Transplant Morbidity and Mortality.
(Abstract #466)
Tacara N. Soones, Shing Lee, Silvia
Hafliger, Lorna M. Dove. New York,
NY.

2:51 PM  High Incidence of Early Cardiac
Death after Liver Transplantation for
NASH Cirrhosis. (Abstract #467)
Bahar Madani, Shahid Malik, Jawad
Ahmad. Pittsburgh, PA.

3:03 PM  Early Indicators of Outcome in Type
1 Hepatorenal Syndrome: Focus
on Serum Creatinine in the Pivotal
Terlipressin Trial. (Abstract #468)
Andrew Keaveny, Guadalupe Garcia-
Tsao, Alice Bexon, Arun Sanyal.

3:15 PM  Cardiovascular Risk Factors and
Mortality in the First Four Years
after Liver Transplantation. Results
of a Spanish Multicentre Database
Focused in Cardiovascular Disease.
(Abstract #469)
J. Ignacio Herrero, V. Cuervas-Mons,
J. Marti, J. Ortiz-de-Urbina, L. Llado,
C. Jimenez, E. Otero, F. Suarez, J.
Rodrigo, M. A. Gomez, E. Fraga, P.
Pamplona, Navarra, Spain; Madrid,
Spain; Barcelona, Spain; Bilbao, Spain;
Santiago, Spain; La Coruña, Spain;
Malaga, Spain; Sevilla, Spain; Cordoba,
Spain; Zaragoza, Spain; Murcia, Spain;
Santander, Spain.

3:27 PM  Portal Vein Thrombosis (PVT) and
Liver Transplant Survival Benefit.
(Abstract #470)
Michael J. Englesbe, Douglas
E. Schauble, Shije Cai, Mary K.
Guidinger, Robert M. Merion. Ann
Arbor, MI.
Concurrent Session 66: Liver: Immunosuppression Issues
2:15 PM – 3:45 PM

Ballroom C
Chairs: Lynt Johnson, MD, MBA, and Hugo Vargas, MD

2:15 PM  Conversion to Cyclosporine Therapy Induces Significant Benefits in Liver Transplant Recipients on Tacrolimus with New Onset Diabetes: The DIALIVER Study. (Abstract #471)
Maria Rendina, Giorgio Rossi, Davide D’Amico, Franco Filippioni, Pierluigi Toniutto, Giorgio E. Gerunda, Oreste Cuomo, Francesco Picciotto, Gian Luca Grazi, Gianpaolo Parrilli, Pasquale Conoscitore, Sabina C. Magalini, Giuseppe Tisone, Mario Strazzabosco, Giuseppe Corbetta, Marta Bartezzaghi, Piero Marchetti. Bari, Italy.

2:27 PM  Alemtuzumab Induction in Non-Hepatitis C Positive Liver Transplant Recipients. (Abstract #472)
Josh Levitsky, Kavitha Thudi, Michael G. Ison, Michael Abecassis. Chicago, IL.

2:39 PM  Successful Use of an Immunosuppressive Regimen Aimed at Temporarily Depleting B Cells and Blocking B-1 Cell Differentiation in ABO-Incompatible Liver Transplantation. (Abstract #473)
Hirofumi Tazawa, Toshimitsu Irei, Yuka Igarashi, Hirotaka Tashiro, Toshimasa Asahara, Hideki Ohdan. Hiroshima, Japan.

2:51 PM  Excellent Efficacy and Renal Function in Liver Recipients with Tacrolimus Once-Daily Prolonged Release: 2-Year Follow-Up. (Abstract #474)
P. Trunecka, O. Boillot, U. Neumann. Prague, Czech Republic; Lyon, France; Berlin, Germany.

3:03 PM  Mycophenolate Mofetil Monotherapy Favour Impact the Histological Course in HCV Transplant Recipients. (Abstract #475)
Tommaso Maria Manzia, Luca Toti, Ilaria Lenci, Roberta Angelico, Andrea Monaco, Matteo Manuelli, Linda De Luca, Laura Tariciotti, Leonardo Baiocchi, Giuseppe Tisone. Rome, Italy.

3:15 PM  Application of CD8+ Cells Count as a Guide of Immunosuppressant Conduction for Very Sick Patients Undergoing Liver Transplantation. (Abstract #476)
Chen-Fang Lee, Ting-Jun Wu, Hong-Shiue Chou, Kun-Ming Chan, Wei-Chen Lee. Taoyuan, Taiwan.

3:27 PM  Impact of an Steroid-Free Immunosuppression Regimen (Tacrolimus + Mycophenolate Mofetil) Versus a Conventional Regimen (Tacrolimus + Steroids) in Cardiovascular Risk Factors after Liver Transplantation: Preliminary Results. (Abstract #477)
Valentin Cuervas-Mons, Jose I. Herrero, Miguel A. Gomez, Ignacio Gonzalez, Trinidad Serrano, Manuel De la Mata, Joan Fabregat, Javier Bustamante, Mikel Gastaca, Itxarone Bilbao, Evaristo Varo, Gloria Sanchez, Miguel Jimenez, Rafael Martin-Vivaldi. Spain.

Concurrent Session 67: Miscellaneous Pathogens
2:15 PM – 3:45 PM

Room 313
Chairs: Upton Allen, MBBS, and Robin Avery, MD

Majdi N. Al-Hasan, Raymund R. Razonable, Jeanette E. Eckel-Passow, Larry M. Baddour. Lexington, KY; Rochester, MN.

2:27 PM  Tuberculosis after Kidney Transplantation; Single Center Experience in Endemic Area. (Abstract #479)

2:51 PM  Pulmonary Zygomycosis in Solid Organ Transplant Recipients: Risks and Outcomes in the Current Era. (Abstract #481)

3:03 PM  Intradermal Influenza Vaccination of Adult Renal Transplant Recipients: Randomised Controlled Phase 2 Trial. (Abstract #482)
Emmanuel Morelon, Claire Pouteil-Noble, Sameh Daoud, Remi Cahen, Jean-Louis Touraine, Catherine Goujon-Henry, Françoise Weber, Pascal Laurent, Dominique Kaiserian, Jean-François Nicolas. Lyon, France; Pierre Bénite, France; Marcy l’Etoile, France.

3:15 PM  Reduced Incidence of Seasonal Influenza with Oseltamivir Prophylaxis in Solid Organ Transplant (SOT) Recipients. (Abstract #483)
Michael G. Ison, P. Szakaly, M. Y. Shapira, G. Kriván, A. Nist, R. Dutkowskii. Chicago, IL; Pécs, Hungary; Jerusalem, Israel; Budapest, Hungary; Nutley, NJ.

3:27 PM  Molecular Evidence of Interhuman Transmission in an Outbreak of Pneumocystis jirovecii Pneumonia in Renal Transplant Recipients. (Abstract #484)
Nicolas J. Mueller, Lea Haeberli, Beda Joos, Bruno Ledergerber, Rudolf P. Wuthrich, Rainer Weber, Herbert Kuster, Philippe M. Hauser, Thomas Fehr, Sara Gianella. Zurich, Switzerland; Lausanne, Switzerland.

Concurrent Session 68: T Cell Costimulation: New Pathways and Implications
2:15 PM – 3:45 PM
Room 311
Chairs: Antje Habicht, MD, and A. M. Waaga-Gasser, MD, Prof

2:15 PM  Central Memory CD8 T Cells Derive from the Effector T Cell Pool and Not from a Separate Lineage. (Abstract #485)
Castle J. Funatake, Erica L. Jacovetty, Elizabeth Ingulli. San Diego, CA; La Jolla, CA.

2:27 PM  A Novel Interaction between PDL1 and B7.1 Is Functional in Inhibiting Alloimmune Responses In Vivo. (Abstract #486)
Jun Yang, Susanne Robles, Leonardo Riella, Mohamed H. Sayegh, Anil Chandraker. Boston, MA.

2:39 PM  The Emerging Role of T Cell Ig Mucin-1 (TIM-1) in the Mechanism of Liver Ischemia and Reperfusion Injury. (Abstract #487)
Yoichiro Uchida, Bibo Ke, Maria Cecilia S. Freitas, Elizabeth R. Benjamin, Nader Najafian, Mohamed H. Sayegh, Ronald W. Busuttil. Los Angeles, CA; Boston, MA.

2:51 PM  TIM-4: An Important T Cell Costimulatory Molecule in Mediating CD28-Independent Alloimmune Responses In Vivo. (Abstract #488)
Melissa Yeung, Takuya Ueno, Olaf Boenisch, Hideo Yagita, Hisaya Akiba, David Rothstein, Nader Najafian, Mohamed Sayegh. Boston, MA; Tokyo, Japan; New Haven, CT.

3:03 PM  TGFβ Attenuates Th17 Responses by c-Maf Induction: A New Regulatory Pathway for IL-10. (Abstract #489)
Jiangnan Xu, Yu Yang, Girdhari Lal, Jonathon S. Bromberg, Yaozhong Ding. New York, NY.
3:15 PM  Impact of Naïve Donor-Reactive Precursor Frequency on the Differentiation of Costimulation-Independent CD8+ Memory T Cells. (Abstract #490)
Mandy L. Ford, Tamara L. Floyd, Maylene E. Wagener, Samantha S. Hanna, Linda Stempora, Rose Hendrix, Allan D. Kirk, Christian P. Larsen. Atlanta, GA.

3:27 PM  MicroRNAs in Lymphocyte Activation. (Abstract #491)
Jessamyn Bagley, Jonathan G. Godwin, Peter Jindra, John Iacomini. Boston, MA

3:45 PM  Break

Concurrent Session 69: Acute Kidney Rejection: Antibody-Mediated
4:00 PM – 5:30 PM

Auditorium
Chairs: Enver Akalin, MD, and Stanley Jordan, MD

4:00 PM  Assessing Pre-Transplant Immunologic Risk – A New Paradigm. (Abstract #492)

4:12 PM  A Virtual Crossmatch Approach to Transplant Sensitized Recipients across a Positive Flow Cytometry Crossmatch. (Abstract #493)

4:24 PM  Characteristics of Patients Who Developed Antibody Mediated Rejection (AMR) Post-Transplant after Desensitization with IVIG + Rituximab: Analysis of Risk Factors & Outcomes. (Abstract #494)
Ashley A. Vo, Kai Cao, Chih-Hung Lai, Nancy Reinsmoen, Mieko Toyoda, Shili Ge, Alice Peng, Rafael Villicana, Stanley C. Jordan. Los Angeles, CA.

4:36 PM  De Novo Other Than Pre-Existing Circulating Antiendothelial Cell Antibodies Are Associated with Post Transplant Allograft Rejection: A Prospective Study. (Abstract #495)
Qiquan Sun, Zhihong Liu, Zhen Cheng, Jinsong Chen, Dongrui Cheng, Shuming Ji, Jiqiu Wen, Leishi Li. Nanjing, China.

4:48 PM  A Single Center Experience: Can a Virtual Crossmatch Replace the Prospective Crossmatch? (Abstract #496)
Christopher P. Johnson, Brian D. Shames, Stephanie Brown, Allan M. Roza, David C. Cronin, Thomas M. Ellis. Milwaukee, WI.

5:00 PM  The Importance of HLA-Cw Typing in Avoiding Antibody Mediated Rejection. (Abstract #497)
Ty Dunn, H. Noreen, D. Maurer, A. Humar, R. Kandaswamy, D. Sutherland, W. Payne, A. Matas. Mpls, MN.

5:12 PM  Differential Evolution of Structural and Functional Changes during the First Year of Kidney Transplantation (KT). (Abstract #498)

Concurrent Session 70: BK Polyoma Virus II: Virological and Clinical Aspects
4:00 PM – 5:30 PM

Ballroom B
Chairs: Fabrizio Ginevri, MD, and Emilio Ramos, MD

4:00 PM  Rational Design of Anti-BK Virus (BKV) Drugs Targeting Functional Domains on BKV Large T-Antigen (LTA). (Abstract #499)
Parmjeet S. Randhawa, Gang Zeng, Marta Bueno, Carlos Camachos, Subramaniam Ananthan, Judith V. Hobraath. PA; Birmingham, AL.


Concurrent Session 71: Chemokines and Cytokines

4:00 PM – 5:30 PM

Room 310

Chairs: Robert Fairchild, PhD, and Gregg Hadley, PhD

4:00 PM  Endothelial Derived MCMV Dominates Dissemination from Heart Transplants during Primary but Not Secondary Viremia. (Abstract #506) Joachim Andrassy, Torsten Sacher, Karl W. Jauch, Ulrich H. Koszinowski. Munich, Germany.


4:36 PM  TNF-α Pathway Plays a Critical Role in Regulating CXCL11 and IP-10 Production in an Initial Allogeneic Human Monocyte-Endothelial Cell Interaction. (Abstract #509) He Xu, Qiansheng Li, Yong Jiang, Xiaoping Wang, Allan D. Kirk. Jinan, Shandong, China; Atlanta.

4:48 PM  Reversal of Established Cardiac Allograft Tolerance Following Bacterial Infection Is Mediated by IFNβ and IL-6. (Abstract #510) Tongmin Wang, Luqiu Chen, Jing Xu, Emily B. Ahmed, Jing Tao, Chyung-Ru Wang, Maria-Luisa Alegre, Anita S. Chong. Chicago, IL.

5:00 PM  Rejection of Single Class II MHC-Disparate Renal Allografts in CCR5 Deficient Mice. (Abstract #511) Daisuke Ishii, Shiro Baba, Robert L. Fairchild. Cleveland, OH; Sagamihara, Kanagawa, Japan.

5:12 PM  CXCL9 Influences the Generation of Donor-Reactive IFN-γ-Producing T Cells. (Abstract #512) Joshua M. Rosenblum, Robert Fairchild. Cleveland, OH.
Concurrent Session 72: Ischemia Reperfusion: Immune Mediators
4:00 PM – 5:30 PM

Room 312
Chairs: Hamid Rabb, MD, and Alexander Rosenkranz, MD

4:00 PM  NK Cells Induce Apoptosis in Tubular Epithelial Cells and Contribute to Renal Ischemia Reperfusion Injury by NKG2D and Perforin-Dependent Mechanisms. (Abstract #513)
Zhu-Xu Zhang, Shuang Wang, Xuyan Huang, Hongtao Sun, Weihua Liu, Bertha Garcia, Anthony M. Jevnikar. London, ON, Canada.

4:12 PM  Donor Dendritic Cells: A Link between Innate and Adaptive Immunity. (Abstract #514)
Mollie Jurewicz, Katsunori Tanaka, Takuya Ueno, Takaya Murayama, Andrea Augello, Paolo Fiorina, Reza Abdi. Boston, MA.

4:24 PM  Therapeutic Targeting of Classical and Lectin Pathways of Complement (C) Protects the Kidney from Ischemia-Reperfusion (I/R) Injury Inhibiting the Activation of Dendritic Cells. (Abstract #515)

4:36 PM  Foxp3+ Regulatory T Cells Play a Role in Repair from Kidney Ischemia-Reperfusion Injury (IRI). (Abstract #516)

4:48 PM  IL-13 Protects Mouse Intestine from Ischemia and Reperfusion Injury through Regulation of Innate and Adaptive Immunity. (Abstract #517)

5:00 PM  Neutralization of Extracellular HMGB-1 Significantly Protects Mice Against Renal Ischemia Reperfusion Injury. (Abstract #518)
Gang Chen, Junhua Li, Quan Gong, Shan Zhong, Yongle Ruan, Song Chen, Ying Xiang, Felli Gong, Shi Chen. Wuhan, Hubei, China.

5:12 PM  Nitric Oxide Homeostasis Prevents Ischemia Reperfusion Injury Related Endothelial Dysfunction after Murine Pancreas Transplantation. (Abstract #519)
Manuel Maglione, Rupert Oberhuber, Paul Hengster, Martin Hermann, Walter Mark, Peter Obst, Gabriele Werner-Felmayer, Ernst Werner, Raimund Margreiter, Gerald Brandacher. Innsbruck, Austria.

Concurrent Session 73: Kidney Immunosuppression: Steroid Minimization – Avoidance Protocols
4:00 PM – 5:30 PM

Room 302/304
Chairs: John Friedewald, MD, and Richard Knight, MD

4:00 PM  Prospective Randomized Trial of Sirolimus (SRL) and Mycophenolate Mofetil (MMF) vs. Tacrolimus (TAC) + MMF Therapy Following Thymoglobulin (THY) Induction with Rapid Steroid Taper (RST) in Primary Kidney Transplantation (KTX). (Abstract #520)

4:12 PM  Optimisation of Mycophenolic Acid (MFA) Exposure for Early Steroid Withdrawal in Kidney Graft Recipients: The OPERA Trial. (Abstract #521)
**Concurrent Session 74: Kidney Living Donor Outcomes I**

**4:00 PM – 5:30 PM**

*Ballroom C*

*Chairs: Diane Cibrik, MD, MS, and Randall Sung, MD*

**4:00 PM** Very Long-Term Data on Living Kidney Donors: A Single Center Experience Since 1959. (Abstract #527)


**4:12 PM** Does Obesity Increase Long-Term Risk of Renal Dysfunction and Cardiovascular Disease in Kidney Donors? (Abstract #528)


**4:24 PM** The Consequences of Diabetic Live Kidney Donors – Analysis of 444 Cases for 23 Yrs in Japanese Single Center. (Abstract #529)


**4:36 PM** Estimated Number of Functioning Glomeruli in Older Living Kidney Donors. (Abstract #530)


**4:48 PM** Effects of Living Kidney Donation on 24-Hour Ambulatory Blood Pressure and Cardiovascular Risk Profile: A 12 Month Prospective Study. (Abstract #531)

G. V. Ramesh Prasad, Deborah Lipszyc, Jennie Huckle, Michael Huang, Michelle M. Nash, Sulagna Sarker, Lindita Rapi. Toronto, ON, Canada.
5:00 PM  Utilization of Older Living Donors Provides Excellent Outcomes after Kidney Transplantation. (Abstract #532)
Vinod Balachandran, David Leeser, Meredith Aull, Marian Charlton, Jose Figueiro, David Servur, Joseph Del Pizzo, Sandip Kapur. NY.

5:12 PM  Prior Living Kidney Donors Who Subsequently Needed Chronic Maintenance Dialysis. (Abstract #533)
Wida Cherikh, Pang-Yen Fan, Charlotte Carroll, Jude Maghirang, Henry Randall, Carlton Young. Richmond, VA; Worcester, MA; Dallas, TX; Birmingham, AL.

Concurrent Session 75: Kidney: Complications III
4:00 PM – 5:30 PM
Room 210
Chairs: Hans Albin Gritsch, MD, FACS, and Mark Walsh, MD

4:00 PM  Is Dialysis-Associated Thrombophilia Corrected by Renal Transplantation? A Prospective Cohort Study on 310 Patients. (Abstract #534)

4:12 PM  Thrombophilic Factors Are Not Predictive of Thrombo-Embollic Events, Acute Renal Allograft Rejection, or Graft Survival in Patients Transplanted after 2000. (Abstract #535)

4:24 PM  Association of Donor to Recipient Serostatus Combination with Survival after Deceased Donor Kidney Transplants. (Abstract #536)
Wida Cherikh, Timothy Pruett. Richmond, VA; Charlottesville, VA.

4:36 PM  Effect of Race on Death Censored Renal Allograft Survival in Different Donor/Recipient Pairs. (Abstract #537)
Anita Patel, Mariella Goggins, Lauren Malinzek, Vanji Karthikeyan, Kathleen Brady. Detroit, MI.

4:48 PM  Lymphopenia Induced by Alemtuzumab Is Not Associated with an Increased Risk of Infection. (Abstract #538)
R. Charif, K. Chan, J. Galliford, A. Tanna, N. Kumar, A. McLean, D. Taube. Hammersmith Hospital, London, United Kingdom.

5:00 PM  Reduced Renal Function Is Associated to Health-Related Quality of Life in Kidney Transplant Recipients. (Abstract #539)
Luca Neri, Daniel Brennan, Paolo Salvadoraggio, Paula Buchanan, Jonathan Dukes, Mark Schnitzler. St. Louis, MO.

5:12 PM  Impact of Renal Tubular Acidosis on Graft Function of Kidney Recipients. (Abstract #540)

Concurrent Session 76: Liver: MELD/Allocation
4:00 PM – 5:30 PM
Ballroom A
Chairs: Julie Heimbach, MD, and Jeffrey Punch, MD

4:00 PM  End Stage Liver Disease (ESLD) Patients with High MELD Scores Have Higher Waitlist Mortality Than Status-1 Patients. (Abstract #541)
Pratima Sharma, Douglas E. Schaubel, Gong Qi, Mary K. Guidinger, Robert M. Merion. Ann Arbor, MI.
4:12 PM  Local and Regional Variation in Donor Risk Index and MELD Scores Translate into Disparate Graft and Patient Survival Rates: Should the Allocation System Be Changed? (Abstract #542)
Michael R. Marvin, Guy N. Brock, Kadiyala V. Ravindra, Mary Eng, Joseph F. Buell. Louisville, KY.

4:24 PM  Modified Liver Allocation Using D-MELD Risk Capping and Rule 14 Improves Post Liver Transplant Survival and Overall Mortality, a Markov Microsimulation Analysis. (Abstract #543)
Jeffrey Halldorson, Robert Carithers, Ramasamy Bakthavatsalam, Andre Dick, Renuka Bhattacharya, Iris Liou, Jorge Reyes, James Perkins. Seattle, WA.

4:36 PM  Pre-Transplant Cystatin C Levels Predict Survival after Liver Transplantation. (Abstract #544)

4:48 PM  ‘Re-Weighted’ MELD and Serum Sodium as Predictors of Liver Transplant Waitlist Mortality. (Abstract #545)

5:00 PM  The Newly Proposed UNOS Guideline Criteria for Simultaneous Liver Kidney Transplantation Are Invalid. (Abstract #546)

5:12 PM  Predictive Factors of Transplant Free Survival in Patients with Fulminant and Subfulminant Hepatic Failure: Results from a Randomized Controlled Multicenter Trial. (Abstract #547)
Faouzi Saliba, Christophe Camus, Francois Durand, Philippe Mathurin, Bertrand Delafosse, Magali Behnard, Alexia Letierce, Karl Barange, Philippe Ichai, Didier Samuel. Villejuif, France; Rennes, France; Clichy, France; Lille, France; Lyon, France; Le Kremlin-Bicetre, France; Toulouse, France.

Concurrent Session 77: Molecular and Humoral Phenotypes of Chronic Renal Allograft Injury
4:00 PM – 5:30 PM
Room 311
Chairs: Roslyn Mannon, MD, and Tibor Nadasdy, MD

4:00 PM  Endothelial Stress Accelerates Graft Loss in Kidneys with Transplant Glomerulopathy Despite Lack of C4D Staining. (Abstract #548)
Banu Sis, Jeff Reeve, Gunilla Einecke, Sakarn Bunnag, Luis Hidalgo, Michael Mengel, Konrad Famulski, Philip Halloran. Edmonton, AB, Canada.

4:12 PM  Transcriptome Changes of Chronic Tubulointerstitial Damage in Early Kidney Transplantation. (Abstract #549)

4:24 PM  High Frequency of Donor Specific HLA-DQ Antibodies in Chronic Renal Graft Failure. (Abstract #550)
Lan Zhu, Ella M. van den Berg-Loonen, Po-Chang Lee, Maarten H. L. Christiaans, Evy V. A. Billen, Paul I. Terasaki. Los Angeles, CA; Maastricht, Netherlands; Tainan, Taiwan; Maastricht, Netherlands.
4:36 PM  Pre-Transplant Donor Specific Antibodies (DSA) Detected by Luminex Are Associated with Inferior Graft Outcomes: Impact Is Modified by Antibody Strength. (Abstract #551)
Westmead, Sydney, NSW, Australia.

4:48 PM  Urine Magnetic Resonance Spectroscopy (UMRS): Results from the Deterioration of Kidney Allograft Function (DeKAF) Study. (Abstract #552)

5:00 PM  MICA Antibodies in a Cohort of 1091 Uremic Patients and Controls: Triggering Factors and Determination of Auto- or Allo-Specificity. (Abstract #553)
Brussels, Belgium.

5:12 PM  The Role of Positive Flow Cytometry Crossmatch in Late Kidney Graft Loss. (Abstract #554)
Solomon Harvey, Ralph Graff, Huiling Xiao, Mark Schnitzler, Ercole Patrick, Krista Lentine.

Concurrent Session 78: Non-Organ Specific: Disparities to Outcome and Access to Healthcare
4:00 PM – 5:30 PM
Room 206
Chairs: Gaetano Ciancio, MD, MBA, and Silas Norman, MD

4:00 PM  Do Donor Conversion Rates Vary by Age or Ethnicity/Race? (Abstract #555)
Richmond, VA; Albany, NY; Baltimore, MD.

4:12 PM  Sociodemographic Differences in Early Access to Liver Transplantation Services. (Abstract #556)

4:24 PM  Long Term Outcomes of Hispanic Liver Transplant Recipients – The Hispanic Paradox. (Abstract #557)

4:36 PM  Racial Disparities in Deceased Donor Kidney Transplantation Are Compounded by Longer Pretransplant Dialysis Duration in African American Patients. (Abstract #558)
Ho Yee Tiong, Charles Modlin, Joan M. Alster, Ismael R. Saad, Barbara Mastroianni, Kathy Savas, Stuart M. Flechner. Cleveland, OH.

4:48 PM  Significant Barriers to Kidney Transplant Evaluation and Listing: A Single-Center Analysis of 3000+ Referrals. (Abstract #559)
Jesse D. Schold, Jon A. Gregg, David Tomlin, Pamela Patton, Herwig-Ulf Meier-Kriesche.

5:00 PM  Long-Term Outcomes of Pediatric Kidney Transplantation in Hispanics. (Abstract #560)
J. Caicedo, S. Gil, A. Daud, A. Skaro, D. Ladner, E. Wang, R. Superina.

5:12 PM  Racial Disparities in Access to Kidney Transplantation Differ by Appropriateness for Transplantation. (Abstract #561)
Colleen F. Hanrahan, Lauren M. Kucirka, Robert A. Montgomery, Dorry L. Segev. Baltimore, MD.
Concurrent Session 79: Optimizing Islet and Cell Transplantation
4:00 PM – 5:30 PM
Room 306
Chairs: Juan Contreras, MD, and Alan Farney, MD, PhD

4:00 PM Pancreata from Donation after Cardiac Death Donors Show Increased Oxidative Stress Which Presents Challenges for the Successful Isolation of Islets for Clinical Transplantation. (Abstract #562)

4:12 PM Combined Treatment with a Nuclear Factor (NF)-κB Inhibitor, DHMEQ, and Tacrolimus Permits a Long-Term Allogeneic Islet Engraftment in Mice. (Abstract #563)
Masaaki Watanabe, Kenichiro Yamashita, Hirofumi Kamachi, Daisuke Kuraya, Yasuyuki Koshizuka, Shigeru Nakakimura, Michitaka Ozaki, Kazuo Umezawa, Michiaki Matsushita, Satoru Todo. Sapporo, Hokkaido, Japan; Yokohama, Kanagawa, Japan.

4:24 PM Rapamycin Induces Autophagy in Islets and Impairs Islet Function. (Abstract #564)
Masahiro Tanemura, Toshinori Ito, Tomohiko Machida, Takashi Deguchi, Syougo Kobayashi, Shigeru Marubashi, Yutaka Takeda, Hirofumi Kamachi, Yoshiki Sawa, Masaki Mori, Yuichirou Doki. Suita, Osaka, Japan.

4:36 PM Endoscopic Gastric Submucosal Transplantation of Islets: Technique and Initial Results. (Abstract #565)

4:48 PM Effectiveness of Exenatide as a Potent Anti-Rejection Therapy for Islet Cell Allo-Transplantation in the Non-Human Primate. (Abstract #566)
Amer Rajab, Jill L. Buss, Elizabeth Diakoff, Kwame Columbus, OH.

5:00 PM Construction of an In Vivo Utilizing Bio-Artificial Liver Based on Hepatic Cells and Decellularized Liver Matrix. (Abstract #567)
Ji Bao, Yujun Shi, Huaiqiang Sun, Hong Bu, Youping Li. Chengdu, Sichuan, China.

5:12 PM Prevention of Graft Failure Caused by IBMIR with a Novel NF-κB Inhibitor, Dehydroxymethylepoxyquinomicin (DHMEQ) after Intraportal Islet Transplantation in Mice. (Abstract #568)
Daisuke Kuraya, Hirofumi Kamachi, Masaaki Watanabe, Yasuyuki Koshizuka, Shigeru Nakakimura, Michitaka Ozaki, Kazuo Umezawa, Kenichiro Yamashita, Michiaki Matsushita, Satoru Todo. Sapporo, Hokkaido, Japan; Yokohama, Kanagawa, Japan.

Concurrent Session 80: Pediatric Transplantation: Kidney
4:00 PM – 5:30 PM
Room 208
Chairs: Paul Brakeman, MD, PhD, and Robert Mathias, MD

4:00 PM Immunosuppressant Therapy Adherence and Graft Failure among Pediatric Renal Transplant Recipients. (Abstract #569)
Marie Chisholm, Christina Spivey, Rick Rehfeld, Mona Zawaiadeh. Tucson, AZ.

4:12 PM Outcome of Kidney Transplants in Recipients of Young Donors – A NAPRTCS Analysis. (Abstract #570)
Asha Moudgil, Karen Martz, Donald M. Stablein, Dechu Puliyanda. Washington, DC; Potomac, MD; Los Angeles, CA.
**Concurrent Session 81: Tolerance III: Chimerism (Rodent Models)/Regulatory Cells**

4:00 PM – 5:30 PM

Room 309

**Chairs: Thomas Fehr, MD, and Thomas Wekerle, MD**

4:00 PM  Expression of Intact Donor MHC Molecules by Recipient APC for the Tolerization of Alloreactive T Cells. (Abstract #576)
Christopher Borges, Megan Sykes, Josef Kurtz. Boston, MA.

4:12 PM  Rapid Deletion of Peripheral Directly and Indirectly Alloreactive CD4 T Cells Following BMT with Costimulatory Blockade. (Abstract #577)
Samuel LoCascio, Megan Sykes, Sang-Mo Kang, Josef Kurtz. Boston, MA; San Francisco, CA.

4:24 PM  Induction of Molecular Chimerism through Genetic Modification of Autologous Hematopoietic Stem Cells Results in Tolerance to MHC Class II Disparate Allografts. (Abstract #578)
Peter T. Jindra, Chaorui Tian, John Iacomini. Boston, MA.

4:36 PM  Mechanisms of PDL1 Mediated Regulation of Fetomaternal Tolerance. (Abstract #579)
Francesca D’Addio, La-Tonya Adams, Indira Guleria. Boston.

4:48 PM  Tissue Stromal Cells Mediate IFN-γ-Evoked Immune Regulation in Periphery. (Abstract #580)
Horng-Ren Yang, Xiaodong Gu, John J. Fung, Lina Lu, Shiguang Qian. Cleveland, OH.

5:00 PM  Role of T Cell TGFβ Signaling in Allograft Acceptance and Chronic Rejection. (Abstract #581)
Susan M. Faust, Guanyi Lu, Bernard L. Marini, Dennis K. Bishop. Ann Arbor, MI.
5:12 PM  Imaging Direct and Indirect Alloreactive T Cell Modulation by Treg in Islet Transplantation Using In Vivo Multiphoton Microscopy. (Abstract #582)

Poster Session IV
5:30 PM – 6:30 PM
Poster Viewing: 8:00 AM – 6:30 PM
Presenters in Attendance:
5:30 PM– 6:30 PM
Exhibit Hall C, Second Floor
John B. Hynes Convention Center
Poster Session IV Program can be found on pages 170-187.

ASTS Business Meeting
5:30 PM – 6:30 PM
Room 313

Industry – Supported Symposium
6:30 PM – 8:30 PM
Chronic Allograft Nephropathy/Interstitial Fibrosis and Tubular Atrophy: Insight into Etiology and Management.
Grand Ballroom, Sheraton Boston Hotel
AMERICAN TRANSPLANT CONGRESS
Day-at-a-Glance, Wednesday, June 3, 2009

7:00 AM – 8:15 AM  Sunrise Symposia

Page 141  Sunrise Symposium I: Sexual Dysfunction Post Transplant: Differences in Men and Women and Role of Transplant Drugs
Room 312

Page 141  Sunrise Symposium II: Cardiac Issues in Non-Cardiac Transplant Candidates and Recipients
Ballroom A

Page 141  Sunrise Symposium III: Options for Sensitized Recipients of Kidney Transplants
Ballroom B

Page 141  Sunrise Symposium IV: Alemtuzumab - Should it Only be Used for Kidneys
Ballroom C

Page 141  Sunrise Symposium V: Ischemia-Reperfusion Injury and Transplantation: Novel Protective Strategies?
Room 302/304

7:00 AM – 8:15 AM  Early Morning Workshops

Page 142

8:15 am  Break

8:30 AM – 10:00 AM  Plenary Session IV

Page 142  Auditorium

10:00 AM – 10:30 AM ESOT Session

Page 143  Impact of the Acceptable Mismatch in Europe on the Transplantation Rate of Highly Sensitized Patients
Auditorium

10:15 AM – 11:45 AM  Concurrent Sessions

Page 143  Concurrent Session 82: Antigen Presentation/Allorecognition
Room 311

Page 143  Concurrent Session 83: Cardiovascular Disease
Ballroom C

Page 144  Concurrent Session 84: Immunosuppression Minimization In Pediatrics Kidney Transplantation
Room 208

Page 145  Concurrent Session 85: Immunosuppression Preclinical Studies II
Room 312

Page 145  Concurrent Session 86: Kidney Induction II
Auditorium

Page 146  Concurrent Session 87: Kidney Living Donor Outcomes II
Room 302/304

Page 147  Concurrent Session 88: Kidney: Complications IV
Ballroom B

Page 147  Concurrent Session 89: Liver: Complications, Recurrent Disease, and Hepatitis IV
Ballroom A

Page 148  Concurrent Session 90: Virus, Local Immune Responses and Fibrosis
Room 309

Page 149  Concurrent Session 91: Xenotransplantation
Room 310

Page 149  Concurrent Session 92: Late-Breaking Oral Abstract Session

Page 150  Room 210

10:30 AM Break

12:15 PM – 1:15 PM What’s Hot, What’s New

Page 150  Auditorium
Wednesday, June 3, 2009

Sunrise Symposia
7:00 AM – 8:15 AM

Sunrise Symposium I: Sexual Dysfunction
Post Transplant: Differences in Men and Women and Role of Transplant Drugs
Room 312
Chair: Margaret Bia, MD

7:00 AM The Frequency of Sexual Dysfunction Post Transplant
Margaret Bia, MD

7:05 AM Frequency and Causes of Sexual Dysfunction Depending on Gender and Age
Carole Goldberg, Psy.D

7:25 AM Frequency and Causes of Sexual Dysfunction in Men and Women after Transplant: How to Approach the Problem
Martha Pavlakis, MD

7:45 AM How Drugs We use in Transplant Patients Can Affect Sexual Function
Kathleen Lake, PharmD

8:10 AM Q & A

Sunrise Symposium II: Cardiac Issues in Non-Cardiac Transplant Candidates and Recipients
Ballroom A
Chairs: Marc Semigran, MD, and Maryl Johnson, MD

This session is co-sponsored with the International Society for Heart and Lung Transplantation (ISHLT)

7:00 AM Cardiac Work-up For the Non-Cardiac Transplant Candidate
Howard Eisen, MD

7:15 AM Cardiac Follow-up After Abdominal Organ Transplantation: Preventive Therapies, Diagnostic Imaging
Leslie Miller, MD

7:30 AM Pulmonary Hypertension in the Non-Thoracic Transplant Patient
Michael Krowka, MD

7:45 AM The Two-edged Sword: Strategies to Reduce the Cardiovascular Risks Associated with Immunosuppression
JoAnn Lindenfeld, MD

8:00 AM Discussion

Sunrise Symposium III: Options for Sensitized Recipients of Kidney Transplants
Ballroom B
Chairs: Milagros Samaniego, MD, and Vineeta Kumar, MD

7:00 AM Desensitization of Wait-Listed Recipients
Denis Glotz, MD, PhD

7:25 AM Outcomes of Kidney Transplantation in Highly Sensitized Recipients
James Gloor, MD

7:50 AM Beyond Rituximab: Novel Treatment Strategies for Disrupting Alloantibody Responses
Stanley Jordan, MD

Sunrise Symposium IV: Alemtuzumab - Should it Only be Used for Kidneys?
Ballroom C
Chairs: Stuart Knechtle, MD, and Alan Wilkinson, FRCP

7:00 AM Immune Reconstitution Following Alemtuzumab
Stuart Knechtle, MD

7:15 AM Current Status of Alemtuzumab in Kidney Transplantation
Gaetano Ciancio, MD

7:30 AM Alemtuzumab in Kidney-Pancreas Transplantation
Dixon Kaufmann, MD, PhD

7:45 AM Alemtuzumab in Extrarenal Transplantation
Andreas Tzakis, MD

8:00 AM Discussion

Sunrise Symposium V: Ischemia-Reperfusion Injury and Transplantation: Novel Protective Strategies
Room 302/304
Chairs: Jerzy Kupiec-Weglinski, MD, PhD, and David Geller, MD

7:00 AM The Injury Hypothesis and IRI; Potential Therapeutic Targets?
Walter Land, MD

7:25 AM Alloimmunity and IRI; Targeting the Adaptive Immune Response
Steven Chadban, B.Med, PhD

7:50 AM From Bench to Bedside: Novel Strategies Ready for Clinical Trials
Hamid Rabb, MD
Early Morning Workshops
7:00 AM – 8:15 AM

27. Cancer Immunology - Lessons for the Field of Transplantation
Nikhil Munshi, MD
Hakan Mellstedt, MD, PhD
Room 103

28. Testing of Generic Drugs in Transplantation: Are They Equivalent?
Rita Alloway, PharmD, BCPS
Bryce Kiberd, MD
Room 305

Mariana Markell, MD
Vincent Armenti, MD, PhD
Room 308

30. Persistent Epstein-Barr Viremia and PTLD in Pediatric Transplantation
Michael Green, MD, MPH
Dechu Puliyanda, MD
Room 301

31. Pre-Transplant Management of Cirrhotic Patients
John Lake, MD
Robert Brown, MD, MPH
Room 303

32. Can you Eliminate Calcineurin Inhibitors in Liver Transplantation?
W. Kenneth Washburn, MD
James Trotter, MD
Room 105

33. Immune Nutrition in Transplant Recipients
J. Wesley Alexander, MD
A. Osama Gaber, MD
Room 104

8:15 AM Break

Plenary Session IV
8:30 AM – 10:00 AM

Auditorium
Chairs: Joren Madsen, MD, DPhil, and Barbara Murphy, MD

8:30 AM New Insights into the Interaction between Regulatory B7-H3 Molecule and Costimulatory CD28-B7 Pathway in Determining the Outcome of the Alloimmune Responses In Vivo. (Abstract #583)
Takuya Ueno, Joyce Popoola, Melissa Yeung, Miyuki Azuma, Gordon J. Freeman, Mohamed H. Sayegh, Nader Najafian. Boston, MA; Tokyo, Japan; Boston, MA.

8:45 AM Racial and Ethnic Disparities in Transplant Rates Have Improved in the MELD Era. (Abstract #584)
Amit K. Mathur, Douglas E. Schaubel, Qi Gong, Mary K. Guidinger, Robert M. Merion. Ann Arbor, MI.

9:00 AM Protecting Renal Grafts in Kidney Transplantation by Triple-Gene Silencing Using siRNA. (Abstract #585)

9:15 AM AST Grants

9:30 AM CMS Performance Criteria for Graft Failure Outcomes in Kidney Transplant Centers: Statistical Power and the Effect of Center Volume. (Abstract #586)
Eric D. Weinhandl, Jon J. Snyder, Ajay K. Israni, Bertram L. Kasiske. Minneapolis, MN.

9:45 AM Improving Education Increases Dialysis Patients’ Pursuit of Transplant: Explore Transplant RCT Findings. (Abstract #587)
Amy D. Waterman, Shelley S. Hyland, Sara Stanley, Ann Barrett, Rachel Millinger. Saint Louis, MO.
10:00 AM – 10:30 AM

ESOT Session

Chairs: Barbara Murphy, MD, and John Roberts, MD
Co-sponsored by the European Society for Organ Transplantation (ESOT)
Auditorium

Impact of the Acceptable Mismatch in Europe on the Transplantation Rate of Highly Sensitized Patients
Frans Claas, PhD

10:30 AM Break

Concurrent Session 82: Antigen Presentation/Allorecognition

10:15 AM – 11:45 AM

Room 311
Chairs: Gilles Benichou, PhD, and Angus Thomson, PhD, DSc

10:15 AM CD45 Expression Regulates Innate Immunity in Response to Islet Allografts. (Abstract #588)
Monica Froicu, Galip Guz, Ying Wang, Geoffrey Camirand, Deng SONYANG, Fadi Lakkis, Waren Shlomchik, David Rothstein. New Haven, CT; Pittsburgh, PA.

10:27 AM Deficiency of Decay Accelerating Factor Facilitates Murine Heart Graft Rejection in the Absence of CD4 T Cells. (Abstract #589)
Staci A. Leisman, Peter S. Heeger. New York, NY.

10:39 AM Alloreactivity of Virus Specific Memory T-Cells. (Abstract #590)

10:51 AM MHC- and NK Cell-Independent Innate Immune Response to Allogeneic Non-Self. (Abstract #591)
Daniel Zecher, David M. Rothstein, Warren D. Shlomchik, Fadi G. Lakkis. Pittsburgh, PA; New Haven, CT.

11:03 AM Heart Transplant Outcome and Anti-Donor T Cell Reactivity in DC-Deficient Recipients of DC-Deficient Organ Grafts. (Abstract #592)
Zhiliang Wang, Daisuke Tokita, Antonino Castellaneta, Angus W. Thomson. Pittsburgh, PA.

11:15 AM Host-Derived Plasmacytoid Dendritic Cells Prolong Cardiac Allograft Survival and Regulate Alloreactive T Cell Responses Via B7 Homolog-1. (Abstract #593)
Benjamin M. Matta, Bridget L. Colvin, Tina L. Sumpter, Angus W. Thomson. Pittsburgh, PA.

11:27 AM Tissue Stromal Cells Induce Development of Suppressor Antigen Presenting Cells. (Abstract #594)
Ching-Chuan Hsieh, Xiaodong Gu, Hong-Ren Yang, Lianfu Wang, John J. Fung, Shiguang Qian, Lina Lu. Cleveland, OH.

Concurrent Session 83: Cardiovascular Disease

10:15 AM – 11:45 AM

Ballroom C
Chairs: Anil Chandraker, MD, FRCP, and G. V. Ramesh Prasad, MBBS

10:15 AM Predicting Coronary Heart Disease after Kidney Transplant. (Abstract #595)
Bertram L. Kasiske, Jon J. Snyder, Melissa A. Skeans, Yi Peng, Eric D. Weinhandl, Ross Maclean, Ajay K. Israni. Minneapolis, MN; Princeton, NJ.

10:27 AM Length of QTc Is Associated with Waitlist Mortality – A Screening Tool for Sudden Death among CKD Patients? (Abstract #596)
Denise R. Simao, Lana Kopilevich, Mehul Gandhi, Brian Gallay, Muralikrishna Golconda, Michael Daily, Christoph Troppmann, John McVicar, Richard Perez, Angelo de Mattos. Sacramento, CA.

10:39 AM Post-Renal Transplant Cardiovascular Disease Is Related to Serum Uric Acid Level. (Abstract #597)
Farah Bandukwala, Michael Huang, Michelle M. Nash, Jeffrey S. Zaltzman, G. V. Ramesh Prasad. Toronto, ON, Canada.
10:51 AM  Reduction in Cardiovascular Death Rates after Kidney Transplantation in Australia and New Zealand. (Abstract #598)
Helen L. Pilmore, Steve Chadban, Hannah Dent, Stephen McDonald. Auckland, New Zealand; Adelaide, Australia.

11:03 AM  Early Corticosteroid Withdrawal Reduces Cardiovascular Events in Renal Transplant Recipients: A Prospective Analysis. (Abstract #599)

11:15 AM  Presence of Carotid Plaque in Renal Transplant Recipients Is Associated with Future Cardiovascular Events and Mortality. (Abstract #600)

11:27 AM  Improvement of Renal Transplantation Outcome with Renin Angiotensin System Blockade: A Prospective Cohort Study. (Abstract #601)
German Perez-Suarez, Esteban Porrini, Marian Cobo, Domingo Marrero, Jose Manuel Gonzalez-Posada, Maria Dolores Checa, Roberto Gallego, Javier Garcia, Armando Torres, Domingo Hernandez. Tenerife, Spain.

Concurrent Session 84:
Immunosuppression Minimization In Pediatric Kidney Transplantation
10:15 AM – 11:45 AM
Room 208
Chairs: Mark Benfield, MD, and Minnie Sarwal, MD, PhD

10:15 AM  The Subclinical Histological Evolution of Pediatric Recipient Kidneys Transplants in and the Impact of Complete Steroid Avoidance: 2 Year Results of the NIH-CCTPT Multicenter Trial. (Abstract #602)
Maarten Naesens, Neeraja Kambham, Oscar Salvatierra, Minnie Sarwal, Minnie Sarwal.

10:27 AM  Coordinated Peripheral Blood Transcriptional Changes with Steroid-Avoidance in Pediatric Kidney Transplantation. (Abstract #603)
Li Li, Amery Chen, Sue Heish, Rong Chen, Oscar Salvatierra, Minnie Sarwal.

10:39 AM  Improved Growth in Pediatric Kidney Recipients after Early Steroid Withdrawal: Daclizumab, Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) Versus TAC, MMF and Steroids (TWIST Study). (Abstract #604)
R. S. Trompeter, R. Grenda, A. Watson. United Kingdom; Poland.

10:51 AM  Prospective Randomized Trial on Late Steroid Withdrawal in Pediatric Renal Transplant Recipients under CsA and MMF: 2-Year Data. (Abstract #605)
B. Hoecker, L. T. Weber, R. Feneberg, J. Drube, U. John, H. Fehrenbach, M. Pohl, M. Zimmering, S. Frund, G. Klaus, E. Wuehl, B. Toenshoff. Heidelberg; Munich; Hanover; Jena; Memmingen; Freiburg; Berlin; Muenster; Marburg, Germany.

11:03 AM  Pediatric Living Donor Kidney Transplantation Using Alemtuzumab Pre-Conditioning and Tacrolimus Monotherapy. (Abstract #606)

11:15 AM  Long Term Follow-Up in Pediatric Renal Transplantation under Steroid-Free Immunosuppressive Regime. (Abstract #607)
Ronaldo Esmeraldo, Petrucia M. A. Pinheiro, Maria L. B. Oliveira, Silvana Daher, Fernando N. Paes, Camilo Soares, Regia P. Evangelista. Fortaleza, CE, Brazil.

Concurrent Session 85: Immunosuppression Preclinical Studies II
10:15 AM – 11:45 AM
Room 312
Chairs: Leslie Kean, MD, PhD, and Richard Pierson, III, MD


10:39 AM  Study Evaluating Efficacy of a Novel Rabbit Anti-Human Leukocyte Polyclonal Antibody in Combination with Rituximab in a Primate Model of Renal and Skin Allotransplantation. (Abstract #611) Xiaoping Wang, He Xu, Pu Wang, Ping Yun, Zidong Liu, Allan D. Kirk. China; Atlanta.


11:15 AM  PPARγ Is Important in Inducing Prolongation of Cardiac Allograft Survival by Purified Eicosapentaenoic Acid. (Abstract #614) Daiki Iwami, Qi Zhang, Hiroyuki Shirato, Osamu Aramaki, Katsuya Nonomura, Nozomu Shirasugi, Masanori Niimi. Tokyo, Japan; Sapporo, Hokkaido, Japan.

11:27 AM  Alveolar Macrophages Have a Crucial Role in Induction of Regulatory Cells by Intratracheal Delivery of Alloantigen in Mice. (Abstract #615) Daiki Iwami, Qi Zhang, Hisashi Ueta, Hiroyuki Shirato, Osamu Aramaki, Katsuya Nonomura, Kenjiro Matsuno, Nozomu Shirasugi, Masanori Niimi. Tokyo, Japan; Sapporo, Hokkaido, Japan; Mibu, Tochigi, Japan; Tokyo, Japan.

Concurrent Session 86: Kidney Induction II
10:15 AM – 11:45 AM
Auditorium
Chairs: Joshua Augustine, MD, and Shamkant Mulgaonkar, MD, FASN

10:15 AM  Single-Dose Induction with Rabbit Anti-Thymocyte Globulin (rATG; 6 mg/kg over 24 Hours) Is Safer and Improves Immediate and Long-Term Renal Allograft Function. (Abstract #616) R. Brian Stevens, Theodore H. Rigley, Kathleen J. Nielsen, Anna Skorupa, John Sandoz, Anna Kellogg, Lucile Wrenshall. Omaha, NE.
Alemtuzumab Induction and Steroid Withdrawal Associated with Low Rejection Rates in African American Renal Transplants Recipients with Delayed Graft Function. (Abstract #617)

Analysis of Subcutaneous (SQ) Campath 1-H Induction Therapy in Highly-HLA Sensitized (HS) Patients Desensitized with IVIG + Rituximab: Three Year Outcomes. (Abstract #618)
Ashley A. Vo, Toyoda Micko, Shili Ge, Kai Cao, Chih-Hung Lai, Nancy Reinsmoen, Alice Peng, Rafael Villicana, Stanley C. Jordan. Los Angeles, CA.

A Pharmacoeconomic Analysis of Alemtuzumab Versus Thymoglobulin Induction in Renal Transplant Recipients. (Abstract #619)
Christine Y. Tseng, Christie B. Truscott, Edward Zavala, Irene Feurer, David Shaffer. Nashville, TN.

478 Living Donor Kidney Transplants Using Alemtuzumab Pre-Conditioning and Tacrolimus Monotherapy: 6 Year Experience. (Abstract #620)

Prevalence and Predictive Factors of Infections Following Rituximab Therapy in Solid-Organ Transplant Patients. (Abstract #621)
Nassim Kamar, Olivier Milioto, Bénédicte Puissant-Lubrano, Abdellatif Ould Mohamed, Antoine Blancher, Lionel Rostaing. Toulouse, France.

Exclusion of Living Kidney Donors: Impact of Gender, Race and Relation to Recipient. (Abstract #623)
Ranjan Chanda, Larry Melton, Kim Rice, Arun Chandrakantan, Bernard Fischbach, Arthi Rajagopal, Yousri Barri. Dallas, TX.

The Relationship of GFR to Comorbidity in Prior Kidney Donors Is Distinct from Patterns in Endogenous Kidney Disease. (Abstract #625)
Krista Lentine, Mark Schnitzler, Hui Lin Xiao, Paolo SalvagGGio, Connie Davis, Kevin Abbott, David Axelrod, Daniel Brennan.

Age, Proteinuria, and Low Iothalamate GFR (iGFR) before Donation Predict Stage 3 CKD Post-Kidney Donation. (Abstract #626)
Yousri Barri, Thomas Parker, Yahya Daoud, Richard Glassock. Dallas, TX; Los Angeles, CA.


11:27 AM  A Prospective, Multi-Site Evaluation of Psychosocial Outcomes of Living Kidney Donors. (Abstract #629) James R. Rodrigue, Didier Mandelbrot, Martha Pavlakis, Scott Johnson, Timothy Antonellis, James Whiting, John Vella, Alan Reed, Bruce Kaplan. Boston, MA; Portland, ME; Iowa City, IA; Tucson, AZ.

Concurrent Session 88: Kidney: Complications IV

10:15 AM – 11:45 AM
Ballroom B
Chairs: Sita Gourishankar, MD, MSc, and Waichi Wong, MD


10:27 AM  Renal Allograft Outcomes in Patients with Membranoproliferative Glomerulonephritis Type I and II. (Abstract #631) Joseph R. Angelo, Cynthia Bell, Michael C. Braun. Houston, TX.


11:27 AM  Kidney Allograft Function and Histology in Recipients Dying with a Functioning Graft (DWF). (Abstract #636) Ziad El-Zoghby, Hatem Amer, Donna D. Lager, Patrick G. Dean, Mark D. Stegall, Fernando G. Cosio. Rochester, MN.

Concurrent Session 89: Liver: Complications, Recurrent Disease, and Hepatitis IV

10:15 AM – 11:45 AM
Ballroom A
Chairs: Michael Voight, MD, and Heidi Yeh, MD

10:27 AM  Anti-High Mobility Group Box Chromosomal Protein 1 Antibodies Improve Survival of Rats with Fulminant Hepatic Failure. (Abstract #638) Kiminori Takano, Masahiro Shinoda, Minoru Tanabe, Shigeshi Ono, Go Oshima, Shingo Yamada, Taku Miyasho, Hideaki Obara, Shigeyuki Kawachi, Yasushi Fuchimoto, Hiroya Takeuchi, Yasuhide Morikawa, Ikuro Maruyama, Akitoshi Ishizaka, Yuko Kitagawa.


Concurrent Session 90: Virus, Local Immune Responses and Fibrosis 10:15 AM – 11:45 AM
Room 309
Chairs: William Baldwin, III, MD, PhD, and Lee Ann Tibbles, MD, FRCP-C


10:51 AM  Local TGFβ Neutralization in Cardiac Allografts by Decorin Gene Transfer Attenuates Chronic Rejection. (Abstract #647) Susan M. Faust, Guanyi Lu, Dennis K. Bishop. Ann Arbor, MI.
11:03 AM  Intragraft Ectopic Lymphoid Tissue during Chronic Rejection: Hijacking of an Embryonic Developmental Program Promotes the Development of a Local Aggressive Alloimmune Response. (Abstract #648)
Olivier Thaunat, Natacha Patey, Chantal Gautreau, Emmanuel Morelon, Stephanie Graff-Dubois, Antonino Nicoletti. Lyon, France; Paris, France.

11:15 AM  The Role of LTβR Signaling in the Formation of Tertiary Lymphoid Organs within Cardiac Allografts. (Abstract #649)

11:27 AM  Donor Age Is Associated with an Augmented Graft Immunogenicity Leading to an Intensified Early NK and Memory T-Cell Response. (Abstract #650)
Christian Denecke, Xupeng Ge, Irene Kim, Daman Bedi, Anke Jurisch, Johann Pratschke, Stefan G. Tullius. Berlin, Germany; Boston, MA.

Concurrent Session 91: Xenotransplantation
10:15 AM – 11:45 AM
Room 310
Chairs: Takaaki Kobayashi, MD, and Michael Rees, MD, PhD

10:15 AM  Cardiac Function after Preclinical Orthotopic Cardiac Xenotransplantation. (Abstract #651)

10:27 AM  Genetically-Engineered Pig Liver Transplantation in Baboons: Initial Results. (Abstract #652)
Burcin Ekser, Cassandra Long, Mohamed Ezzelarab, Chih Che Lin, Gabriel Echeverri, Hidetaka Hara, David Ayares, Anthony Demetris, David K. C. Cooper, Bruno Gridelli. PA; Italy; Blacksburg, VA; Palermo, Italy.

10:39 AM  Comparison of GTKO and GTKO:hDAF Donor Organs in Heterotopic Cardiac Xenotransplantation. (Abstract #653)

10:51 AM  Potential Impacts of Human DAF and Thrombomodulin on Thrombin Regulation. (Abstract #654)
Yuko Miwa, Koji Yamamoto, Akira Onishi, Masaki Iwamoto, Shoichi Maruyama, Akimasa Nakao, Kenji Kadomatsu, Takaaki Kobayashi. Nagoya, Japan; Tsukuba, Japan; Tsuchiura, Japan.

11:03 AM  Evidence of Cytotoxicity of Antibodies Against N-glycolylneuraminic Acid Determinants in Xenotransplantation by Using CMAH-/− Mice. (Abstract #655)

11:15 AM  Long-Term Function of Transplanted Chimeric Liver with Autologous Hepatocyte and Xenobiotic Scaffold in Mouse and Rat Combination. (Abstract #656)
Toshiyuki Hata, Junji Iwasaki, Eiji Kobayashi, Shinji Uemoto. Kyoto, Japan; Shimotsuke, Tochigi, Japan.

Hidetaka Hara, Cassandra Long, Zac Pawlikowski, Naoko Koike, Mohamed Ezzelarab, Peter Yeh, David Ayares, Mark Yazer, David K. C. Cooper. Pittsburgh, PA; Blacksburg, VA.
Late-Breaking Oral Abstract Session
10:15 PM – 11:45 AM

Room 210
Chairs: James Markmann, MD, PhD, and Stephen Tomlanovich, MD, PhD

10:15 AM The JAK Inhibitor CP-690,550 Inhibits Effector T Cells but Does Not Affect the Function of Human CD4^CD25^brightFoxP3^+ Regulatory T Cells. (Abstract #LB01)
Varsha Sewgobind, Monique Quaedackers, Luc van der Laan, Rens Kraaijveeld, Gary Chan, Willem Weimar, Carla Baan. Rotterdam, Netherlands; New London, CT.

10:27 AM Immunosuppression with Belatacept-Based, CNI-Free, Steroid-Avoiding Regimens in Kidney Transplant Recipients: 6 Month, Interim Results. (Abstract #LB02)

10:39 AM Adoptive Transfer of Ex Vivo Donor Alloantigen-Stimulated CD4^CD25^FoxP3^+ Regulatory T Cells Ameliorates Rejection of Lung Transplantation between Fully Mismatched Miniature Swines. (Abstract #LB03)
Tsuyoshi Shoji, Ying Li, Naoki Satoda, Hidenori Ohe, Hiroyuki Kanazawa, Toru Bando, Shinji Uemoto, Eiji Kobayashi, Hiromi Wada, Shimon Sakaguchi, Hiroshi Date, Takaaki Koshiha. Kyoto, Japan; Shimono, Tochigi, Japan.

10:51 AM Long Term Follow-Up of Recipients of Kidney Transplants from Centers for Disease Control Increased Risk Donors. (Abstract #LB04)

11:03 AM Optimizing Bortezomib To Remove Donor Specific HLA Antibodies Prior to Allograft Dysfunction. (Abstract #LB05)

11:15 AM Fibrogenic Potential of Human Multipotent Mesenchymal Stromal Cells in Injured Liver. (Abstract #LB06)
Carmen Gonelle-Gispert, Reto Marc Baertschiger, Veronique Serre-Beinier, Philippe Morel, Domenico Bosco, Marion Peyrou, Sophie Clement, Antonino Sgroi, Andre Kaelin, Leo Buhler. 1211 Geneve 4, Switzerland; 1211 Geneva 4, Switzerland.

11:27 AM Antibody Mediated Microcirculation Damage Is the Major Cause of Late Kidney Transplant Loss. (Abstract #LB07)
G. Einecke, B. Sis, J. Reeve, M. Mengel, L. G. Hidalgo, B. Kaplan, P. F. Halloran. Edmonton, Canada; Chicago.

What's Hot, What's New
12:15 PM – 1:15 PM
Auditorium
Chairs: Joren Madsen, MD, DPhil and Robert Merion, MD

12:15 PM Clinical Science
Sandy Feng. MD, PhD

12:45 PM Basic Science
John Iacomini, PhD